finasteride and Adenoma, Prostatic

finasteride has been researched along with Adenoma, Prostatic in 767 studies

Research

Studies (767)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	286 (37.29)	18.2507
2000's	261 (34.03)	29.6817
2010's	170 (22.16)	24.3611
2020's	50 (6.52)	2.80

Authors

Authors	Studies
Ballard, S; Blagg, J; Fox, D; Kenny, B	1
Amos, RM; Barr, RJ; Boodhoo, A; Borromeo, PS; Chen, K; Dodge, JA; Durst, GL; Guo, S; Jones, SA; Krishnan, V; Lugar, CW; Montrose-Rafizadeh, C; Norman, BH; Osborne, HE; Richardson, TI; Wang, Y	1
Dahai, Y; En-Si, W; Jiazhen, W; Jinfeng, L; Jing, Y; Lijuan, Y; Shuang, Z; Xuexun, F; Yongtao, L; Zhuo, L	1
An, HJ; Cheon, SY; Chung, KS	1
An, HJ; Cheon, SY; Jin, BR; Kim, HJ	1
Chen, K; Jiang, Z; Liu, S; Xi, B; Yang, F; Zeng, LY; Zeng, Y	1
Jeong, EJ; Lee, H; Moon, SJ; Rho, JR; Yoo, YD	1
Li, X; Peng, C; Peng, Y; Sun, C; Wu, Y	1
Bauer, SR; Covinsky, K; Ensrud, KE; Liu, TT; McVary, KT; Newman, JC; Ricke, WA; Suskind, AM; Walter, LC	1
Goudarzi, M; Kalantar, H; Kalantar, M; Kalantari, H; Mansouri, E; Shabani, E	1
Ateya, AI; Ezz, MA; Fehaid, A; Marghani, BH; Saleh, RM	1
Bhojani, N; Nguyen, DD; Trinh, QD	1
Hong, GL; Jung, JY; Kim, KH; Kim, TW; Kim, YJ; Lee, HJ	1
Romero Pérez, P	1
Bae, SM; Choi, YJ; Fan, M; Hwang, JY; Kim, EK; Tang, Y; Wedamulla, NE	1
Baev, DS; Bakarev, MA; Lushnikova, EL; Meshkova, YV; Sorokina, IV; Tolstikova, TG; Zhukova, NA	1
Campbell, J; Dekalo, S; McArthur, E; Ordon, M; Power, N; Welk, B	1
Fall, K; Garcia-Argibay, M; Hiyoshi, A; Montgomery, S	1
Alfahmy, A; Fernstrum, AJ; Hijaz, AK; Ju, M; Pham, K; Ray, AW; Ray, S; Sheyn, D	1
An, J; Kim, K; Kim, S; Kong, H; Song, Y	1
Dray-Spira, R; Jollant, F; Laanani, M; Weill, A; Zureik, M	1
Ateya, AI; Ezz, MA; Fehaid, A; Marghani, BH; Rezk, S; Saleh, RM	1
Abdelaziz, A; Batekh, AE; Emad, N; Galal, M; Hussien, M; Karem, M; Moukhtar, DA; Salem, H	1
Agu, PC; Aja, PM; Ajayi, CO; Ifie, JE; Munezero, J; Namale, N; Okoboi, J; Ssedyabane, F; Tusubira, D	1
Abdel Rahman, AAS; Darwish, A; Elbaz, EM; Gad, AM; Safwat, MH	1
Arias-Chávez, DJ; Bravo, G; Campos-Pérez, E; Ledesma-Aparicio, J; Mailloux-Salinas, P; Medina-Campos, ON; Pedraza-Chaverri, J	1
Hu, H; Li, Y; Liu, D; Pan, L; Shen, L; Su, S; Wang, H; Wen, J; Zheng, R	1
Da Matta, SLP; Da Silva, J; Gonçalves, RV; Lozi, AA; Santana, FFV	1
Ge, JP; Han, DH; He, HW; Xu, S; Xue, S; Yi, XM; Zeng, T; Zhou, WQ	1
Antonelli, A; Busetto, GM; Celia, A; Chung, BI; Cindolo, L; D'Agostino, D; De Berardinis, E; Del Giudice, F; Kim, JH; Maggi, M; Minervini, A; Porreca, A; Rocco, B; Romagnoli, D; Schiavina, R; Sciarra, A	1
Fano-Sizgorich, D; Gasco, M; Gonzales, GF; Vásquez-Velásquez, C	1
Traish, AM	1
Cao, J; Chen, K; Ji, X; Lei, Z; Li, X; Ullah, MW; Xiao, J; Yang, G; Yuan, X	1
Abbaszadeh-Hasiri, M; Ahrari Khafi, MS; Derakhshandeh, N; Golchin-Rad, K; Mogheiseh, A; Nazifi, S	1
Frendl, DM; Olumi, AF; Wang, Z; Zhang, H	1
Chi, NJ; Feng, J; Liu, MY; Shi, XP; Wen, AD	1
Cantrell, MA; Dyson, TE; Lund, BC	1
Adamowicz, J; Drewa, T; Juszczak, K	1
Angrimani, DSR; Brito, MM; Francischini, MCP; Vannucchi, CI	1
Chughtai, B; Harrell, MB; Ho, K; Kaplan, SA; Te, AE	1
Cao, J; Li, B; Li, Q; Li, X; Panday, R; Ullah, MW; Wang, L; Yang, G; Zhang, Y	1
Amin, HAA; Elbaz, EM; Helmy, HS; Ibrahim, SM; Kamel, AS	1
Gupta, AK; Gupta, MA; Vujcic, B	1
Angrimani, DSR; Brito, MM; Nichi, M; Rui, BR; Vannucchi, CI	1
Juan, YS; Lee, HY; Li, CC; Wang, CS; Wu, WJ	1
Ayyash, O; Bandari, J; Davies, BJ; Jacobs, BL; Kumar, P; Macleod, LC; Odisho, AY; Ogunmola, AG; Sabik, LM; Shah, AA; Yabes, JG	1
Basaria, S; Bhojani, N; Cone, EB; Marchese, M; Nguyen, DD; Paciotti, M; Trinh, QD	1
Angrimani, DSR; Flores, RB; Lima, CB; Vannucchi, CI	1
An, HJ; Jin, BR; Ju, JY; Lee, M; Nugroho, A	1
Roehrborn, CG; Rukstalis, DB	1
Aboumohamed, A; Agalliu, I; Fram, E; Kovac, EZ; Sankin, AI; Schoenberg, MP; Srivastava, A; Zhu, D	1
Boukovala, M; Brössner, C; Efstathiou, E; Gustafsson, JA; Spetsieris, N; Wang, L; Warner, M; Wu, WF	1
Loughlin, KR	1
An, J; Cao, Y; Li, Y; Lin, S; Ma, X; Wang, S; Xu, L; Yang, M; Yuan, J; Zhang, Y; Zhao, Y	1
Anderson, KK; Dixon, S; Hayward, J; McArthur, E; Ordon, M; Welk, B	1
Gelfond, J; Kabra, A; Liss, MA	1
Ghadian, A; Rezaei, M	1
Álvarez-Véliz, S; Berroeta-Mauriziano, D; Carrasco-Zuber, JE; Carreño-Orellana, N; Moll-Manzur, C; Porras-Kusmanic, N	1
Corona, G; Dicuio, M; Gacci, M; Maggi, M; Mannucci, E; Maseroli, E; Santi, D; Sforza, A; Tirabassi, G	1
Aboshora, W; Li, J; Xiao, T; Zhang, L; Zou, Y	1
Arora, A; Bansal, A	1
Bruha, M; Welliver, C	1
Kaplan, SA	9
Abiola, OJ; Adaramoye, OA; Akanni, OO; Akinloye, O; Olapade-Olaopa, EO; Owumi, SE	1
Liss, MA; Thompson, IM	1
McArthur, E; Ordon, M; Welk, B	1
Christopoulos, P; Dimopoulos, P; Kampantais, S	1
Han, B; Jiang, C; Jing, Y; Luo, G; Shi, F; Wang, X; Xia, S; Yang, B; Zhao, R; Zhu, Y; Zhuo, J	1
Bolin, K; Brasso, K; Emneus, M; Ersbøll, AK; Green, A; Iversen, P; Meijer, M; Pukkala, E; Stavem, K; Thygesen, LC	1
Albertsen, PC; Duan, Y; Grady, JJ; Helen Wu, Z	1
Frye, CA; Kaurejo, S; Walf, AA	1
Dirk, J; Dixon, S; Garg, AX; McArthur, E; Ordon, M; Welk, B	1
Ahmed, TA; Al-Abd, AM	1
Dynda, D; Gupta, N; Helo, S; Holland, B; McVary, KT; Rogers, T	1
Abreu, RA; Almeida, LL; Angrimani, DSR; Brito, MM; Silvestrini, GR; Vannucchi, CI	1
Cheng, YD; Huang, T; Wang, AX; Xu, YF; Yang, J; Zhu, XY	1
Cai, HC; Huang, YF; Liu, W; Mo, DS; Qing, XR; Shang, XJ; Song, LB; Zhan, XX; Zhang, GW	1
Konety, BR; Sathianathen, NJ	1
Choi, BR; Karna, KK; Kim, HK; Lee, SW; Park, JK; So, I; Soni, KK	1
Cao, X; Fu, Y; Gao, W; Han, S; Wang, J; Wang, L; Wu, E	1
Bjartell, A; Bolton, DM; Caris, C; Davis, NF; de la Taille, A; Jack, GS; Lawrentschuk, N; Patel, A; Tubaro, A; Witjes, WP	1
Jia, DY; Li, R; Li, Z; Luo, SY; Xu, DR	1
Arenas-Duque, A; Garcia-Perdomo, HA; Guevara-Cuellar, CA; Parody-Rúa, E	1
Andrade, C	1
Kajdy, A; Maksym, RB; Rabijewski, M	1
An, HJ; Chung, KS; Jin, BR; Kim, HJ	1
Baek, DH; Kang, SC; Kim, CW; Koo, YT; Kwon, JE; Lee, SH; Negi, M; Noh, YH; Park, BK	1
Becher, KF; Madersbacher, S; Michel, MC	1
Culig, Z; Madersbacher, S; Sampson, N	1
Andrew, R; Kao-Yang, YH; Lai, EC; MacDonald, TM; Walker, BR; Wei, L	1
Leverson, GE; Macoska, JA; McVary, KT; Ricke, WA; Uchtmann, KS	1
Alexandrov, VA; Barakova, NV; Baranenko, DA; Bespalov, VG; Ermakova, ED; Kovalevskaya, EI; Lukin, DЕ; Romanov, VA; Semenov, AL; Tochilnikov, GV; Tumanyan, IA; Vasilyeva, IN; Zhilinskaya, NT	1
Cho, SY; Kang, JY; Kim, CS; Kim, HG; Park, S; Son, H	1
Kormos, W	1
Li, M; Wang, H; Xi, Z; Xu, E; Yang, X	1
Arena, F	1
Abrahim-Vieira, B; Cabral, LM; De Sousa, VP; Do Carmo, FA; Lopes, M; Padula, C; Pupe, CG; Ribeiro, AJ; Rodrigues, CR; Santi, P; Veiga, F	1
Casabé, A; Da Pozzo, LF; Henderson, RJ; Henneges, C; Roehrborn, CG; Sorsaburu, S; Viktrup, L; Wong, DG; Zepeda, S	1
Choyke, PL; Chua, C; Harris, C; Hoang, AN; Logan, J; Nix, J; Pinto, PA; Pusateri, C; Rais-Bahrami, S; Shuch, B; Siddiqui, MM; Stamatakis, L; Truong, H; Turkbey, B; Vourganti, S; Walton-Diaz, A; Wood, BJ	1
Burrows, PK; Eggers, PW; Fwu, CW; Kirkali, Z; Kusek, JW; McVary, KT	1
Choi, JY; Park, T	1
Caiwen, W; Changxiao, H; Shibing, Y; Zhengyong, Y	1
Carini, M; Corona, G; Ficarra, V; Gacci, M; Maggi, M; Novara, G; Sebastianelli, A; Serni, S; Shariat, SF; Zattoni, F	1
Bauman, TM; Bruskewitz, RC; Huang, W; Johnson, KA; Pier, T; Ricke, WA; Sehgal, PD	1
Morgia, G; Russo, GI; Urzì, D	1
Cui, Y; Fan, Y; He, Q; Hu, S; Jin, J; Li, X; Liu, J; Lv, T; Sun, M; Xiao, F; Yu, W	1
Andrew, R; Gray, CD; Hughes, KA; Livingstone, DE; Macfarlane, DP; Marshall, I; Minns, FC; Stewart, LH; Upreti, R; Walker, BR	1
Cauci, S; Cecchin, E; De Mattia, E; Mazzon, G; Toffoli, G; Trombetta, C	1
Ząbkowski, T	2
Bosch, JL; de Boer, A; De Bruin, ML; Duijnhoven, RG; Hoes, AW; Souverein, PC; Straus, SM	1
Hsieh, YW; Kao, CH; Lin, CL; Lin, WL; Sung, FC; Wu, CH	1
Adjei, S; Afriyie, DK; Asare, GA; Bugyei, K; Hong, ZF; Lin, JM; Peng, J	1
Li, J; Sun, Q; Yang, C; Yang, J; Zhang, L; Zou, Y	1
Büttner, H; Esen, A; Glina, S; Henneges, C; Plekhanov, A; Roehrborn, CG; Sorsaburu, S; Viktrup, L	1
Butorac, MZ; Ćupič, DF; Mačukat, IR; Marinovič, M; Orlič, ZC; Spanjol, J	1
Linmao, D; Lizhen, Y; Qinglin, Z; Shan, H; Shoujun, Y; Xiaocheng, C; Yuxing, L	1
Cyrus, A; Farmani, E; Goodarzi, D; Kabir, A; Moghimi, M; Moradi, A; Rafiee, M; Shahbazi, E; Talaei, A	1
Chou, CH; Kao, CH; Lin, CL; Lin, MC; Sung, FC	1
Casabé, A; Glina, S; Henneges, C; Roehrborn, CG; Sorsaburu, S; Viktrup, L	1
Oh-Oka, H	1
Masumori, N	1
Castellan, P; Cindolo, L; De Nunzio, C; Lombardo, R; Pirozzi, L; Presicce, F; Romero, M; Schips, L; Sountoulides, P; Tubaro, A	1
Antoshina, EE; Belitsky, GA; Blagosklonny, MV; Chernova, OB; Gorkova, TG; Kirsanov, KI; Lesovaya, EA; Salimov, RM; Shipaeva, EV; Trukhanova, LS; Yakubovskaya, MG	1
Dai, B; Shi, GH; Ye, DW; Zhang, HL; Zhu, YP	1
Doros, G; Haider, A; Haider, KS; Traish, AM	1
Azoulay, L; Benayoun, S; Eberg, M; Pollak, M	1
Figg, WD; Thompson, IM	1
Bortolato, M; Garcia-Segura, LM; Melcangi, RC; Traish, AM; Zitzmann, M	1
La Vecchia, C	1
Cai, W; Guo, Y; Jiang, Y; Li, W; Wang, X; Yang, S	1
Kaplan, SA; Kusek, JW; Lee, JY; Meehan, AG	2
Seftel, AD	1
Ding, J; Duan, L; Qi, J; Qian, X; Xu, D; Zhu, Y	1
Pirozzi Farina, F; Pischedda, A	1
Alcántara-Montero, A; Brenes-Bermúdez, FJ	1
Alcaraz, A; Baena-González, V; Brenes-Bermúdez, FJ; Carballido-Rodríguez, J; Cózar-Olmo, JM; García-Rojo, D; Manasanch, J; Medina-López, R; Rodríguez-Rubio, F; Ruiz-Cerdá, JL; Unda-Urzaiz, M	1
Ahmed, OA; Hussein, AK; Mady, FM	1
Bolin, K; Brasso, K; Emneus, M; Ersbøll, AK; Green, A; Hallas, J; Iversen, P; Kjærulff, TM; Pukkala, E; Stavem, K; Thygesen, LC	1
Alnajar, K; Aminsharifi, A; Noorafshan, A; Salehi, A	1
Dabanović, V; Janković, S; Kostić, M	1
Akhter, S; Faisal, M; Jamil, MI; Khwaja, MA; Muhammad, S; Nawaz, G	1
Chen, L; Li, YC; Marcovici, G; Mouser, G; Wang, J	1
Arias-Santiago, S; Camacho-Martínez, FM	1
Daneshmand, S; Shamie, N; Zhang, Y	1
Kang, R; Li, E; Li, F; Liu, L; Luo, J; Luo, L; Wan, S; Zhao, S; Zhao, Z	1
Adamo, EB; Altavilla, D; Crea, G; Irrera, N; Lorenzini, C; Marini, H; Micali, A; Minutoli, L; Pisani, A; Puzzolo, D; Rinaldi, M; Squadrito, F; Valenti, A	1
Bezemer, ID; Driessen, MT; Herings, RM; Kuiper, JG; Penning-van Beest, FJ; Roehrborn, CG; Vasylyev, A	1
Bell, CF; DerSarkissian, M; Duh, MS; Lefebvre, P; Swensen, AR; Xiao, Y	1
El-Sahar, AE; Saad, MA; Sayed, RH	1
Huang, A; Juurlink, D; Law, MR; Macdonald, EM; Mamdani, MM; Paterson, JM; Skeldon, SC	1
Jeong, MY; Jung, Y; Kang, J; Kim, HL; Park, J; Seok Ahn, K; Sethi, G; Um, JY; Youn, DH	1
Kang, J; Liu, J; Liu, Q; Qi, J; Zhu, Y	1
Georgescu, SR; Manea, M; Motofei, IG; Păunică, I; Rowland, DL; Sinescu, I	1
Cui, Y; Fan, Y; Han, W; He, Q; Hu, S; Jin, J; Li, J; Liu, J; Liu, L; Lv, T; Sun, Y; Yang, Y; Yu, W	1
Davis, EA; Fenter, TC; Lin, PJ; Shah, MB	1
Hogue, SL; Naslund, M; Ong, C; Regan, TS	1
Davis, EA; Eaddy, MT; Issa, MM; Lin, PJ; Shah, MB	1
Eaddy, MT; Hogue, SL; Kruep, EJ; Naslund, M	1
Andersson, KE	1
Acevedo, C; Cabezas, J; Castellón, EA; Contreras, HR; Huidobro, C; Mendoza, P; Noé, G; Sánchez, C; Vergara, J	1
Kaplan, SA; Kusek, JW; Lee, JY; McConnell, JD; Meehan, AG; Nyberg, LM; Roehrborn, CG; Rotonda, J; Surynawanshi, S	1
Shan, YX; Xiang, G; Xue, BX	1
Vastag, B	1
Richie, JP	1
Romics, I	4
Cheetham, TC; Haque, R; Jacobsen, SJ; Loo, RK; Shi, JM	1
Arnold, KB; Goodman, PJ; Kristal, AR; Lin, DW; Neuhouser, ML; Schenk, JM; Song, Y; Stanczyk, FZ; Thompson, IM	1
Altwein, J; Dörsam, J	1
Park, DS; Shim, JY	1
Erdemir, F; Harbin, A; Hellstrom, WJ	1
Brito-Babapulle, F; Malone, P; Viegas, S	1
Chorzepa-Nowicka, K; Gaczarzewicz, D; Laszczyńska, M; Piasecka, M; Wylot, M	1
Bobba, RK; Bollu, M; Marte-Grau, AC	1
Alcaraz, A; Castro, R; Desgrandchamps, F; Hammerer, P; Montorsi, F; Schröder, F	1
Jiang, YG; Li, MC; Lin, YH; Peng, T	1
Barron, R; Knight, TK; Nichol, MB; Penson, DF; Wu, J	1
Kuo, HC; Liu, HT	1
Montie, JE	1
Simon, HB	2
Kraljic, I; Kusic, Z; Spajic, B; Tarle, M	1
Acquaro, C; Carvalho, RF; Felisbino, SL; Justulin, LA; Silva, MD	1
Christianson, DW; Di Costanzo, L; Drury, JE; Penning, TM	1
O'Leary, M	1
Wyllie, MG	1
Dusková, M; Hanus, M; Hill, M; Matousková, M; Stárka, L	1
Mira Laguarda, JM; Moreno-Fernandez, A; Rubio Sotes, M; Ruiz-Hornillos, FJ	1
Cho, ST; Kim, S; Ko, SB; Lee, JW; Na, HR; Park, SM	1
Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA	1
Walsh, PC	3
Bortolato, M; Cannas, A; Marrosu, F; Muroni, A; Puligheddu, M; Solla, P	1
Hori, S; Ohtani, H; Satoh, H; Sawada, Y; Suzuki, R	1
Chen, LF; Du, XL; Ma, HS; Ma, YX; Shi, JD; Yang, R; Yang, ZP; Zhang, J; Zhou, Y; Zhu, Y	1
Blackwell, RH; Helfand, BT; McVary, KT	1
Fornari, A; Rhoden, CR; Rhoden, EL; Ribeiro, EP; Zettler, CG	1
Breau, RH; Dahm, P; Lavallée, LT	1
Milani, C; Mollo, A; Romagnoli, S; Sontas, BH	1
Pais, P	1
Cui, L; Gao, JP; Hong, BF; Lü, XY; Xu, AX; Zhang, X; Zhu, J	1
Chung, BH; Kim, CI; Kim, CS; Kim, SJ; Lee, HM; Lee, JY; Lee, SH	1
Kim, ED; White, WM	1
Shah, NB; Wittich, CM	1
Bertele', V; Garattini, S	1
Schmidt, LJ; Tindall, DJ	1
Fink, HA; Macdonald, R; Rutks, I; Tacklind, J; Wilt, TJ	1
Jiang, Y; Long, YF	1
Alfarone, A; Cattarino, S; Gentile, V; Gentilucci, A; Nesi, G; Salciccia, S; Sciarra, A	1
Dalela, D; Gupta, G; Jain, A; Jain, RK; Kumar, R; Maikhuri, JP; Sarswat, A; Sharma, VL; Verma, V	1
Gu, X; Spaliviero, M; Strom, KH; Wong, C	1
Krome, S	1
Doležal, T; Hanuš, T; Karmazínová, Z; Zámečník, L	1
Albanes, D; Brasky, TM; Goodman, P; King, IB; Kristal, AR; Neuhouser, ML; Song, X; Thompson, IM; Till, C; White, E	1
Arnold, KB; Kristal, AR; Lin, DW; Neuhouser, ML; Schenk, JM; Tangen, CM; Thompson, IM; White, E	1
Chang, HC; Chen, SC; Hsieh, JT; Yu, HJ	1
Gilling, P; Morrill, B; Nickel, JC; Rittmaster, RS; Tammela, TL; Wilson, TH	1
Dixit, VK; Nahata, A	2
Gasco, M; Gonzales, C; Gonzales, GF; Leiva-Revilla, J; Rubio, J	1
Kirby, R	3
Curveco, D; Gámez, R; García, H; Goicochea, E; Marrero, G; Martínez, AG; Mas, R; Mendoza, N; Noa, M; Pardo, B; Valle, M	1
Kirch, W; Lochner, S	1
Friedman, AE	1
Peng, XX; Yang, CC; Zhang, Y; Zong, HT	1
Ganju, J; Zhou, K	1
Abdelhafez, AA; Abuzeid, AM; Badawy, AA	1
Justman, S	1
Jiang, YG; Lin, YH; Luo, Y; Wang, JS	2
Carter, HB; Feng, Z; Landis, P; Pierorazio, PM; Ross, AE; Schaeffer, EM; Trock, BJ; Walsh, PC	1
Bubley, G; Dumas, C; Slater, S	1
Cvijetić, S; Dodig, S; Jurasović, J; Milković-Kraus, S; Mück-Šeler, D; Mustapić, M; Pašalić, D; Pauković, P; Pavlović, M; Pivac, N; Pizent, A	1
Arnold, KB; Kristal, AR; Messer, K; Parsons, JK; Schenk, JM; Thompson, IM; Till, C	1
Andriole, GL; Freedland, SJ; Hamilton, RJ	1
Kuehn, BM	1
Chang, SN; Kao, CH; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC	1
Paller, CJ; Smith, TJ	1
Balercia, G; Corona, G; Forti, G; Maggi, M; Mannucci, E; Maseroli, E; Rastrelli, G; Sforza, A	1
Chung, DE; Kaplan, SA; Lee, RK; Scofield, S; Te, AE	1
Lee, HJ; Lee, JW	1
Gur, S; Hellstrom, WJ; Kadowitz, PJ	1
Block, NL; Djavan, B; Kazzazi, A; Rick, FG; Saadat, SH; Schally, AV; Szalontay, L	1
Autorino, R; Berardinelli, F; Cindolo, L; Fanizza, C; Pirozzi, L; Romero, M; Schips, L	1
Eggers, PW; Fwu, CW; Kaplan, SA; Kirkali, Z; Kusek, JW; Lee, JY	1
Bergner, D; Cook, TJ; Gray, T; Johnson-Levonas, AO; McConnell, JD; Narayan, P; Quezada, WA; Roehrborn, CG; Saltzman, B; Waldstreicher, J	1
Betambeau, N; Coyne, K; Jones, CR; Kouriefs, C; Rowbotham, C; Rowley, M	1
Bales, GT; Gerber, GS; Laven, BA; O'Connor, RC	1
Bergh, A; Damber, JE; Häggström, S; Jensen, E; Lund, L; Møller, K; Nielsen, JE; Tørring, N	1
de la Rosette, JJ; Farmer, RD; Herings, RM; Leufkens, HG; Man in 't Veld, AJ; Souverein, PC	2
Alapont, JM; Aznar, J; España, F; Estellés, A; Jiménez-Cruz, JF; Martínez, M; Navarro, S; Royo, M	1
Bartsch, G; Klocker, H; Rittmaster, RS	3
Bartsch, G; Horninger, W	1
Baykara, M; Ciftcioglu, MA; Emreoglu, I; Erdoğru, T; Gulkesen, KH; Koksal, T; Ozbilim, G; Usta, MF	1
Gausa Gascon, L; Millán Rodríguez, F; Palou Redorta, J; Salvador Bayarre, J; Segarra Tomás, J; Villavicencio Mavrich, H	1
Bracken, B; Cook, T; Daurio, C; Imperato-McGinley, J; Matsumoto, AM; McConnell, J; Meehan, A; Pappas, F; Roy, J; Stoner, E; Sullivan, M; Vaughan, D; Waldstreicher, J	1
Edwards, JE; Moore, RA	1
Armenakas, NA; Basillote, JB; Fracchia, JA; Hochberg, DA; Pareek, G; Shevchuk, M; Vasovic, L	2
Foley, CL; Kirby, RS	1
Kassabian, VS	1
Johansen, TE	1
Bartsch, G; Boyle, P; Cary, MM; Grossman, EB; Jardin, A; Kirby, RS; Roehrborn, C; Sweeney, M	1
Lam, JS; Lowe, FC; Romas, NA	1
Kanetake, H; Sakai, H	1
Akakura, K	1
Doherty, AP	1
Auerbach, S; Bach, MA; Bannow, J; Culbertson, J; Fitch, W; Grayhack, J; Herlihy, R; Labasky, R; Lee, M; Matsumoto, AM; Parra, R; Rajfer, J; Roy, J; Tenover, L; Waldstreicher, J; Wessells, H	1
Larson, TR	1
Andriole, GL; Bartsch, G; Boake, R; Bruskewitz, RC; Cook, T; Elhilali, M; Geller, J; Hudson, PB; Imperto-McGinely, J; Ko, A; Lieber, M; Lowe, FC; McConnell, JD; Nacey, JN; Pappas, F; Romas, NA; Shah, S; Stoner, E; Waldstreicher, J; Walsh, PC	1
Lynch, TH	1
de la Rosette, JJ; Erkens, JA; Herings, RM; Leufkens, HG; Souverein, PC	1
Elhilali, MM; Nickel, JC	1
O'Leary, MP	2
Issa, MM; Johnson, TM; Jones, K; Kutner, MH; Lepor, H; Williford, WO	1
Del Llano Señarís, J; Jiménez Cruz, JF; Quecedo Gutiérrez, L	1
Chung, BH; Hong, SJ; Kim, SI; Ko, WJ	1
Gonzalez, CM; McVary, KT	1
Lee, M	1
Fitzpatrick, JM	2
Dunn, TA; Ewing, CM; Isaacs, WB; Luo, J; Walsh, PC	1
Thompson, CA	1
Djavan, B	1
Beer, TM	1
Lee, M; Meehan, A; Roehrborn, CG; Waldstreicher, J	1
Brausi, M; Porru, D; Rigatti, P; Rizzi, CA; Scarpa, RM; Schumacher, H	1
Andriole, GL; Bautista, OM; Clarke, HS; Crawford, ED; Diokno, A; Dixon, CM; Foley, JP; Foster, HE; Jacobs, SC; Kaplan, SA; Kreder, KJ; Kusek, JW; Lepor, H; Lieber, MM; Lucia, MS; McConnell, JD; McVary, KT; Menon, M; Milam, DF; Miller, GJ; Nyberg, LM; Ramsdell, JW; Roehrborn, CG; Schenkman, NS; Slawin, KM; Smith, JA	1
Vaughan, ED	1
Bruskewitz, R; Drisko, J; Gittelman, MC; Gottesman, JE; Malek, GH; McConnell, JD; Meehan, A; Nickel, JC; Roehrborn, CG; Saltzman, B; Suryawanshi, S; Waldstreicher, J	1
Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C	1
Brown, GA; Sussman, DO	1
Farinas, E; Wysowski, DK	1
Bosch, RJ; Sturkenboom, MC; Verhamme, KM	1
Rannikko, A; Ruutu, M	1
Boyle, P; de la Rosette, J; Emberton, M; Harkaway, R; Logie, J; Roehrborn, C	1
Fitzpatrick, JM; Kirby, RS	1
Bott, SR; Foley, CL; Kirby, RS; Shergill, IS	1
Doggrell, SA	2
Hoa Huynh, T; Hung Nguyen, T; Huynh, H; Ma, Z; Tien Do, P	1
Chen, ZD; He, ZF; Li, GH; Li, XD; Yu, DM	1
Baudendistel, KT; Henry, H; Heverhagen, JT; Jia, G; Knopp, MV; Levine, AL; Polzer, H; Rosol, TJ; von Tengg-Kobligk, H	2
Rosner, W	1
Kim, ED	1
Sandhu, JS; Te, AE	1
Chung, K; Dalton, JT; Gao, W; Kearbey, JD; Miller, DD; Nair, VA; Parlow, AF	1
Andriole, G; Bruchovsky, N; Chung, LW; Matsumoto, AM; Rittmaster, R; Roehrborn, C; Russell, D; Tindall, D	1
Bernard, L; Brisson, M; Hux, M; McDonald, H; Nickel, JC	1
Hausmann, R; Reich, O; Steif, CG; Thalmann, G	1
Andre, J; Benahmed, M; Bozec, A; Decaussin, M; Devonec, M; Mauduit, C; Ruffion, A	1
Rabasseda, X	1
McNeill, SA; Turner, K	1
Albanesi, L; Bosman, C; Cardi, A; Ciccariello, M; Di Silverio, F; Proietti Pannunzi, L; Salvatori, G; Salvatori, M; Sciarra, A	1
Howe, RW; MacDonald, R; Wilt, TJ	1
Wyllie, M	1
Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Muzi, P; Vicentini, C	1
Anastasi, G; Crea, G; Inferrera, A; Magno, C; Sanfilippo, G; Vizzini, C	1
Chiu, KY; Yong, CR	1
Biddle, AK; DiSantostefano, RL; Lavelle, JP	1
Jacobsen, SJ; Jacobson, DJ; Lieber, MM; McGree, ME; Roberts, RO; Sarma, AV	1
Carlson, AM; Naslund, MJ; Williams, MJ	1
Hutson, T; Mariani, S; Price, N; Sartor, O	1
Raynaud, JP; Schulman, CC; Teillac, P; Zlotta, AR	1
Gould, AL	1
Te, AE; Yang, J	1
Benli, K; Bulut, S; Gökkaya, S; Memiş, A; Ozdal, OL; Ozden, C	1
Erik Nielsen, J; Lund, L; Møller Ernst-Jensen, K; Tørring, N	1
Nehra, A	1
Allory, Y; Cochand Priollet, B; de la Taille, A; Leroy, X; Molinié, V; Paraf, F; Ruffion, A	1
Kuritzky, L	1
Ichikawa, T; Komiya, A; Suzuki, H	1
Beckman, TJ; Mynderse, LA	1
Garcia-Cardoso, JV; Gonzalez-Enguita, C; Granizo, JJ; Manzarbeitia, F; Sarasa-Corral, JL; Vela-Navarrete, R	1
Donohue, JF; Foster, MC; Hayne, D; Karnik, U; Thomas, DR	1
Millán Rodríguez, F	1
Kaplan, SA; Kusek, JW; Lee, MW; McConnell, JD; Meehan, AG; Noble, WR; Nyberg, LM; Roehrborn, CG	1
Cheng, TO	1
Botto, H; Comenducci, A; Lan, O; Poulain, JE	1
Albala, DM; Curtis, LH; Schulman, KA; Sung, JC	1
Federman, DG	1
Andriole, GL; Bullock, TL	1
Bautista, OM; Crawford, ED; Kusek, JW; Lieber, MC; McConnell, JD; Meehan, AG; Noble, WR; Nyberg, LM; Roehrborn, CG; Slawin, KM; Smith, JA; Wilson, SS	1
Atiemo, H; Borkowski, A; Jacobs, SC; Kyprianou, N; Sutton, MT; Vyas, A; Yingling, M	1
Ding, J; Peng, KL; Qi, L; Tang, ZY; Zu, XB	1
Fleshner, N; Kulkarni, G	1
Chrisofos, M; Deliveliotis, C; Lappas, D; Lazaris, AC; Lekas, AG; Papatsoris, AG; Patsouris, E	1
Ankerst, DP; Chi, C; Coltman, CA; Goodman, PJ; Lippman, SM; Lucia, MS; Parnes, HL; Tangen, CM; Thompson, IM	1
Anwarul Islam, AK; Kashem, MA; Kibria, SA; Shameem, IA	1
Ammar, H; Gupta, C; Malani, AK	1
Knottnerus, JA; Norg, RJ; Portegijs, PJ; van de Beek, K; van Schayck, CP	1
Auvinen, A; Hakama, M; Määttänen, L; Murtola, TJ; Tammela, TL	1
Mintzes, B; Musini, V; Perry, TL; Tejani, A; Wright, JM	1
Batiste, LR; Black, L; Eaddy, M; Naslund, M	1
Black, L; Eaddy, M; Fenter, TC; Runken, MC	1
Connolly, SS; Fitzpatrick, JM	1
Gasco, M; Gonzales, GF; Maldonado, C; Mormontoy, J; Pajuelo, M; Portella, J; Rodriguez, D; Vasquez, V; Villegas, L	1
Dalton, JT; Gao, W	1
Miner, M; Naslund, MJ	1
Feliciano, AE; Hennenfent, BR; Lazarte, AR	1
Istad, JA; Johansen, TE	1
Borst, SE; Carter, CS; Conover, CF; Gregory, CM; Leeuwenburgh, C; Marzetti, E; Vandenborne, K; Wronski, TJ	1
Levy, A; Samraj, GP	1
Bhardwa, J; Goldstraw, M; Kirby, R; Tzortzis, S	1
Jewett, MA; Klotz, LH	1
Issa, MM; Kraft, KH	1
Bartoletti, R; Cai, T; Gavazzi, A; Giubilei, G; Gontero, P; Lombardi, G; Mondaini, N	1
Hasan, M; Kibria, MD; Parveen, F; Shamsuzzaman, AK	1
Burrows, PK; Johnson, TM; Kusek, JW; Lepor, H; Nyberg, LM; Roehrborn, CG; Tenover, JL	1
Kreder, KJ; Lutgendorf, SK; Ullrich, PM	1
Gratzke, C; Reich, O; Schlenker, B; Seitz, M; Stief, CG; Weidlich, P	1
Averch, TD; Matoka, DJ	1
Jin, J; Kong, CZ; Li, NC; Na, YQ; Qiu, SP; Song, YS; Sun, G; Sun, YC; Sun, YH; Wang, XF; Wu, SL; Ye, ZQ	1
Chen, WS; Huang, BB; Li, TJ; Qiu, Y; Sun, H; Sun, LN; Yi, B	1
MacDonald, R; Wilt, TJ	1
Dagres, E; Issa, SA	1
Araki, M; Culkin, DJ; Lam, PN; Wong, C	1
Arnold, KB; Goodman, P; Kristal, AR; Neuhouser, ML; Penson, DF; Schenk, JM; Thompson, IM	1
Helling, TJ	1
Rich, KT; Safranek, S	1
Guzel, O; Han, O; Memis, A; Ozdal, OL; Ozden, C; Seckin, S	1
Hagerty, K; Kramer, BS; MacDonald, R; Schellhammer, P; Wilt, TJ	1
Kumar, VL; Wahane, VD	1
de la Taille, A	1
Gasco, M; Gonzales, GF; Gonzales-Castañeda, C; Malheiros-Pereira, A	1
Schmid, HP	1
Gormley, GJ; Guess, HA; Oesterling, JE; Stoner, E	1
Andersen, JT; Beisland, HO; Ekman, P; Johansson, JE; Kontturi, M; Lehtonen, T; Tveter, K; Wolf, H	2
Rittmaster, RS	1
Stoner, E	6
Hansen, BJ; Hvidt, V	1
Gormley, GJ; Guess, HA; Heyse, JF; Oesterling, JE; Stoner, E	1
Cook, T; Gormley, GJ; Guess, H; Ng, J; Stoner, E; Walsh, P	1
Grino, P; Stoner, E	1
Barry, MJ; Bruskewitz, RC; McConnell, JD	1
Konen, JC	1
Braf, Z; Chen, J; Matzkin, H	1
Oesterling, JE	2
Bartek, JK	1
Ferguson, D; Gormley, GJ; Round, E; Stoner, E	1
Bokelman, DL; Gordon, LR; Hertzog, PR; Keenan, KP; Peter, CP; Prahalada, SR; Soper, KA; van Zwieten, MJ	1
Tomera, KM	1
Harvengt, C	1
Ekman, P	6
Rossetti, R	1
Webb, D	1
Schröder, FH	1
Long, K; Long, R	1
Gilad, S; Jaffe, A; Matzkin, H; Stern, N	1
Vela Navarrete, R	1
Andriole, GL; Keetch, DW	1
Imperato-McGinley, J	2
Gormley, GJ; Stoner, E	1
Delahunt, B; Meffan, PJ; Nacey, JN	1
al-Rimawi, M; Boake, RC; Griffiths, DJ; Johnson, MA; Mador, DR	1
Cohen, SM; Harris, G; Jacobs, JG; Malatesta, PF; Nett, TM; Prahalada, S; Rasmusson, GH; Tanaka, WK; Werrmann, JG	1
Appell, RA	1
Narayan, P; Shinohara, K; Tewari, A	1
Geller, J	5
Geller, J; Kirchenbaum, A; Lepor, H; Levine, AC	1
Caturelli, E; Dragone, M; Sperandeo, G; Sperandeo, M; Varriale, A	1
Debus, M; Krieg, M; Tunn, S; Weisser, H	1
Schlegel, PN	1
Chute, CG; Girman, CJ; Guess, HA; Jacobsen, SJ; Lieber, MM; Oesterling, JE; Panser, LA	1
Sane, T	1
Guess, H; Stoner, E	1
Dell'Orto, P; Trinchieri, A	1
McConnell, JD	2
Boni, S; Chiodera, P; Coiro, V; Maccarini, PA; Volpi, R	1
Claes, H; De Jaegher, K; Kozyreff, P	1
Steers, WD; Zorn, B	1
Kreder, KJ	1
Gajendran, V; Jacob, G; Mahmood, I; Narayan, P; Presti, J; Tewari, A	1
Krieg, M; Tunn, S; Weisser, H	1
Andersen, JT	2
Bentué, C; Córdoba, R	1
Kontturi, MJ; Tammela, TL	2
Bono, AV; Fava, C	1
Benvenuti, F; Del Popolo, G; Rizzo, M; Tosto, A	1
Marberger, M	1
Miller, MI; Puchner, PJ	2
Cohen, SM; Duprat, P; Laroque, PA; Molon-Noblot, S; Peter, CP; Prahalada, S; Soper, K; van Zwieten, MJ	1
Chmiel, JJ; Hillman, AL; Lowe, FC; McDaniel, RL	1
Geller, DM	1
Blumenstein, BA	1
DuBeau, CE	1
Andersen, JT; Blaivas, JG; Bruskewitz, R; Cook, T; Grino, PB; Siroky, MB; Stoner, E	1
Gormley, GJ; Guess, HA; Heyse, JF	1
Partin, AW; Tempany, CM; Walsh, PC; Zerhouni, EA; Zinreich, SJ	1
Steiner, JF	2
Ellenberger, B	1
Ball, RA; Leder, P; Ornitz, DM; Richie, JP; Tutrone, RF	1
Ramsey, EW	1
Holdcroft, C	1
Monda, JM; Oesterling, JE	1
Bryan, J; Holmes, K; Kirby, RS; Vale, J; Webb, JA	1
Anand, A	1
Peters, DH; Sorkin, EM	1
Coakes, KE; Norman, RW; Rittmaster, RS; Wright, AS	1
Gregoire, S; Hegland, J; Hunninghake, DB; Taylor, AM; Winchell, GA	1
Moul, JW	1
Cramarossa, L; Defidio, L; Piccinno, A	1
Alberti, C	1
Ianev, V; Milushev, N	1
Bensadoun, H	1
Smith, RC; Sullivan, MJ	1
Gormley, GJ	3
Espié, J; Gibelin, B; Roylance, P	1
Bruskewitz, RC; Madsen, FA	1
Bracken, B; Bremner, W; Geller, J; Imperato-McGinley, J; McConnell, J; Moore, E; Pappas, F; Roy, J; Tenover, L; Vaughan, D	1
Kaplan, SA; Olsson, CA; Te, AE	1
Norman, RW; Rittmaster, RS; Rowden, G; Thomas, LN	1
Fabris, G; Montironi, R; Valli, M	1
Andersen, JT; Ekman, P; Wolf, H	1
Casparie, AF; Janknegt, RA; McDonnell, J; Nijs, HG; Stoevelaar, HJ; van de Beek, C	1
Barry, MJ; Brawer, MK; Dixon, CM; Gormley, G; Haakenson, C; Lepor, H; Machi, M; Narayan, P; Padley, RJ; Williford, WO	1
Itokawa, Y; Komatz, Y; Matsuda, T; Mizutani, Y; Oishi, K; Okada, K; Okada, Y; Takeuchi, H; Tomoyoshi, T; Yoshida, O	1
Binkowitz, BS; Bolognese, JA; Girman, CJ; Kolman, C; Liss, CL; Stoner, E	1
Portet-Brunet, L	1
Boudon, C; Gibelin, B; Lechevallier, E; Lobaccaro, JM; Lumbroso, S; Mottet, N; Sultan, C	1
Frankel, S	3
Djavan, B; McConnell, J	1
Berg, S; Greenspan, SL; Rosen, HN; Saltzman, B; Tollin, SR; Zeind, AJ; Zurowski, K	1
Fourcroy, JL; Green, L; Wysowski, DK	1
Aparicio Patino, J; de Palacio Rubio, ML; Lárran López, J; López Munñoz, A; Muñoz de la Pascua, MC; Rodríguez Vallejoo, JM; Romero Gutiĕrrez, L; Salido Peracaula, M	1
Boyle, P; Gould, AL; Roehrborn, CG	1
Huang, JK; Jiaan, BP; Lee, YH; Wu, TT	1
Chiu, TY; Chueh, SC; Huang, CY; Lai, MK; Yu, HJ	1
Byrne, JP; Lear, JT	1
Carraro, JC; Cauquil, J; Chisholm, GD; Chopin, DK; Da Silva, FC; Di Silverio, F; Hamdy, FC; Hanus, M; Hauri, D; Kalinteris, A; Koch, G; Marencak, J; Perier, A; Perrin, P; Raynaud, JP; Teillac, P	1
Edet, E; Freemantle, S; Mann, RD; Pearce, G; Stephens, MD; Wilton, L	1
Barak, M; Braf, Z; Matzkin, H	1
Bruskewitz, RC; Sall, M	1
Carlin, BI; Resnick, ML	1
Afridi, SK; Boake, RC; Elhilali, MM; Fradet, Y; Nickel, JC; Perreault, JP; Pommerville, PJ	1
Magoha, GA	2
Hampl, R; Hill, M; Petrik, R; Stárka, L	1
Sherwood, LM	1
Chen, W; Orfanos, CE; Zouboulis, CC	1
Zacks, M	1
Neĭkov, K; Panchev, P; Simeonov, P	1
Kirschenbaum, A; Levine, AC; Pacheco, E; Schuval, BJ	1
Gabrilove, JL; Kirschenbaum, A; Levine, AC	1
Avogadro, A; Blanc, M; Gattoni, F; Sacrini, A; Secreto, G; Spadone, M	1
Andersen, JT; Beisland, HO; Ekman, P; Johansson, JE; Kontturi, M; Lehtonen, T; Tveter, KJ; Wolf, H	1
Eri, LM; Tveter, KJ	1
Beaty, TH; Binkowitz, B; Doehring, CB; Hale, E; Partin, AW; Sanda, MG; Stoner, E; Walsh, PC	1
Barkin, J	1
Akdaş, A; Ilker, Y; Tarcan, T	1
Haan, J; Hollander, JM; Saxena, PR; van Duinen, SG; Wintzen, AR	1
Froschermaier, SE; Helke, C; Wirth, MP	1
Alonso Sainz, F; Fernández Gómez, JM; Pérez García, FJ; Rábade Rey, CJ; Sahagún Argüello, JL; San Martín Blanco, A	1
Chisholm, GD; Habib, FK; Ross, M; Tate, R	1
Binkowitz, B; Bonilla, J; Grino, P; Stoner, E; Taylor, A	1
Cunningham, GR; Marcelli, M; Padayatty, SJ; Shao, TC	1
Ruud Bosch, JL	1
deKernion, JB; Dorey, FJ; Garris, JB; Gormley, GJ; Marks, LS; Partin, AW; Shery, ED; Stoner, E; Subong, EN	1
Albertsen, PC	1
Farmer, A; Noble, J	1
McDermott, T	1
Guthrie, R	1
Bianco, G; Carella, M; Cera, A; Scarale, MG; Sperandeo, G; Sperandeo, M; Viola, M	1
Hofstetter, A	1
Bodner, DR; Carlin, BI; Resnick, MI; Spirnak, JP	1
Andersen, JT; Boyle, P; Marshall, VR; Nickel, JC; Schulman, CC	1
Evans, MF; Frank, J	1
Cuñat Albert, E; Jiménez Cruz, JF; López Alcina, E; Martínez Sarmiento, M; Pontones Moreno, JL; Sanz Chinesta, S	1
Agha, A; Bach, M; Gormley, G; Johansen, T; Krarup, T; Lagerkvist, M; Oesterling, JE; Roy, J; Shown, T; Waldstreicher, J	1
Carlin, BI; Findlay, J; Resnick, MI; Seftel, AD	1
Berthaut, I; Cussenot, O; Mestayer, C; Mowszowicz, I; Portois, MC	1
Mendelsohn, R; Thompson, D	1
Collins, GN	1
Taneja, S	1
Bayraktar, Y; Demirel, A; Gül, O; Ozbey, I; Polat, O	1
Clarke, HS	1
Albrecht, J; Sökeland, J	1
Neĭkov, K; Panchev, P	1
Trinkler, FB	1
Iguer-Ouada, M; Verstegen, JP	1
Andriole, GL; Catalona, WJ; Keetch, DW; Ratliff, TL	1
Allensworth, D; Gray, M	1
Albertsen, P; Andriole, G; Bruskewitz, R; Holtgrewe, HL; Lieber, M; McConnell, JD; Nickel, JC; Roehrborn, CG; Taylor, AM; Waldstreicher, J; Walsh, P; Wang, DZ	1
Wasson, JH	1
Chavez-Eng, CM; Constanzer, ML; Matuszewski, BK	1
Nickel, JC	1
Bartsch, G; Dreikom, K; Schöntöger, PS	1
Kuo, HC	1
Aparicio Patino, J; Larrán Lopez, J; López Muñoz, A; Salido Peracaula, M; Vilches Troya, J	1
Roehrborn, CG	2
Altuğ, U; Arik, AI; Erol, D; Uygur, MC	1
Caceres, C; De Torres, I; Gonzalez, J; Morote, J; Reventos, J; Rodriguez-Vallejo, JM; Schwartz, S	1
Marberger, MJ	1
Boyle, P	1
Lieber, MM	1
Atan, A	1
Casey, CM; Johnson, KH	1
Chan, DW; Gormley, GJ; Kelley, CA; Marks, LS; Pannek, J; Partin, AW; Pearson, JD; Rittenhouse, HG; Shery, ED; Stoner, E; Subong, EN	1
Sun, ZY; Tu, ZH	1
Boudon, C; Lechevallier, E; Lobaccaro, JM; Lumbroso, S; Mottet, N; Rebillard, X; Sultan, C	1
Schulman, CC; Zlotta, AR	1
Andriole, GL; Cook, TJ; Crawford, ED; Epstein, JI; Guess, HA; Hudson, P; Jackson, CL; Kadmon, D; Patterson, L; Romas, NA; Waldstreicher, J; Wise, H	1
Cote, RJ; Henderson, BE; Mertes, SJ; Pike, MC; Ross, RK; Salem, CE; Skinner, EC; Stanczyk, FZ	1
Altwein, JE	1
Colloi, D; Debruyne, FM; Delauche-Cavallier, MC; Geffriaud-Ricouard, C; Jardin, A; McCarthy, C; Resel, L; Witjes, WP	1
Barry, MJ; Haakenson, C; Jones, K; Lepor, H; Williford, WO	1
Kurokawa, K; Mamiya, Y; Okazaki, H; Ono, Y; Onuma, E; Suzuki, K; Suzuki, T; Takanashi, H; Yamanaka, H	1
Giráldez, J; González-Baena, AC; González-Esteban, J; Japón, MA; Miranda, G; Rodríguez-Vallejo, JM; Sáez, C; Segura, DI; Torrubia, F	2
Krieg, M; Weisser, H	1
Gillenwater, JY	1
Ishani, A; Lau, J; MacDonald, R; Mulrow, C; Stark, G; Wilt, TJ	1
Bonastre, J; Le Pen, C; Lukacs, B; Rumeau-Pichon, C	1
Litwin, MS	1
Holtgrewe, HL	1
Feneley, MR; Kirby, RS; Schalken, JA; Smals, AG; Span, PN; Sweep, FG; Völler, MC	1
Segars, LW	1
Montironi, R; Muzzonigro, G; Pomante, R; Santinelli, A	1
Castellanos, R; Coffield, S; Cook, TJ; Geller, J; Kaplan, S; Lieber, M; Malek, GH; McConnell, JD; Resnick, M; Roehrborn, CG; Saltzman, B; Waldstreicher, J	1
deKernion, JB; Dorey, FJ; Epstein, JI; Garris, JB; Gormley, GJ; Macairan, ML; Marks, LS; Partin, AW; Santos, PB; Shery, ED; Stoner, E	1
Goldwasser, B; Marberger, M; McConnell, JD	1
Ellis, WJ	1
Baladi, JF; Menon, D; Otten, N	1
Boake, R; Bruskewitz, RC; Elhilali, M; Geller, J; Hudson, PB; Jacobsen, CA; Ko, A; Lieber, MM; Malek, GH; Narayan, P; Norman, R; Patterson, L; Perreault, JP; Romas, NA; Rosenblatt, S; Roy, JB; Stoner, E; Trachtenberg, J	1
Bannow, J; Epstein, JI; Fitch, WP; Gottesman, J; Hodge, GB; Lecksell, K; Parra, R; Peterson, L; Rouse, S; Schellhammer, PF; Short, K; Waldstreicher, J; Yang, XJ	1
Abrams, P; Andersen, JT; Bach, MA; Barrett, DM; Bruskewitz, R; Cannon, A; Gormley, GJ; Hald, T; Hedlund, H; Jacobsen, CA; Kirby, R; Malice, MP; Matos-Ferreira, A; Miller, P; Mustonen, S; Nordling, J; Rollema, HJ; Schäfer, W; Tammela, TL	1
Goa, KL; Wilde, MI	1
Payne, L; Persey, M; Webley, M	1
Brawer, MK; Jones, K; Lepor, H; Lin, DW; Williford, WO	1
Quan, H; Shih, WJ	1
Bruskewitz, RC; Krogh, RH; Rhodes, PR	1
Granados Loarca, EA	1
Gilhooly, P; Miller, JA; Pramanik, B	1
Hammarlund-Udenaes, M; Hermann, D; Karlsson, MO; Olsson Gisleskog, P	1
Chatelain, C	1
Albertsen, PC; Girman, CJ; Lowe, FC; Pellissier, JM; Roehrborn, CG	1
Abrams, P; Andersen, JT; Bach, MA; Barrett, DM; Bruskewitz, R; Cannon, A; Hald, T; Hedlund, H; Jacobsen, CA; Malice, MP; Matos-Ferriera, A; Miller, P; Mustonen, S; Nordling, J; Rollema, HJ; Schäfer, W; Tammela, TL	1
MacDonagh, R; Pearcy, R	1
Bostwick, DG; Cheng, L; Ramnani, D	1
Bracken, RB; Bruskewitz, R; Fowler, J; Fusilier, HA; Girman, CJ; Johnson, EL; Kantor, SD; Kozlowski, D; Rigby, OF; Sullivan, M; Waldstreicher, J; Wang, DZ	1
Schulman, C	1
Lee, TH	1
Bartels, PH; Duval da Silva, V; Mazzucchelli, R; Montironi, R; Pomante, R; Thompson, D; Vaught, L	1
Ehren-van Eekelen, C; Helin, H; Kallioniemi, OP; Koivisto, PA; Schleutker, J; Trapman, J	1
Casparie, AF; McDonnell, J; Stoevelaar, HJ; van de Beek, C	1
Isotalo, T; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T	1
Brenner, S; Matz, H	1
Cohen, P; Lazier, CB; Rittmaster, RS; Thomas, LN; Wright, AS	1
Basketter, V; Foley, SJ; Holmes, SA; Kashif, KM; Soloman, LZ; Summerton, D; Wedderburn, AW	1
Lehtonen, T; Lukkarinen, O; Lundstedt, S; Taari, K; Talja, M; Tiitinen, J	1
Carpentier, F; Cousse, H; Delaby, G; Dupouy, JP; Le Bourhis, X; Prevarskaya, N; Raynaud, JP; Van Coppenolle, F	1
Ablondi, F; Banchini, A; Benedetti, R; Cecchetti, A; Cortellini, P; Denti, L; Ferretti, S; Pasolini, G; Sanfelici, L; Valenti, G	1
Cerrato, PL	1
Anderson, R; Brown, BT; Bruskewitz, R; Cox, C; Glickman, S; Herlihy, R; Holtgrewe, HL; Kandzari, S; Kornitzer, G; Nickel, GC; Roehrborn, CG; Taylor, A; Waldstreicher, J; Wang, D	1
Clifford, GM; Farmer, RD	1
Marks, LS	1
Sökeland, J	1
Ablondi, F; Benedetti, R; Bruschieri, L; Cecchetti, A; Cortellini, P; Denti, L; Ferretti, S; Pasolini, G; Sanfelici, L; Valenti, G	1
Garvin, D; Gilhooly, P; Kaplan, S; Koppel, M; Labasky, R; Lee, M; Milsten, R; Pappas, F; Reddy, P; Rosenberg, S; Sussman, D; Waldstreicher, J; White, C	1
Djavan, B; Marberger, M	2
Caprino, L	1
Andersen, JT; Gabriel, M; Malice, MP; Marberger, MJ; Meehan, A; Nickel, JC; Pappas, F; Stoner, E; Waldstreicher, J	1
Zimmern, P	1
Fukabori, Y; Ito, K; Shibata, Y; Suzuki, K; Yamanaka, H	1
Bluemke, DA; Christens-Barry, WA; Epstein, JI; Marks, LS; Partin, AW; Simon, I; Snow, PB	1
Borkowski, A; Chon, JK; Glassman, DT; Jacobs, SC; Kyprianou, N	1
Harrison, RH	1
Kyllönen, AP; Lukkarinen, O; Marttila, T; Porvari, KS; Vaarala, MH; Vihko, PT	1
Baldwin, KC; Ginsberg, PC; Harkaway, RC	1
Chow, RD	1
Margiotti, K; Novelli, G; Reichardt, JK; Sangiuolo, F	1
Cilotti, A; Danza, G; Serio, M	1
Bhagat, K; Samkange, C	1
Vale, J	1
Johnston, GR; Johnston, SD; Kustritz, MV; Memon, MA; Sarkar, DK; Sirinarumitr, K	1
Cruz Santos, PB; Dorey, FJ; Hess, DL; Luz Macairan, M; Marks, LS; Tyler, VE	1
Clementi, G; Costantino, G; Matera, M	1
Atwa, MA; Mahassini, SH; Mosli, HA	1
Bruskewitz, R; Cook, TJ; Holtgrewe, HL; Kaplan, SA; Lund, RH; Meehan, A; Mobley, D; Narayan, P; Saltzman, B; Waldstreicher, J; Weiner, S; Wells, G	1
Koltveit, AJ	1
Mann, RD; Pearce, G; Shakir, S	1
Barbaud, A; Schmutz, JL; Trechot, P	1
Hellström, P; Isotalo, T; Perttilä, I; Talja, M; Tammela, TL; Törmälä, P; Välimaa, T	1
Cranidis, A; Delakas, D; Karyotis, I; Lianos, E	1
Baldwin, KC; Ginsberg, PC; Harkaway, RC; Roehrborn, CG	1
Brooks, JD; DePrimo, SE; Shinghal, R; Vidanes, G	1
Eri, LM; Nagelhus, J; Sivertsen, S	1
Dutkiewics, S	1
Abrams, P; Garnett, S	1
Batista-Miranda, JE; Bertrán, PA; Diez, MD; Villavicencio, H	1
Bailey, DM; Hahn, RG; Sandfeldt, L	1
Steers, WD	1
Ghafar, MA; Kang, YM; Kaplan, SA; Littlejohn, JO	1
Scarpa, RM	1
Speakman, MJ	1
Geller, J; Sullivan, MJ	1
Howe, W; MacDonald, R; Wilt, TJ	1
Barbalias, G; Gyftopoulos, K; Markou, S; Perimenis, P	1
Andriole, GL; Binkowitz, B; Bracken, BR; Bruskewitz, RC; Geller, J; Gormley, GJ; Imperato-McGinley, J; McConnell, JD; Ng, J; Pappas, F; Stoner, E; Taylor, A; Tenover, JS; Vaughan, ED; Walsh, PC	1
Johnston, SD; Kustritz, MV; Sarkar, DK; Sirinarumitr, K; Sirinarumitr, T	1
Djurhuus, JC; Lund, L; Møller-Ernst Jensen, K; Nexø, E; Nielsen, JE; Poulsen, SS; Tørring, N	1
Flanagan, M; Geller, J; Grayhack, J; Kadmon, D; Lee, M; Matsumoto, AM; McClung, M; Mobley, D; Schmidt, J; Sullivan, M; Taylor, AM; Tenover, L; Waldstreicher, J; Wessells, H; Zhang, GK	1
Bergland, R; Bingham, J; Kearney, MC; Meade-D'Alisera, P; Puchner, PJ	1
Vahlensieck, W	1
Md, EO; Wise, GJ	1
Eaton, JD; Kirby, RS; Oades, GM	1
Monga, M	1
Hasinski, S; Miller, JL; Rose, LI	1
Bruskewitz, RC	1
Ayalon, D; Braf, Z; Chen, J; Lewyshon, O; Matzkin, H	1
Heinzl, S	2
Braf, Z; Chen, J; Goldray, D; Jaccard, N; Matzkin, H; Pappas, F; Weisman, Y	1
Beisland, HO; Binkowitz, B; Brekkan, E; Ekman, P; Kontturi, M; Lehtonen, T; Lundmo, P; Pappas, F; Round, E; Shapiro, D	1
Geller, J; Sionit, L	1
Geller, J; George, FW; McConnell, JD; Pappas, F; Stoner, E; Wilson, JD	1
Braf, Z; Chayen, R; Gilad, S; Goldfarb, H; Matzkin, H	1
Bryan, J; Christmas, TJ; Eardley, I; Holmes, SA; Kirby, RS; Liu, S; Shanmuganathan, K; Vale, JA; Webb, JA	1
Nightingale, SL	1
Andriole, GL; Bracken, BR; Bruskewitz, RC; Geller, J; Gormley, GJ; Imperato-McGinley, J; McConnell, JD; Stoner, E; Tenover, JS; Walsh, PC	1
Lange, PH	1
Imperato-McGinley, J; Orlic, S; Shackleton, C; Stoner, E	1
Barbolt, TA; Batzold, FH; Hollenbaugh, DM; Juniewicz, PE; Lemp, BM; McCarthy, M; Reel, JR; Shaw, C; Winneker, RC	1
Fiorelli, G; Serio, M	1
Berman, C; Bryan, RN; Carlin, JR; Cohen, SM; Cordes, EH; Malatesta, PF; Prahalada, S; Shpungin, J; Taber, KH; Werrmann, JG	1
Buntinx, A; De Schepper, P; Giagulli, VA; Vermeulen, A	1
Jenks, S	1
Schmidt, JD	1

Reviews

173 review(s) available for finasteride and Adenoma, Prostatic

Article	Year
Pharmacological options in the treatment of benign prostatic hyperplasia. Journal of medicinal chemistry, 1997, Apr-25, Volume: 40, Issue:9 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship	1997
Voratins A-C: Pyridinium Alkaloids from the Marine Dinoflagellate Journal of natural products, 2022, 06-24, Volume: 85, Issue:6 Topics: Alkaloids; Animals; Biomarkers; Dinoflagellida; Humans; Male; Plant Extracts; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley	2022
Post-Finasteride Syndrome. Literature Review. Archivos espanoles de urologia, 2022, Volume: 75, Issue:5 Topics: 5-alpha Reductase Inhibitors; Alopecia; Female; Finasteride; Humans; Iatrogenic Disease; Male; Prostatic Hyperplasia; Retrospective Studies; Syndrome	2022
Comparative effects of finasteride and minoxidil on the male reproductive organs: A systematic review of in vitro and in vivo evidence. Toxicology and applied pharmacology, 2023, 11-01, Volume: 478 Topics: Administration, Oral; Adult; Alopecia; Animals; Finasteride; Humans; Male; Mice; Minoxidil; Prostatic Hyperplasia; Treatment Outcome	2023
Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2020, Jan-13, Volume: 91, Issue:4 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Treatment Outcome	2020
Post-finasteride syndrome: a surmountable challenge for clinicians. Fertility and sterility, 2020, Volume: 113, Issue:1 Topics: 5-alpha Reductase Inhibitors; Alopecia; Clinical Trials as Topic; Finasteride; Humans; Male; Observational Studies as Topic; Prostatic Hyperplasia; Sexual Dysfunction, Physiological; Syndrome; Withholding Treatment	2020
The clinical applications of five-alpha reductase inhibitors. The Canadian journal of urology, 2021, Volume: 28, Issue:2 Topics: 5-alpha Reductase Inhibitors; Alopecia; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2021
[Finasteride adverse effects: An update]. Revista medica de Chile, 2016, Volume: 144, Issue:12 Topics: 5-alpha Reductase Inhibitors; Alopecia; Blood Glucose; Erectile Dysfunction; Finasteride; Humans; Lipid Metabolism; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Spermatogenesis	2016
Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis. Andrology, 2017, Volume: 5, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Dutasteride; Erectile Dysfunction; Finasteride; Humans; Libido; Male; Middle Aged; Penile Erection; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Risk Factors; Sexual Behavior; Sexual Dysfunctions, Psychological; Treatment Outcome	2017
Is There a Role for Preoperative 5 Alpha Reductase Inhibitors in Reducing Prostate Vascularity and Blood Loss? Current urology reports, 2017, Volume: 18, Issue:10 Topics: 5-alpha Reductase Inhibitors; Blood Loss, Surgical; Dutasteride; Finasteride; Hematuria; Humans; Male; Preoperative Care; Prostate; Prostatic Hyperplasia	2017
Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies. Current opinion in urology, 2018, Volume: 28, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Dihydrotestosterone; Dutasteride; Early Detection of Cancer; Finasteride; Humans; Male; Organ Size; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Androgen; Risk Factors	2018
A Focused Review on the Effects of Preoperative 5α-Reductase Inhibitors Treatment in Patients Undergoing Holmium Laser Enucleation of the Prostate: What Do We Know So Far? Journal of endourology, 2018, Volume: 32, Issue:2 Topics: 5-alpha Reductase Inhibitors; Dutasteride; Finasteride; Humans; Laser Therapy; Lasers, Solid-State; Male; Morcellation; Operative Time; Preoperative Care; Prostatectomy; Prostatic Hyperplasia; Retrospective Studies	2018
Post-finasteride syndrome - does it really exist? The aging male : the official journal of the International Society for the Study of the Aging Male, 2019, Volume: 22, Issue:4 Topics: 5-alpha Reductase Inhibitors; Alopecia; Drug-Related Side Effects and Adverse Reactions; Finasteride; Humans; Iatrogenic Disease; Male; Prostatic Hyperplasia; Quality of Life; Sexual Dysfunction, Physiological	2019
[Do benign prostatic hyperplasia drugs affect mood or cognition?] Der Urologe. Ausg. A, 2019, Volume: 58, Issue:3 Topics: 5-alpha Reductase Inhibitors; Affect; Cognition; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia	2019
Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology, 2019, Volume: 65, Issue:5 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aging; Diabetes Mellitus; Dihydrotestosterone; Dutasteride; Dyslipidemias; Finasteride; Humans; Inflammation; Lower Urinary Tract Symptoms; Male; Metabolic Syndrome; Prostatic Hyperplasia; Receptors, Androgen	2019
Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. World journal of urology, 2014, Volume: 32, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Azasteroids; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Middle Aged; Organ Size; Prostate; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Treatment Outcome; Urological Agents	2014
Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. The journal of sexual medicine, 2014, Volume: 11, Issue:6 Topics: Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Doxazosin; Dutasteride; Ejaculation; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Sexual Dysfunction, Physiological; Sulfonamides; Tamsulosin; Urological Agents	2014
[5ARI and PSA: evidences]. Urologia, 2014, Sep-23, Volume: 81 Suppl 24 Topics: 5-alpha Reductase Inhibitors; Dutasteride; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia	2014
Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride? Current drug targets, 2015, Volume: 16, Issue:11 Topics: 5-alpha Reductase Inhibitors; Dutasteride; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Treatment Outcome	2015
Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. BMC urology, 2015, Jun-02, Volume: 15 Topics: 5-alpha Reductase Inhibitors; Blood Loss, Surgical; Finasteride; Follow-Up Studies; Humans; Male; Postoperative Hemorrhage; Preoperative Care; Prostatectomy; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Transurethral Resection of Prostate; Treatment Outcome	2015
Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know? Reviews in endocrine & metabolic disorders, 2015, Volume: 16, Issue:3 Topics: 5-alpha Reductase Inhibitors; Alopecia; Animals; Central Nervous System; Cholestenone 5 alpha-Reductase; Cognition Disorders; Depression; Diabetes Mellitus; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Psychoses, Substance-Induced; Sexual Dysfunction, Physiological; Steroids	2015
Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. The journal of sexual medicine, 2016, Volume: 13, Issue:9 Topics: 5-alpha Reductase Inhibitors; Drug Therapy, Combination; Ejaculation; Erectile Dysfunction; Finasteride; Humans; Libido; Male; Middle Aged; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	2016
Apoptotic Pathways Linked to Endocrine System as Potential Therapeutic Targets for Benign Prostatic Hyperplasia. International journal of molecular sciences, 2016, Aug-11, Volume: 17, Issue:8 Topics: Apoptosis; Dutasteride; Endocrine System; Finasteride; Humans; Male; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Urological Agents	2016
Safety Profile of Finasteride: Distribution of Adverse Effects According to Structural and Informational Dichotomies of the Mind/Brain. Clinical drug investigation, 2017, Volume: 37, Issue:6 Topics: 5-alpha Reductase Inhibitors; Alopecia; Brain; Cognition; Finasteride; Humans; Male; Prostatic Hyperplasia; Sexual Behavior	2017
[Conservative treatment of benign prostatic hyperplasia]. Orvosi hetilap, 2008, Oct-05, Volume: 149, Issue:40 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Organ Size; Phytotherapy; Plant Extracts; Prostate; Prostatic Hyperplasia; Urination Disorders	2008
5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. Prostate cancer and prostatic diseases, 2009, Volume: 12, Issue:2 Topics: 5-alpha Reductase Inhibitors; Antineoplastic Agents; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2009
5-alpha reductase inhibitors and erectile dysfunction: the connection. The journal of sexual medicine, 2008, Volume: 5, Issue:12 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Drug Therapy, Combination; Dutasteride; Ejaculation; Erectile Dysfunction; Finasteride; Humans; Libido; Male; Prostatic Hyperplasia	2008
[Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2008, Volume: 25, Issue:150 Topics: Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Humans; Male; Oxidoreductases; Prostatic Diseases; Prostatic Hyperplasia	2008
A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits. The Prostate, 2009, Jun-01, Volume: 69, Issue:8 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Aging; Azasteroids; Dihydrotestosterone; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Sulfonamides; Tamsulosin; Testosterone; Urinary Tract Infections	2009
Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer. The Journal of steroid biochemistry and molecular biology, 2011, Volume: 125, Issue:1-2 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Clinical Trials as Topic; Dutasteride; Finasteride; Humans; Male; Molecular Structure; Prostatic Hyperplasia; Prostatic Neoplasms	2011
Finasteride for benign prostatic hyperplasia. The Cochrane database of systematic reviews, 2010, Oct-06, Issue:10 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatism; Randomized Controlled Trials as Topic	2010
[Effects of finasteride on hematuria associated with benign prostatic hyperplasia: a meta-analysis]. Zhonghua nan ke xue = National journal of andrology, 2010, Volume: 16, Issue:8 Topics: Finasteride; Hematuria; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	2010
[How effective is finasteride?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:8 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin	2011
A systematic review of the effects and mechanisms of preoperative 5α-reductase inhibitors on intraoperative haemorrhage during surgery for benign prostatic hyperplasia. Asian journal of andrology, 2011, Volume: 13, Issue:6 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Blood Loss, Surgical; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Treatment Outcome	2011
Dutasteride for the treatment of prostate-related conditions. Expert opinion on drug safety, 2012, Volume: 11, Issue:2 Topics: 5-alpha Reductase Inhibitors; Animals; Antineoplastic Agents, Hormonal; Azasteroids; Dutasteride; Evidence-Based Medicine; Finasteride; Humans; Male; Patient Selection; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Assessment; Risk Factors; Treatment Outcome	2012
Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert opinion on drug safety, 2013, Volume: 12, Issue:1 Topics: 5-alpha Reductase Inhibitors; Animals; Azasteroids; Dutasteride; Ejaculation; Erectile Dysfunction; Finasteride; Humans; Male; Penile Erection; Prevalence; Prostatic Hyperplasia; Quality of Life; Risk Assessment; Risk Factors; Sexual Behavior; Sexual Dysfunction, Physiological; Treatment Outcome	2013
Hormonal manipulation of benign prostatic hyperplasia. Current opinion in urology, 2013, Volume: 23, Issue:1 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Cost-Benefit Analysis; Dutasteride; Finasteride; Gonadotropin-Releasing Hormone; Growth Hormone-Releasing Hormone; Humans; Male; Prostatic Hyperplasia; Treatment Outcome	2013
[Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia]. Der Urologe. Ausg. A, 2002, Volume: 41, Issue:5 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adult; Aged; Azasteroids; Clinical Trials as Topic; Dihydrotestosterone; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Isoenzymes; Male; Middle Aged; Prostate; Prostatic Hyperplasia	2002
[Drug therapy of benign prostatic hyperplasia. Is combination therapy with 5 alpha-reductase inhibitors and alpha-receptor blockers effective?]. Der Urologe. Ausg. A, 2002, Volume: 41, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Multicenter Studies as Topic; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Treatment Outcome	2002
Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC urology, 2002, Dec-12, Volume: 2 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	2002
5 alpha-reductase inhibitors: what's new? Current opinion in urology, 2003, Volume: 13, Issue:1 Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Aged; Azasteroids; Dose-Response Relationship, Drug; Drug Administration Schedule; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prognosis; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome	2003
Sexual function in patients treated for benign prostatic hyperplasia. Lancet (London, England), 2003, Jan-04, Volume: 361, Issue:9351 Topics: Adult; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Humans; Male; Middle Aged; Postoperative Complications; Prostatic Hyperplasia; Transurethral Resection of Prostate	2003
[Hormonal therapy for benign prostatic hyperplasia]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 11 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Azasteroids; Depression, Chemical; Dihydrotestosterone; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Androgen; Testosterone; Treatment Outcome	2002
[New agents developed for the treatment of benign prostatic hyperplasia]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 11 Topics: 5-alpha Reductase Inhibitors; Aromatase Inhibitors; Clinical Trials as Topic; Drug Design; Endothelin Receptor Antagonists; Enzyme Inhibitors; Estrogen Receptor Modulators; Finasteride; Humans; Male; Potassium Channels; Prostatic Hyperplasia; Pyrimidines; Sulfonamides	2002
Current treatment options for benign prostatic hyperplasia and their impact on sexual function. Urology, 2003, Volume: 61, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Erectile Dysfunction; Finasteride; Humans; Laser Coagulation; Male; Middle Aged; Minimally Invasive Surgical Procedures; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Quinazolines; Sexual Behavior; Transurethral Resection of Prostate	2003
[Finasteride: 10 years of clinical use. Systematic review of the literature]. Actas urologicas espanolas, 2003, Volume: 27, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Case-Control Studies; Clinical Trials as Topic; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Organ Size; Prospective Studies; Prostate; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome	2003
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Current urology reports, 2003, Volume: 4, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Treatment Outcome	2003
Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Jul-15, Volume: 60, Issue:14 Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Delayed-Action Preparations; Drug Interactions; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia; Quality of Life; Quinazolines	2003
Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life. Urology, 2003, Volume: 62, Issue:3 Suppl 1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Finasteride; Humans; Male; Phytotherapy; Prostatic Hyperplasia; Quality of Life; Serenoa; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Urinary Bladder Neck Obstruction; Urinary Incontinence; Urinary Retention	2003
[Pharmacologic treatment of benign prostatic hyperplasia]. Orvosi hetilap, 2003, Sep-14, Volume: 144, Issue:37 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin	2003
[Treatment of benign prostatic hypertrophy]. Orvosi hetilap, 2003, Nov-09, Volume: 144, Issue:45 Topics: Adrenergic alpha-Antagonists; Diagnosis, Differential; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia	2003
An update on the use of 5alpha-reductase inhibitors. Drugs of today (Barcelona, Spain : 1998), 2004, Volume: 40, Issue:3 Topics: Adrenergic alpha-Antagonists; Azasteroids; Cholestenone 5 alpha-Reductase; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Isoenzymes; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2004
Proscar and propecia--a therapeutic perspective. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:7 Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2004
The use of baseline clinical measures to predict those at risk for progression of benign prostatic hyperplasia. Current urology reports, 2004, Volume: 5, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Risk; Urologic Diseases	2004
The role of 5-alpha-reductase inhibition as monotherapy in view of the MTOPS data. Current urology reports, 2004, Volume: 5, Issue:4 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2004
After ALLHAT: doxazosin for the treatment of benign prostatic hyperplasia. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:9 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Delivery Systems; Drug Therapy, Combination; Erectile Dysfunction; Finasteride; Humans; Male; Prostatic Hyperplasia	2004
Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. The Journal of urology, 2004, Volume: 172, Issue:4 Pt 1 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Clinical Trials as Topic; Dihydrotestosterone; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Treatment Outcome; Urinary Bladder Neck Obstruction	2004
Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU international, 2004, Volume: 94, Issue:9 Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Doxazosin; Drug Combinations; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Treatment Outcome; Urinary Retention	2004
Saw palmetto and finasteride in the treatment of category-III prostatitis/chronic pelvic pain syndrome. Current urology reports, 2005, Volume: 6, Issue:4 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Enzyme Inhibitors; Finasteride; Humans; Male; Pelvic Pain; Phytotherapy; Plant Extracts; Prostatic Hyperplasia; Prostatitis; Serenoa; Syndrome; Treatment Outcome	2005
Selecting therapy for maintaining sexual function in patients with benign prostatic hyperplasia. BJU international, 2005, Volume: 96, Issue:3 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Humans; Male; Penile Erection; Prostatic Hyperplasia; Sexual Dysfunction, Physiological	2005
[Is tumour grade applicable to finasteride-treated prostate cancer?]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2005, Volume: 15, Issue:3 Topics: 5-alpha Reductase Inhibitors; Animals; Atrophy; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Staging; Prostate; Prostatic Hyperplasia; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms	2005
Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting. Comprehensive therapy, 2005,Fall, Volume: 31, Issue:3 Topics: Adrenergic alpha-Antagonists; Azasteroids; Clinical Trials as Topic; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Primary Health Care; Prostatic Hyperplasia; Sexual Dysfunction, Physiological; Urination Disorders	2005
[5alpha-dihydrotestosterone (DHT)]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 8 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Biomarkers; Diagnostic Techniques, Endocrine; Dihydrotestosterone; Enzyme Inhibitors; Female; Feminization; Finasteride; Humans; Isoenzymes; Male; Prostatic Hyperplasia; Radioimmunoassay; Receptors, Androgen	2005
Emerging drug therapies for benign prostatic hyperplasia. Expert opinion on emerging drugs, 2006, Volume: 11, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Antineoplastic Agents; Calcitriol; Cell Proliferation; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Indazoles; Male; Naphthalenes; Phytotherapy; Piperazines; Plant Extracts; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Receptors, Adrenergic, alpha-1; Serenoa	2006
Treatment and pharmacologic management of BPH in the context of common comorbidities. The American journal of managed care, 2006, Volume: 12, Issue:5 Suppl Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Comorbidity; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Global Health; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome	2006
Should finasteride be used to prevent prostate cancer? Current treatment options in oncology, 2006, Volume: 7, Issue:5 Topics: Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2006
Medical treatment of benign prostatic hyperplasia. Postgraduate medical journal, 2007, Volume: 83, Issue:976 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prostatic Hyperplasia	2007
Ockham's razor and selective androgen receptor modulators (SARMs): are we overlooking the role of 5alpha-reductase? Molecular interventions, 2007, Volume: 7, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Enzyme Inhibitors; Female; Finasteride; Forecasting; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Androgen; Testosterone; Tissue Distribution	2007
A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clinical therapeutics, 2007, Volume: 29, Issue:1 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Azasteroids; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	2007
Benign prostatic hyperplasia: when to 'watch and wait,' when and how to treat. Cleveland Clinic journal of medicine, 2007, Volume: 74 Suppl 3 Topics: Adrenergic alpha-Antagonists; Azasteroids; Diagnosis, Differential; Disease Progression; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Observation; Prostatic Hyperplasia; Time Factors	2007
Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia. Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:9 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2007
5alpha-reductase inhibition for men with enlarged prostate. Journal of the American Academy of Nurse Practitioners, 2007, Volume: 19, Issue:8 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Decision Trees; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Long-Term Care; Male; Nurse Practitioners; Nurse's Role; Nursing Assessment; Palpation; Patient Selection; Practice Guidelines as Topic; Primary Health Care; Prostatic Hyperplasia; Severity of Illness Index; Treatment Outcome; Urodynamics	2007
[Benign prostatic hyperplasia: medical therapy]. MMW Fortschritte der Medizin, 2007, Aug-16, Volume: 149, Issue:33-34 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Disease Progression; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Muscarinic Antagonists; Phosphodiesterase Inhibitors; Phytotherapy; Plant Extracts; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome	2007
Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clinical interventions in aging, 2006, Volume: 1, Issue:4 Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Combinations; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urinary Tract; Urodynamics	2006
FPIN's clinical inquiries. Medical treatment of benign prostatic hyperplasia. American family physician, 2008, Mar-01, Volume: 77, Issue:5 Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Antineoplastic Agents; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Practice Guidelines as Topic; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Treatment Outcome	2008
Five-alpha-reductase Inhibitors for prostate cancer prevention. The Cochrane database of systematic reviews, 2008, Apr-16, Issue:2 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2008
Current status of 5alpha-reductase inhibitors in the treatment of benign hyperplasia of prostate. Indian journal of medical sciences, 2008, Volume: 62, Issue:4 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androgens; Azasteroids; Cholestenone 5 alpha-Reductase; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Treatment Outcome	2008
The effect of finasteride on prostate specific antigen: review of available data. The Journal of urology, 1996, Volume: 155, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adult; Age Factors; Aged; Aged, 80 and over; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Reference Values; Sensitivity and Specificity; Time Factors	1996
Finasteride. The New England journal of medicine, 1994, Jan-13, Volume: 330, Issue:2 Topics: Acne Vulgaris; Alopecia; Androgens; Finasteride; Hirsutism; Humans; Male; Oxidoreductases; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms	1994
Endocrine therapies for symptomatic benign prostatic hyperplasia. Urology, 1994, Volume: 43, Issue:2 Suppl Topics: Androgen Antagonists; Antineoplastic Agents; Aromatase Inhibitors; Clinical Trials as Topic; Finasteride; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Hyperplasia	1994
5 alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. Recent progress in hormone research, 1994, Volume: 49 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Clinical Trials, Phase III as Topic; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia	1994
[Finasteride in the treatment of benign prostatic hypertrophy]. Journal d'urologie, 1993, Volume: 99, Issue:6 Topics: Finasteride; Humans; Male; Prostatic Hyperplasia	1993
[Newly approved specialty drugs in Austria and new knowledge about already available specialty drugs. Proscar film tablets (Finasterid, MSD)]. Wiener klinische Wochenschrift, 1994, Volume: 106, Issue:10 Topics: 5-alpha Reductase Inhibitors; Austria; Clinical Trials as Topic; Dihydrotestosterone; Drug Approval; Finasteride; Humans; Male; Prostatic Hyperplasia; Tablets	1994
5 alpha-reductase inhibitors and prostatic disease. Clinical endocrinology, 1994, Volume: 41, Issue:2 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgens; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Finasteride; Humans; Male; Prostate; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms; Testosterone	1994
Benign prostatic hyperplasia. Medical and minimally invasive treatment options. The New England journal of medicine, 1995, Jan-12, Volume: 332, Issue:2 Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Hyperthermia, Induced; Male; Oxidoreductases; Prostatectomy; Prostatic Hyperplasia; Stents	1995
Benign prostatic hyperplasia: dihydrotestosterone and 5 alpha-reductase inhibition therapy. Progress in clinical and biological research, 1994, Volume: 386 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 5; Finasteride; Humans; Male; Multicenter Studies as Topic; Prostatic Hyperplasia	1994
Pharmacological treatment of benign prostatic hyperplasia with finasteride: a clinical review. Archivos espanoles de urologia, 1994, Volume: 47, Issue:9 Topics: Clinical Trials, Phase III as Topic; Finasteride; Humans; Male; Prostatic Hyperplasia	1994
Pathogenesis and medical management of benign prostatic hyperplasia. Seminars in nephrology, 1994, Volume: 14, Issue:6 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Androgen Antagonists; Finasteride; Humans; Male; Mass Screening; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms	1994
Medical management of benign prostatic hypertrophy. Comprehensive therapy, 1994, Volume: 20, Issue:12 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	1994
Therapeutic controversies: clinical treatment of benign prostatic hyperplasia. The Journal of clinical endocrinology and metabolism, 1995, Volume: 80, Issue:3 Topics: Adrenergic alpha-Antagonists; Cholestenone 5 alpha-Reductase; Clinical Trials as Topic; Drug Therapy, Combination; Finasteride; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Oxidoreductases; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin	1995
The role of community-based longitudinal studies in evaluating treatment effects. Example: benign prostatic hyperplasia. Medical care, 1995, Volume: 33, Issue:4 Suppl Topics: Community Health Planning; Data Collection; Finasteride; Humans; Longitudinal Studies; Male; Minnesota; Outcome Assessment, Health Care; Patient Acceptance of Health Care; Prostate-Specific Antigen; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Research Design	1995
[Drug therapy for prostatic hyperplasia]. Duodecim; laaketieteellinen aikakauskirja, 1993, Volume: 109, Issue:20 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgens; Dihydrotestosterone; Finasteride; Humans; Male; Prostatic Hyperplasia	1993
Benign prostatic hyperplasia. Hormonal treatment. The Urologic clinics of North America, 1995, Volume: 22, Issue:2 Topics: Androgen Antagonists; Androgens; Cholestenone 5 alpha-Reductase; Finasteride; Humans; Male; Oxidoreductases; Prostatic Hyperplasia	1995
Benign prostatic hyperplasia. Disease-a-month : DM, 1995, Volume: 41, Issue:7 Topics: Adrenergic alpha-Antagonists; Aging; Dihydrotestosterone; Finasteride; Humans; Male; Prostate; Prostatectomy; Prostatic Hyperplasia; Urodynamics	1995
Alpha 1-blockers vs 5 alpha-reductase inhibitors in benign prostatic hyperplasia. A comparative review. Drugs & aging, 1995, Volume: 6, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Double-Blind Method; Finasteride; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	1995
Finasteride and benign prostatic hyperplasia. Drug and therapeutics bulletin, 1995, Volume: 33, Issue:3 Topics: Finasteride; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	1995
Finasteride: a 5 alpha-reductase inhibitor. Clinical pharmacy, 1993, Volume: 12, Issue:1 Topics: 5-alpha Reductase Inhibitors; Aged; Androstenes; Azasteroids; Finasteride; Humans; Male; Prostatic Hyperplasia	1993
Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists. Mayo Clinic proceedings, 1993, Volume: 68, Issue:7 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstenes; Azasteroids; Finasteride; Humans; Male; Prostatic Hyperplasia	1993
Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. Drugs, 1993, Volume: 46, Issue:1 Topics: Animals; Drug Evaluation; Drug Interactions; Drug Tolerance; Finasteride; Humans; Male; Prostatic Hyperplasia	1993
Benign prostatic hyperplasia. New concepts in the 1990s. Postgraduate medicine, 1993, Nov-01, Volume: 94, Issue:6 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Catheterization; Finasteride; Humans; Hyperthermia, Induced; Laser Therapy; Male; Medical History Taking; Microwaves; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; Stents; Urinary Tract Infections; Urination Disorders; Urodynamics	1993
[The current principles of the conservative treatment of patients with benign prostatic hypertrophy]. Khirurgiia, 1994, Volume: 47, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Aromatase Inhibitors; Delayed-Action Preparations; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia	1994
[Medical treatment of benign hypertrophy of the prostate]. Presse medicale (Paris, France : 1983), 1995, Oct-28, Volume: 24, Issue:32 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Plant Extracts; Prostatic Hyperplasia; Ultrasonography; Urinary Retention	1995
Finasteride: a clinical review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1995, Volume: 49, Issue:7-8 Topics: Alopecia; Enzyme Inhibitors; Finasteride; Hirsutism; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	1995
Current treatment of BPH. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1995, Volume: 49, Issue:7-8 Topics: Adrenergic alpha-Antagonists; Adult; Animals; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Plant Extracts; Prostatic Hyperplasia	1995
Benign prostatic hyperplasia: pathophysiology and pharmacological treatment. Current opinion in nephrology and hypertension, 1995, Volume: 4, Issue:5 Topics: Adrenergic alpha-Antagonists; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	1995
5alpha-reductase inhibitors/finasteride. The Prostate. Supplement, 1996, Volume: 6 Topics: Cholestenone 5 alpha-Reductase; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Oxidoreductases; Prostatic Hyperplasia	1996
[The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia]. Wiener medizinische Wochenschrift (1946), 1996, Volume: 146, Issue:8 Topics: 5-alpha Reductase Inhibitors; Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Treatment Outcome	1996
Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology, 1996, Volume: 48, Issue:3 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Predictive Value of Tests; Prostate; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	1996
Clinical pharmacokinetics and pharmacodynamics of finasteride. Clinical pharmacokinetics, 1996, Volume: 30, Issue:1 Topics: Drug Interactions; Finasteride; Humans; Male; Prostatic Hyperplasia	1996
Evaluation of men on finasteride. Seminars in urologic oncology, 1996, Volume: 14, Issue:3 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Mass Screening; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	1996
Treatment of benign prostatic hyperplasia: surgery, medical therapy, or watchful waiting. Comprehensive therapy, 1996, Volume: 22, Issue:9 Topics: Adrenergic alpha-Antagonists; Enzyme Inhibitors; Finasteride; Humans; Male; Medical History Taking; Patient Selection; Prostatectomy; Prostatic Hyperplasia; Treatment Outcome	1996
Assessment of the patient with benign prostatic hyperplasia. Comprehensive therapy, 1996, Volume: 22, Issue:9 Topics: Adrenergic alpha-Antagonists; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; Risk Factors; Severity of Illness Index; Urodynamics	1996
Medical management of benign prostatic hyperplasia: a review. East African medical journal, 1996, Volume: 73, Issue:7 Topics: Adrenergic alpha-Antagonists; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Treatment Outcome	1996
Benign prostatic hyperplasia: natural history, endocrine pathogenesis, and medical treatment with finasteride. The Mount Sinai journal of medicine, New York, 1996, Volume: 63, Issue:1 Topics: Adolescent; Adult; Aged; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Risk Factors; Urination Disorders	1996
The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology (Basel, Switzerland), 1996, Volume: 193, Issue:3 Topics: Acne Vulgaris; Adult; Alopecia; Amino Acids; Androgens; Cholestenone 5 alpha-Reductase; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 5; Dermatitis, Seborrheic; Enzyme Inhibitors; Epidermis; Epididymis; Fibroblasts; Finasteride; Hair Follicle; Hirsutism; Humans; Isoenzymes; Keratinocytes; Male; Oxidoreductases; Prostate; Prostatic Hyperplasia; Sebaceous Glands; Seminal Vesicles; Skin; Skin Diseases; Sweat Glands; Testosterone	1996
Measures of Proscar, Hytrin, and Cardura side effects. Neurourology and urodynamics, 1997, Volume: 16, Issue:1 Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia	1997
Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. Drugs & aging, 1997, Volume: 10, Issue:2 Topics: Adrenergic alpha-Antagonists; Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Prazosin; Prevalence; Prostatectomy; Prostatic Hyperplasia; Severity of Illness Index; Treatment Outcome	1997
[Significance of 5-alpha-reductase inhibitors in therapy of benign prostatic hyperplasia with mild to modern symptoms]. Der Urologe. Ausg. A, 1997, Volume: 36, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Isoenzymes; Male; Prostate; Prostatic Hyperplasia; Treatment Outcome; Urodynamics	1997
[Retrospective study of the treatment of 329 patients with prostatism syndrome and review of the literature]. Archivos espanoles de urologia, 1996, Volume: 49, Issue:9 Topics: Adrenergic alpha-Antagonists; Aged; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Phytotherapy; Prostatic Hyperplasia; Retrospective Studies; Urinary Bladder Neck Obstruction	1996
Conservative non-instrumental treatment of benign prostatic hyperplasia. Urological research, 1997, Volume: 25 Suppl 2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Anticholesteremic Agents; Controlled Clinical Trials as Topic; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Plant Extracts; Prostatic Hyperplasia	1997
Prostate disease in older men: 1. Benign hyperplasia. Hospital practice (1995), 1997, May-15, Volume: 32, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction	1997
Benign prostatic hyperplasia in elderly men. What are the special issues in treatment? Postgraduate medicine, 1997, Volume: 101, Issue:5 Topics: Adrenergic alpha-Antagonists; Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatectomy; Prostatic Hyperplasia	1997
Benign prostatic hypertrophy. Current therapy in endocrinology and metabolism, 1997, Volume: 6 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	1997
Benign prostatic hyperplasia. The American journal of the medical sciences, 1997, Volume: 314, Issue:4 Topics: Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatectomy; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Urinary Bladder; Urination; Urination Disorders	1997
Medical management of benign prostatic hyperplasia. Urologic nursing, 1997, Volume: 17, Issue:4 Topics: Adrenergic alpha-Antagonists; Androgen Antagonists; Antineoplastic Agents, Hormonal; Finasteride; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Hyperplasia	1997
A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia. Drug safety, 1998, Volume: 18, Issue:3 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	1998
Meta-analysis of randomized clinical trials of finasteride. Urology, 1998, Volume: 51, Issue:4A Suppl Topics: Finasteride; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	1998
Some remarks on the epidemiology of acute urinary retention. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 1998, Volume: 70, Issue:2 Topics: Acute Disease; Adult; Age Distribution; Aged; Alcohol Drinking; Anesthetics, General; Cohort Studies; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Middle Aged; Prevalence; Prostatic Hyperplasia; Risk Factors; Urinary Retention; Urodynamics	1998
Pharmacologic therapy for prostatism. Mayo Clinic proceedings, 1998, Volume: 73, Issue:6 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Long-Term Care; Male; Middle Aged; Prostatic Hyperplasia; Treatment Outcome; Urinary Bladder Neck Obstruction	1998
[5 alpha-reductase and prostate]. Annales d'endocrinologie, 1997, Volume: 58, Issue:5 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Cell Division; Cells, Cultured; Enzyme Inhibitors; Finasteride; Gene Expression Regulation, Enzymologic; Growth Substances; Humans; Isoenzymes; Male; Mice; Prostate; Prostatic Hyperplasia	1997
Obstructive benign prostatic hyperplasia: therapeutical aspects. European urology, 1998, Volume: 34 Suppl 1 Topics: Adrenergic alpha-Antagonists; Combined Modality Therapy; Costs and Cost Analysis; Enzyme Inhibitors; Finasteride; Humans; Male; Patient Satisfaction; Phenoxybenzamine; Prognosis; Prostatectomy; Prostatic Hyperplasia; Treatment Outcome	1998
Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA, 1998, Nov-11, Volume: 280, Issue:18 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Plant Extracts; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Serenoa	1998
[Medical-economic models of benign prostatic hypertrophy]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1998, Volume: 8, Issue:6 Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Clinical Trials as Topic; Costs and Cost Analysis; Endoscopy; Enzyme Inhibitors; Finasteride; Humans; Life Expectancy; Male; Markov Chains; Middle Aged; Models, Theoretical; Monte Carlo Method; Placebos; Probability; Prostatectomy; Prostatic Hyperplasia; Urinary Retention	1998
The medical management of lower urinary tract symptoms and benign prostatic hyperplasia. The Urologic clinics of North America, 1998, Volume: 25, Issue:4 Topics: Adrenergic alpha-Antagonists; Enzyme Inhibitors; Finasteride; Forecasting; Humans; Male; Oxidoreductases; Plant Extracts; Prostatic Hyperplasia; Urination Disorders	1998
Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. Drugs, 1999, Volume: 57, Issue:4 Topics: Controlled Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quality of Life	1999
Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology, 1999, Volume: 53, Issue:6 Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Placebo Effect; Prostatic Hyperplasia; Quality of Life	1999
[New therapeutic trends in benign hypertrophy of the prostate]. Chirurgie; memoires de l'Academie de chirurgie, 1999, Volume: 124, Issue:3 Topics: Adrenergic alpha-Antagonists; Catheter Ablation; Electrosurgery; Endoscopy; Enzyme Inhibitors; Evaluation Studies as Topic; Finasteride; Hot Temperature; Humans; Laser Therapy; Male; Microwaves; Phytotherapy; Prospective Studies; Prostatectomy; Prostatic Hyperplasia; Prosthesis Implantation; Randomized Controlled Trials as Topic; Ultrasonic Therapy	1999
Quality-of-life aspects in urology - benign prostatic hyperplasia. World journal of urology, 1999, Volume: 17, Issue:4 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Enzyme Inhibitors; Finasteride; Humans; Hyperthermia, Induced; Laser Therapy; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Quality of Life	1999
Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy. The Urologic clinics of North America, 1999, Volume: 26, Issue:3 Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Enzyme Inhibitors; Finasteride; Humans; Immunohistochemistry; Male; Prostatic Hyperplasia; Prostatic Neoplasms	1999
Finasteride in the treatment of benign prostatic hypertrophy: an update. New indications for finasteride therapy. Scandinavian journal of urology and nephrology. Supplementum, 1999, Volume: 203 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	1999
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. European urology, 2000, Volume: 37, Issue:4 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Aging; Clinical Trials as Topic; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prognosis; Prostatic Hyperplasia; Sensitivity and Specificity	2000
Medical therapy for benign prostatic hyperplasia: a review of the literature. European urology, 2000, Volume: 38, Issue:1 Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin	2000
Finasteride revisited: Proscar for the prostate and Propecia for the pate. Harvard men's health watch, 2000, Volume: 4, Issue:12 Topics: Adrenergic alpha-Antagonists; Alopecia; Enzyme Inhibitors; Finasteride; Humans; Male; Minoxidil; Prostatic Hyperplasia	2000
Transurethral microwave thermotherapy: an alternative to medical management in patients with benign prostatic hyperplasia? Journal of endourology, 2000, Volume: 14, Issue:8 Topics: Adrenergic alpha-Antagonists; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Humans; Hyperthermia, Induced; Male; Microwaves; Oxidoreductases; Prostatic Hyperplasia	2000
[Drugs for the treatment of benign prostatic hypertrophy]. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2000, Volume: 52, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Androgen Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Muscle, Smooth; Plant Extracts; Prazosin; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Serenoa; Sulfonamides; Tamsulosin; Urinary Bladder Neck Obstruction; Urodynamics	2000
Medical treatment modalities for lower urinary tract symptoms: what are the relevant differences in randomised controlled trials? European urology, 2000, Volume: 38 Suppl 1 Topics: Finasteride; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Urination Disorders	2000
Minimally invasive procedures as an alternative to medical management for lower urinary tract symptoms of benign prostatic hyperplasia. Current opinion in urology, 2001, Volume: 11, Issue:1 Topics: Adrenergic alpha-Antagonists; Combined Modality Therapy; Diathermy; Enzyme Inhibitors; Finasteride; Humans; Male; Microwaves; Patient Selection; Prostatic Hyperplasia; Urination Disorders	2001
Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics, 2001, Volume: 2, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Finasteride; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Androgen	2001
Enlarged prostate gland. Many treatment options. Mayo Clinic health letter (English ed.), 2001, Volume: 19, Issue:4 Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Minimally Invasive Surgical Procedures; Prostatic Hyperplasia; Transurethral Resection of Prostate	2001
Clinical application of 5alpha-reductase inhibitors. Journal of endocrinological investigation, 2001, Volume: 24, Issue:3 Topics: 5-alpha Reductase Inhibitors; Alopecia; Enzyme Inhibitors; Female; Finasteride; Hirsutism; Humans; Isoenzymes; Male; Pregnancy; Prostate; Prostatic Hyperplasia; Scalp; Skin	2001
Pharmacological management of benign prostatic hyperplasia. The Central African journal of medicine, 2000, Volume: 46, Issue:8 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Diagnosis, Differential; Family Practice; Finasteride; Humans; Male; Patient Selection; Primary Health Care; Prostatic Hyperplasia; Referral and Consultation; Severity of Illness Index; Urology	2000
Benign prostatic hyperplasia and erectile dysfunction--is there a link? Current medical research and opinion, 2000, Volume: 16 Suppl 1 Topics: Adrenergic alpha-Antagonists; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Humans; Male; Postoperative Complications; Prostatic Hyperplasia; Transurethral Resection of Prostate	2000
Benign prostatic hyperplasia. The Saudi perspective in the year 2000. Saudi medical journal, 2000, Volume: 21, Issue:10 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Age Distribution; Age of Onset; Aged; Finasteride; Humans; Male; Mass Screening; Middle Aged; Needs Assessment; Population Surveillance; Prazosin; Prostatectomy; Prostatic Hyperplasia; Risk Factors; Saudi Arabia; Treatment Outcome; Urology; Workload	2000
Prevention of prostate cancer. Hematology/oncology clinics of North America, 2001, Volume: 15, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adenocarcinoma; Androgen Antagonists; Androgens; Animals; Anticarcinogenic Agents; Antioxidants; Carotenoids; Case-Control Studies; Cohort Studies; Dietary Fats; Double-Blind Method; Enzyme Inhibitors; Finasteride; Genetic Predisposition to Disease; Humans; Incidence; Insulin-Like Growth Factor I; Life Style; Lycopene; Male; Mice; Mice, Transgenic; Micronutrients; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Hyperplasia; Prostatic Neoplasms; Racial Groups; Randomized Controlled Trials as Topic; Risk Factors; Selenium; Soybean Proteins; Vitamin D; Vitamin E	2001
Managing benign prostatic hyperplasia. The Practitioner, 2001, Volume: 245, Issue:1627 Topics: Adrenergic alpha-Antagonists; Enzyme Inhibitors; Finasteride; Humans; Male; Mass Screening; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia	2001
Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions. PharmacoEconomics, 2001, Volume: 19, Issue:11 Topics: Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Transurethral Resection of Prostate; Treatment Outcome	2001
5alpha-reductase activity in the prostate. Urology, 2001, Volume: 58, Issue:6 Suppl 1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Cryptorchidism; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Forecasting; Humans; Infertility, Male; Isoenzymes; Male; Mice; Mice, Knockout; Mutation; Penile Erection; Penis; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Androgen; Testis; Tumor Cells, Cultured	2001
5alpha-reductase inhibitors: what role should they play? Urology, 2001, Volume: 58, Issue:6 Suppl 1 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prazosin; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic	2001
Transurethral resection of the prostate: the new old standard. Current opinion in urology, 2002, Volume: 12, Issue:1 Topics: Blood Loss, Surgical; Enzyme Inhibitors; Ethanol; Exercise Therapy; Finasteride; Glycine; Humans; Laser Therapy; Male; Pelvic Floor; Preoperative Care; Prostate; Prostatic Hyperplasia; Solvents; Therapeutic Irrigation; Transurethral Resection of Prostate; Treatment Outcome	2002
Initial choices and final outcomes in lower urinary tract symptoms. European urology, 2001, Volume: 40 Suppl 4 Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome; Urinary Retention	2001
Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU international, 2002, Volume: 89, Issue:3 Topics: Adrenergic alpha-Antagonists; Aged; Drug Combinations; Enzyme Inhibitors; Finasteride; Humans; Male; Patient Dropouts; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic; Sulfonamides; Tamsulosin; Urinary Retention; Urination	2002
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World journal of urology, 2002, Volume: 19, Issue:6 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Administration, Oral; Aged; Aging; Azasteroids; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Administration Schedule; Dutasteride; Finasteride; Humans; Male; Middle Aged; Multicenter Studies as Topic; Probability; Prognosis; Prostatic Hyperplasia; Treatment Outcome	2002
Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions. Urology, 2002, Volume: 59, Issue:6 Topics: Acute Disease; Adrenergic alpha-Antagonists; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Incidence; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Urinary Retention	2002
Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons. Current urology reports, 2001, Volume: 2, Issue:4 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2001
The clinical role of alpha-blockers in the treatment of benign prostatic hyperplasia. Current urology reports, 2000, Volume: 1, Issue:2 Topics: Adrenergic alpha-Antagonists; Cardiovascular Physiological Phenomena; Drug Therapy, Combination; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Humans; Male; Prostatic Hyperplasia	2000
Update on the medical management of benign prostatic hyperplasia. International urology and nephrology, 2002, Volume: 33, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Administration, Oral; Aged; Biopsy, Needle; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Treatment Outcome	2002
Finasteride for benign prostatic hyperplasia. American family physician, 1992, Volume: 46, Issue:5 Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Androstenes; Azasteroids; Dihydrotestosterone; Finasteride; Humans; Male; Prostatic Hyperplasia	1992
Benign prostatic hyperplasia: drug and nondrug therapies. Geriatrics, 1992, Volume: 47, Issue:12 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androgen Antagonists; Androstenes; Azasteroids; Catheterization; Finasteride; Humans; Hyperthermia, Induced; Male; Prostatectomy; Prostatic Hyperplasia	1992
[Prostatic adenoma: new drugs, new surgical techniques]. Medizinische Monatsschrift fur Pharmazeuten, 1992, Volume: 15, Issue:12 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androstenes; Azasteroids; Cystoscopes; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatectomy; Prostatic Hyperplasia; Stents	1992
Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors. Journal of cellular biochemistry. Supplement, 1992, Volume: 16H Topics: 5-alpha Reductase Inhibitors; Aged; Androgens; Androstenes; Animals; Azasteroids; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms	1992
Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. The Urologic clinics of North America, 1990, Volume: 17, Issue:3 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstenes; Azasteroids; Finasteride; Flutamide; Humans; Luteinizing Hormone; Male; Orchiectomy; Prostatic Hyperplasia	1990
The clinical development of a 5 alpha-reductase inhibitor, finasteride. The Journal of steroid biochemistry and molecular biology, 1990, Nov-20, Volume: 37, Issue:3 Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Drug Evaluation; Finasteride; Humans; Male; Prostatic Hyperplasia	1990
Dual control by androgens and peptide growth factors of prostatic growth in human benign prostatic hyperplasia. Molecular and cellular endocrinology, 1991, Volume: 78, Issue:1-2 Topics: 5-alpha Reductase Inhibitors; Androgens; Androstenes; Azasteroids; Carcinoma; Cell Division; Cells, Cultured; Dihydrotestosterone; Epidermal Growth Factor; Finasteride; Gonadotropin-Releasing Hormone; Growth Substances; Humans; Insulin-Like Growth Factor I; Male; Peptides; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Tumor Cells, Cultured	1991

Trials

176 trial(s) available for finasteride and Adenoma, Prostatic

Article	Year
Safety profile of colocasia esculenta tuber extracts in benign prostate hyperplasia. BMC complementary medicine and therapies, 2023, Jun-08, Volume: 23, Issue:1 Topics: Animals; Colocasia; Finasteride; Hyperplasia; Male; Plant Extracts; Prostate; Prostatic Hyperplasia; Rats; Saline Solution; Testosterone Propionate	2023
Hormonal manipulation with finasteride or oral contraception does not influence incidence of renal cell carcinoma. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2018, Volume: 27, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Carcinoma, Renal Cell; Colorectal Neoplasms; Contraception; Contraceptives, Oral; Dutasteride; Female; Finasteride; Follow-Up Studies; Humans; Incidence; Kidney Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors; Self Report	2018
Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Inflammopharmacology, 2017, Volume: 25, Issue:4 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Drug Therapy, Combination; Fatty Acids, Omega-3; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Single-Blind Method; Sulfonamides; Tamsulosin; Treatment Outcome; Urological Agents	2017
Transurethral Resection of Prostate and Bleeding: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial to See the Efficacy of Short-Term Use of Finasteride and Dutasteride on Operative Blood Loss and Prostatic Microvessel Density. Journal of endourology, 2017, Volume: 31, Issue:9 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Dutasteride; Finasteride; Humans; Male; Microvessels; Middle Aged; Preoperative Care; Prospective Studies; Prostate; Prostatic Hyperplasia; Time Factors; Transurethral Resection of Prostate; Treatment Outcome	2017
Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial. The Journal of urology, 2018, Volume: 200, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Cystoscopy; Disease Progression; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Hyperthermia, Induced; Male; Middle Aged; Organ Size; Prostate; Prostatic Hyperplasia; Steam; Time Factors; Treatment Outcome	2018
Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs. Theriogenology, 2018, Jul-01, Volume: 114 Topics: Animals; Case-Control Studies; Dog Diseases; Dogs; Finasteride; Male; Prostate; Prostatic Hyperplasia; Urological Agents	2018
Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study. The Journal of urology, 2019, Volume: 202, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Biopsy; Cohort Studies; Disease Progression; Doxazosin; Drug Therapy, Combination; Fibrosis; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Time Factors; Treatment Outcome	2019
Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. The Journal of urology, 2014, Volume: 191, Issue:3 Topics: Aged; Aged, 80 and over; Carbolines; Double-Blind Method; Drug Therapy, Combination; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urological Agents	2014
Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. The Journal of urology, 2014, Volume: 191, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Sexuality; Surveys and Questionnaires; Treatment Outcome; Urination	2014
Randomized controlled trial on the efficacy of bladder training before removing the indwelling urinary catheter in patients with acute urinary retention associated with benign prostatic hyperplasia. Scandinavian journal of urology, 2014, Volume: 48, Issue:4 Topics: Aged; Aged, 80 and over; Catheters, Indwelling; Combined Modality Therapy; Device Removal; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Muscle Tonus; Muscle, Smooth; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Bladder; Urinary Catheterization; Urinary Retention; Urological Agents	2014
5α-reductase type 1 modulates insulin sensitivity in men. The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:8 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adipose Tissue; Adult; Aged; Aged, 80 and over; Azasteroids; Blood Glucose; Body Composition; Double-Blind Method; Dutasteride; Finasteride; Humans; Insulin Resistance; Male; Middle Aged; Prostatic Hyperplasia; Young Adult	2014
Evaluation of the clinical indications, adverse drug reactions, and finasteride use in patients with benign prostatic hyperplasia in Poland. Pharmacological reports : PR, 2014, Volume: 66, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Finasteride; Humans; Male; Middle Aged; Poland; Prostatic Hyperplasia; Treatment Outcome	2014
Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. The journal of sexual medicine, 2015, Volume: 12, Issue:1 Topics: Carbolines; Coitus; Comorbidity; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2015
Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing f International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:6 Topics: 5-alpha Reductase Inhibitors; Aged; Double-Blind Method; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Organ Size; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatism; Severity of Illness Index; Tadalafil	2015
Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial. The Journal of urology, 2016, Volume: 195, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Incidence; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Time Factors	2016
Effect of Preoperative Finasteride on the Volume or Length Density of Prostate Vessels, Intraoperative, Postoperative Blood Loss during and after Monopolar Transurethral Resection of Prostate: A Dose Escalation Randomized Clinical Trial Using Stereolog Me Urology journal, 2016, Mar-05, Volume: 13, Issue:1 Topics: 5-alpha Reductase Inhibitors; Blood Loss, Surgical; Dose-Response Relationship, Drug; Finasteride; Follow-Up Studies; Humans; Incidence; Iran; Male; Postoperative Hemorrhage; Prostate; Prostatic Hyperplasia; Time Factors; Transurethral Resection of Prostate; Treatment Outcome	2016
The Effect of Two Weeks Preoperative Finasteride Therapy in Reducing Prostate Vascularity. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2016, Volume: 26, Issue:3 Topics: Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Humans; Male; Microcirculation; Middle Aged; Prostate; Prostatectomy; Prostatic Hyperplasia; Treatment Outcome; Vascular Endothelial Growth Factor A	2016
Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. The Journal of urology, 2008, Volume: 180, Issue:3 Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Time Factors; Ultrasonography	2008
[Clinical evaluation on fengweicao granule in treating benign prostatic hyperplasia]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2008, Volume: 28, Issue:5 Topics: Diuresis; Drugs, Chinese Herbal; Enzyme Inhibitors; Finasteride; Humans; Male; Medicine, Chinese Traditional; Prostatic Hyperplasia; Pteris	2008
Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. American journal of epidemiology, 2008, Dec-15, Volume: 168, Issue:12 Topics: Aged; Finasteride; Follow-Up Studies; Gonadal Steroid Hormones; Humans; Incidence; Male; Middle Aged; Prevalence; Prognosis; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies; Sex Hormone-Binding Globulin; Surveys and Questionnaires; Time Factors; United States	2008
Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy. Scandinavian journal of urology and nephrology, 2009, Volume: 43, Issue:3 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Azasteroids; Botulinum Toxins, Type A; Cholestenone 5 alpha-Reductase; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Treatment Failure	2009
Comparative effect of finasteride and dutasteride on chromogranin A levels. Anticancer research, 2010, Volume: 30, Issue:11 Topics: 5-alpha Reductase Inhibitors; Aged; Azasteroids; Chromogranin A; Dutasteride; Finasteride; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Hyperplasia	2010
Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. The Journal of urology, 2011, Volume: 185, Issue:4 Topics: 5-alpha Reductase Inhibitors; Disease Progression; Finasteride; Humans; Male; Middle Aged; Organ Size; Prostatic Hyperplasia; Time Factors	2011
Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. American journal of epidemiology, 2011, Jun-15, Volume: 173, Issue:12 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Case-Control Studies; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Finasteride; Humans; Male; Middle Aged; Prevalence; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors	2011
Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. American journal of epidemiology, 2011, Jun-15, Volume: 173, Issue:12 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Case-Control Studies; Finasteride; Humans; Male; Middle Aged; Prevalence; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors	2011
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU international, 2011, Volume: 108, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Azasteroids; Double-Blind Method; Dutasteride; Finasteride; Gynecomastia; Humans; Hypertension; Male; Middle Aged; Organ Size; Prostatic Hyperplasia; Sexual Dysfunction, Physiological; Treatment Outcome	2011
Finasteride for treatment of refractory hemospermia: prospective placebo-controlled study. International urology and nephrology, 2012, Volume: 44, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adolescent; Adult; Double-Blind Method; Finasteride; Follow-Up Studies; Hemospermia; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Young Adult	2012
Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. European urology, 2012, Volume: 62, Issue:2 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Risk; Treatment Outcome	2012
Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. The Journal of urology, 2013, Volume: 190, Issue:1 Topics: Administration, Oral; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Drug Administration Schedule; Drug Therapy, Combination; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Reference Values; Severity of Illness Index; Statistics, Nonparametric; Time; Treatment Outcome	2013
Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. European urology, 2002, Volume: 42, Issue:1 Topics: Acute Disease; Adult; Area Under Curve; Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Predictive Value of Tests; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; ROC Curve; Surveys and Questionnaires; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Retention	2002
Effects of finasteride on vascular endothelial growth factor. Scandinavian journal of urology and nephrology, 2002, Volume: 36, Issue:3 Topics: 5-alpha Reductase Inhibitors; Blotting, Western; Endothelial Growth Factors; Enzyme Inhibitors; Finasteride; Humans; Immunohistochemistry; Lymphokines; Male; Microcirculation; Prospective Studies; Prostate; Prostatic Hyperplasia; Transurethral Resection of Prostate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002
Changes in molecular forms of prostate-specific antigen during treatment with finasteride. BJU international, 2002, Volume: 90, Issue:7 Topics: Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Hyperplasia	2002
Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology, 2002, Volume: 60, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urination	2002
The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. The Journal of urology, 2003, Volume: 169, Issue:1 Topics: Aged; Antigens, CD34; Endothelial Growth Factors; Finasteride; Hematuria; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Microcirculation; Neovascularization, Pathologic; Prospective Studies; Prostate; Prostatic Hyperplasia; Urethra; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology, 2003, Volume: 61, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Diuresis; Double-Blind Method; Doxazosin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Placebo Effect; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome	2003
Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology, 2003, Volume: 61, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Patient Dropouts; Prostatic Hyperplasia; Treatment Outcome	2003
Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology, 2003, Volume: 61, Issue:3 Topics: Aged; Double-Blind Method; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Humans; Incidence; Male; Middle Aged; Placebo Effect; Prostatic Hyperplasia; Severity of Illness Index; Sexual Dysfunctions, Psychological	2003
Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology, 2003, Volume: 61, Issue:4 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Placebos; Prostate; Prostatic Hyperplasia; Sexual Dysfunctions, Psychological; Treatment Outcome	2003
Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. The Journal of urology, 2003, Volume: 170, Issue:1 Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Urination Disorders	2003
Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology, 2003, Volume: 62, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Body Composition; Body Mass Index; Body Weight; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Sexual Dysfunction, Physiological; Testosterone; Treatment Outcome	2003
A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate cancer and prostatic diseases, 2003, Volume: 6, Issue:4 Topics: Aged; Aged, 80 and over; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Sexual Behavior; Sulfonamides; Tamsulosin; Urination Disorders	2003
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. The New England journal of medicine, 2003, Dec-18, Volume: 349, Issue:25 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Analysis of Variance; Disease Progression; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Severity of Illness Index	2003
Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. The Journal of urology, 2004, Volume: 171, Issue:3 Topics: Acute Disease; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Middle Aged; Prostatic Hyperplasia; Urinary Retention	2004
Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:5 Topics: Clinical Trials as Topic; Doxazosin; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin	2004
[Effect of finasteride on intraoperative bleeding and irrigating fluid absorption during transurethral resection of prostate: a quantitative study]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2004, Volume: 33, Issue:3 Topics: Absorption; Aged; Blood Loss, Surgical; Finasteride; Humans; Intraoperative Complications; Male; Middle Aged; Prostatic Hyperplasia; Therapeutic Irrigation; Transurethral Resection of Prostate	2004
Dutasteride: a potent dual inhibitor of 5-alpha-reductase for benign prostatic hyperplasia. Drugs of today (Barcelona, Spain : 1998), 2004, Volume: 40, Issue:8 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Administration, Oral; Animals; Azasteroids; Double-Blind Method; Drug Administration Schedule; Drug Evaluation, Preclinical; Dutasteride; Finasteride; Humans; Injections, Intravenous; Isoenzymes; Male; Middle Aged; Prostatic Hyperplasia; Spain	2004
Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). European urology, 2005, Volume: 47, Issue:1 Topics: Aged; Aged, 80 and over; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Lactones; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Sulfones; Urologic Diseases	2005
Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urologia internationalis, 2005, Volume: 74, Issue:1 Topics: Aged; Blood Loss, Surgical; Endoscopy; Finasteride; Humans; Male; Preoperative Care; Prostatic Hyperplasia	2005
Effects of finasteride on prostate volume and prostate-specific antigen. Journal of the Chinese Medical Association : JCMA, 2004, Volume: 67, Issue:11 Topics: Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Treatment Outcome	2004
Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:3 Topics: Age Factors; Aged; Anticoagulants; Aspirin; Finasteride; Hemoglobins; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Renal Insufficiency; Risk; Time Factors; Transurethral Resection of Prostate; Urethra; Warfarin	2005
Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. Scandinavian journal of urology and nephrology, 2005, Volume: 39, Issue:2 Topics: Aged; Aged, 80 and over; Blood Loss, Surgical; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Perioperative Care; Prospective Studies; Prostatectomy; Prostatic Hyperplasia; Time Factors; Treatment Outcome	2005
Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU international, 2005, Volume: 96, Issue:9 Topics: Aged; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Microcirculation; Prostate; Prostatic Hyperplasia; Treatment Outcome; Vascular Endothelial Growth Factor A	2005
Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. The Journal of urology, 2006, Volume: 175, Issue:1 Topics: Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Urination Disorders	2006
[Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2005, Volume: 15, Issue:6 Topics: Aged; Azasteroids; Dihydrotestosterone; Double-Blind Method; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prospective Studies; Prostatic Hyperplasia	2005
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. The Journal of urology, 2006, Volume: 175, Issue:4 Topics: Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Placebo Effect; Prostatic Hyperplasia; Treatment Outcome	2006
[Therapeutic effect of harnal and proscar in treating benign prostatic hyperplasia]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2005, Volume: 30, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urination Disorders; Urodynamics	2005
Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia. Urology, 2006, Volume: 68, Issue:2 Topics: Aged; Aged, 80 and over; Biomarkers; Cell Hypoxia; Enzyme Inhibitors; Finasteride; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Prospective Studies; Prostate; Prostatic Hyperplasia; Vascular Endothelial Growth Factor A	2006
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. Journal of the National Cancer Institute, 2006, Aug-16, Volume: 98, Issue:16 Topics: Aged; Area Under Curve; Biopsy; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Research Design; ROC Curve; Sensitivity and Specificity	2006
The effectiveness of a treatment protocol for male lower urinary tract symptoms in general practice: a practical randomised controlled trial. The British journal of general practice : the journal of the Royal College of General Practitioners, 2006, Volume: 56, Issue:533 Topics: Aged; Clinical Protocols; Cohort Studies; Enzyme Inhibitors; Family Practice; Finasteride; Humans; Male; Middle Aged; Netherlands; Practice Guidelines as Topic; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Retention; Urinary Tract Infections	2006
Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? The journal of sexual medicine, 2007, Volume: 4, Issue:6 Topics: Aged; Double-Blind Method; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Follow-Up Studies; Humans; Libido; Male; Middle Aged; Multivariate Analysis; Orgasm; Prostatic Hyperplasia; Sexual Behavior; Sexual Dysfunctions, Psychological; Surveys and Questionnaires	2007
Comparison of efficacy between Tamsulosin and Finasteride on symptomatic Benign Prostatic Hyperplasia. Mymensingh medical journal : MMJ, 2007, Volume: 16, Issue:2 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome	2007
The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. The Journal of urology, 2007, Volume: 178, Issue:5 Topics: Adrenergic alpha-Antagonists; Dose-Response Relationship, Drug; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Nocturia; Pilot Projects; Prostatic Hyperplasia; Treatment Outcome; Urodynamics	2007
[Comparison of different drugs on the treatment of benign prostate hyperplasia]. Zhonghua wai ke za zhi [Chinese journal of surgery], 2007, Jul-15, Volume: 45, Issue:14 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; Double-Blind Method; Doxazosin; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Plant Extracts; Prazosin; Prostate; Prostatic Hyperplasia; Quality of Life; Secale; Sulfonamides; Tamsulosin; Treatment Outcome	2007
Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia. Urologia internationalis, 2008, Volume: 80, Issue:2 Topics: Aged; Enzyme Inhibitors; Finasteride; Hematuria; Humans; Male; Microcirculation; Middle Aged; Neovascularization, Pathologic; Prospective Studies; Prostate; Prostatic Hyperplasia	2008
Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology, 1995, Volume: 46, Issue:5 Topics: Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Remission Induction	1995
Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group. Archives of internal medicine, 1994, Jan-10, Volume: 154, Issue:1 Topics: Adult; Aged; Double-Blind Method; Drug Tolerance; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Time Factors	1994
Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia. Results from the North American phase III clinical trial. The Urologic clinics of North America, 1993, Volume: 20, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia	1993
Effect of finasteride on prostate-specific antigen density. Urology, 1994, Volume: 43, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Finasteride; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Predictive Value of Tests; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Sensitivity and Specificity	1994
Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. The Finasteride Study Group. European urology, 1994, Volume: 25 Suppl 1 Topics: Aged; Dihydrotestosterone; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia	1994
Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology, 1994, Volume: 43, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Dihydrotestosterone; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Severity of Illness Index; Urodynamics	1994
Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group. The Journal of urology, 1994, Volume: 151, Issue:5 Topics: Aged; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Palpation; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	1994
[Finasteride in the treatment of benign prostatic hypertrophy]. Journal d'urologie, 1993, Volume: 99, Issue:6 Topics: Finasteride; Humans; Male; Prostatic Hyperplasia	1993
Clinical results with finasteride. Progress in clinical and biological research, 1994, Volume: 386 Topics: Biomarkers; Dihydrotestosterone; Double-Blind Method; Finasteride; Follow-Up Studies; Humans; Male; North America; Placebos; Prostate; Prostatic Hyperplasia; Time Factors; Urodynamics	1994
The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia. The Australian and New Zealand journal of surgery, 1995, Volume: 65, Issue:1 Topics: Aged; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Urodynamics	1995
Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostatic volume. British journal of urology, 1994, Volume: 74, Issue:5 Topics: Double-Blind Method; Finasteride; Humans; Magnetic Resonance Imaging; Male; Prostate; Prostatic Hyperplasia; Sensitivity and Specificity; Ultrasonography	1994
Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients. Urology, 1995, Volume: 45, Issue:2 Topics: Double-Blind Method; Finasteride; Follow-Up Studies; Humans; Male; Predictive Value of Tests; Prostatic Hyperplasia; Urodynamics	1995
[Ureteral jet during medical treatment of benign prostatic hypertrophy]. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 1994, Volume: 66, Issue:4 Suppl Topics: Aged; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Ultrasonography, Doppler, Color; Ureter; Urodynamics	1994
Differential suppression of serum prostatic acid phosphatase and prostate-specific antigen by 5-alpha-reductase inhibitor. British journal of urology, 1995, Volume: 75, Issue:5 Topics: Acid Phosphatase; Double-Blind Method; Finasteride; Follow-Up Studies; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia	1995
Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. European urology, 1995, Volume: 27, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Urination	1995
Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia. The Journal of urology, 1995, Volume: 154, Issue:4 Topics: Aged; Aged, 80 and over; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Time Factors; Urethral Obstruction; Urodynamics	1995
Endocrine therapy for benign prostatic hyperplasia in the 90's. Journal d'urologie, 1995, Volume: 101, Issue:1 Topics: Androstenedione; Aromatase Inhibitors; Controlled Clinical Trials as Topic; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Placebos; Prostatic Hyperplasia; Testolactone	1995
Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia. Urology, 1995, Volume: 46, Issue:4 Topics: Adrenergic alpha-Antagonists; Aged; Decision Trees; Enzyme Inhibitors; Finasteride; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Prazosin; Prostatectomy; Prostatic Hyperplasia; Severity of Illness Index	1995
Maximum urinary flow rate by uroflowmetry: automatic or visual interpretation. The Journal of urology, 1993, Volume: 149, Issue:2 Topics: 5-alpha Reductase Inhibitors; Aged; Androstenes; Artifacts; Azasteroids; Double-Blind Method; Finasteride; Humans; Male; Observer Variation; Prostatic Hyperplasia; Urodynamics	1993
Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia. The Journal of urology, 1993, Volume: 149, Issue:2 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androstenes; Azasteroids; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Urodynamics	1993
The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. The Prostate, 1993, Volume: 22, Issue:1 Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia	1993
The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. The Prostate, 1993, Volume: 22, Issue:1 Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Finasteride; Humans; Magnetic Resonance Imaging; Male; Prostate; Prostatic Hyperplasia	1993
The effect of finasteride in men with benign prostatic hyperplasia. The Journal of urology, 1993, Volume: 149, Issue:4 Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Double-Blind Method; Finasteride; Humans; Male; Prostatic Hyperplasia	1993
Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group. The Prostate, 1993, Volume: 22, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androstenes; Azasteroids; Dihydrotestosterone; Double-Blind Method; Drug Tolerance; Finasteride; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Testosterone; Ultrasonography; Urination	1993
Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study. European urology, 1993, Volume: 24, Issue:1 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androstenes; Azasteroids; Dihydrotestosterone; Dose-Response Relationship, Drug; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Pilot Projects; Prostate-Specific Antigen; Prostatic Hyperplasia; Time Factors; Urodynamics	1993
Androgen metabolism in men receiving finasteride before prostatectomy. The Journal of urology, 1993, Volume: 150, Issue:5 Pt 2 Topics: Androstane-3,17-diol; Combined Modality Therapy; Dihydrotestosterone; Double-Blind Method; Finasteride; Humans; Male; Preoperative Care; Prostate; Prostatectomy; Prostatic Hyperplasia; Testosterone	1993
Proscar: five-year experience. European urology, 1995, Volume: 28, Issue:4 Topics: Aged; Cholestenone 5 alpha-Reductase; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Oxidoreductases; Prostatic Hyperplasia	1995
Evidence for atrophy and apoptosis in the prostates of men given finasteride. The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:2 Topics: 5-alpha Reductase Inhibitors; Apoptosis; Atrophy; Dihydrotestosterone; DNA; Double-Blind Method; Enzyme Inhibitors; Epithelium; Finasteride; Humans; Male; Placebos; Prostate; Prostatic Hyperplasia; Transglutaminases	1996
Finasteride in the treatment of benign prostatic hyperplasia. Acta urologica Belgica, 1996, Volume: 64, Issue:1 Topics: Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia	1996
The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The New England journal of medicine, 1996, Aug-22, Volume: 335, Issue:8 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Oxidoreductases; Prazosin; Prostatic Hyperplasia; Treatment Outcome; Urodynamics	1996
Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia. Hinyokika kiyo. Acta urologica Japonica, 1996, Volume: 42, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Testosterone; Urodynamics	1996
Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group. The Prostate, 1996, Volume: 29, Issue:2 Topics: Aged; Anxiety; Double-Blind Method; Enzyme Inhibitors; Finasteride; Health Status; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quality of Life; Sexual Behavior; Surveys and Questionnaires	1996
The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1995, Volume: 56, Issue:6 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia	1995
Treating benign prostatic hyperplasia with finasteride in Chinese men: one-year experience. Journal of the Formosan Medical Association = Taiwan yi zhi, 1996, Volume: 95, Issue:8 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; China; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Statistics, Nonparametric; Taiwan	1996
Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. The Prostate, 1996, Volume: 29, Issue:4 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cholestenone 5 alpha-Reductase; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; International Cooperation; Male; Middle Aged; Oxidoreductases; Phytotherapy; Plant Extracts; Prostate; Prostatic Hyperplasia; Serenoa; Sexual Behavior; Treatment Outcome	1996
Effect of finasteride on free and total serum prostate-specific antigen in men with benign prostatic hyperplasia. British journal of urology, 1996, Volume: 78, Issue:3 Topics: Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Sensitivity and Specificity	1996
Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1996, Nov-01, Volume: 155, Issue:9 Topics: Aged; Aged, 80 and over; Canada; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Safety; Urination	1996
[Finanseride in symtomatic benign prostatic hyeprtrophy. A 2-year placebo-controlled study]. Ugeskrift for laeger, 1996, Sep-02, Volume: 158, Issue:36 Topics: Aged; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia	1996
The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1996, Volume: 28, Issue:10 Topics: 5-alpha Reductase Inhibitors; Aged; Androstenedione; Dihydrotestosterone; Enzyme Inhibitors; Epitestosterone; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Steroids; Testosterone	1996
Terazosin vs finasteride for BPH. The Journal of family practice, 1996, Volume: 43, Issue:6 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Combinations; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Placebos; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome; Urination	1996
[Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1996, Nov-10, Volume: 116, Issue:27 Topics: Aged; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Patient Dropouts; Prostatic Hyperplasia; Scandinavian and Nordic Countries	1996
Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Clinical endocrinology, 1997, Volume: 46, Issue:2 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androgens; Androstenedione; Dihydrotestosterone; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Testosterone	1997
Intra- and interobserver variability of MRI prostate volume measurements. The Prostate, 1997, May-01, Volume: 31, Issue:2 Topics: Aged; Finasteride; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prostate; Prostatic Hyperplasia	1997
Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. The Journal of urology, 1997, Volume: 157, Issue:6 Topics: Aged; Dihydrotestosterone; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Hyperplasia; Remission Induction; Ultrasonography	1997
Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia. The Prostate, 1997, May-15, Volume: 31, Issue:3 Topics: Enzyme Inhibitors; Finasteride; Follow-Up Studies; Hematuria; Humans; Male; Prospective Studies; Prostatic Hyperplasia; Recurrence	1997
Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology, 1997, Volume: 49, Issue:6 Topics: Acute Disease; Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Surgical Procedures, Operative; Urinary Retention	1997
[Treatment of benign prostatic hyperplasia with finasteride. Results after 7 years of follow-up]. Actas urologicas espanolas, 1997, Volume: 21, Issue:2 Topics: Double-Blind Method; Finasteride; Follow-Up Studies; Humans; Male; Prostatic Hyperplasia	1997
Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology, 1997, Volume: 50, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	1997
Pharmacotherapy of benign prostatic hyperplasia: inhibitor of 5 alpha-reductase. International urology and nephrology, 1997, Volume: 29, Issue:3 Topics: Aged; Aged, 80 and over; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Oxidoreductases; Prostatic Hyperplasia; Treatment Outcome	1997
[Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study]. Der Urologe. Ausg. A, 1997, Volume: 36, Issue:4 Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Finasteride; Humans; Long-Term Care; Male; Middle Aged; Plant Extracts; Prostatic Hyperplasia; Treatment Outcome; Urinary Bladder Neck Obstruction; Urodynamics	1997
[Therapy of benign prostatic hyperplasia: terazosin or finasteride?]. Praxis, 1997, Aug-20, Volume: 86, Issue:34 Topics: Adrenergic alpha-Antagonists; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Prazosin; Prospective Studies; Prostatic Hyperplasia; Urodynamics	1997
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. The New England journal of medicine, 1998, Feb-26, Volume: 338, Issue:9 Topics: 5-alpha Reductase Inhibitors; Aged; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Urinary Retention; Urination	1998
Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology, 1998, Volume: 51, Issue:2 Topics: Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Hematuria; Humans; Male; Prostatic Hyperplasia; Time Factors	1998
Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. British journal of urology, 1998, Volume: 81, Issue:3 Topics: Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Placebo Effect; Placebos; Prostatic Hyperplasia; Treatment Outcome; Urinary Retention; Urination	1998
Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group. European urology, 1998, Volume: 33, Issue:3 Topics: 5-alpha Reductase Inhibitors; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia; Urodynamics	1998
Comparative study of therapeutic effect of dibenyline, finasteride, and combination drugs for symptomatic benign prostatic hyperplasia. Urologia internationalis, 1998, Volume: 60, Issue:2 Topics: Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Phenoxybenzamine; Prospective Studies; Prostatic Hyperplasia; Quality of Life; Recurrence; Treatment Outcome; Urinary Retention; Urodynamics	1998
Effects of the 5 alpha-reductase inhibitor finasteride on serum levels of gonadal, adrenal, and hypophyseal hormones and its clinical significance: a prospective clinical study. Steroids, 1998, Volume: 63, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aldosterone; Androgens; Dehydroepiandrosterone; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Follicle Stimulating Hormone; Gonadotropins, Pituitary; Humans; Hydrocortisone; Luteinizing Hormone; Male; Middle Aged; Pregnenediones; Prospective Studies; Prostatic Hyperplasia; Testosterone	1998
Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology, 1998, Volume: 51, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Analysis of Variance; Double-Blind Method; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Linear Models; Longitudinal Studies; Male; Middle Aged; Placebos; Proportional Hazards Models; Prostate; Prostatic Hyperplasia; Urinary Retention; Urination	1998
Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. The Journal of urology, 1998, Volume: 159, Issue:2 Topics: Aged; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia	1998
Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology, 1998, Volume: 52, Issue:2 Topics: Aged; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Sensitivity and Specificity	1998
The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. British journal of cancer, 1998, Volume: 78, Issue:3 Topics: Adenocarcinoma; Aged; Biopsy; Cell Division; Enzyme Inhibitors; Epithelial Cells; Evaluation Studies as Topic; Finasteride; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms	1998
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. European urology, 1998, Volume: 34, Issue:3 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines	1998
The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The Journal of urology, 1998, Volume: 160, Issue:4 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Severity of Illness Index; Treatment Outcome	1998
Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. The Journal of urology, 1999, Volume: 161, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Enzyme Inhibitors; Finasteride; Humans; Isoenzymes; Male; Prostate; Prostatic Hyperplasia	1999
Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology, 1999, Volume: 53, Issue:3 Topics: Acute Disease; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Hyperplasia; Urinary Retention	1999
Long-term effects of finasteride on prostate tissue composition. Urology, 1999, Volume: 53, Issue:3 Topics: Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Time Factors	1999
Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. Urology, 1999, Volume: 53, Issue:4 Topics: Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Patient Dropouts; Prostatic Hyperplasia; Time Factors	1999
Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology, 1999, Volume: 53, Issue:4 Topics: Aged; Biopsy, Needle; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms; Time Factors	1999
Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group. The Journal of urology, 1999, Volume: 161, Issue:5 Topics: Aged; Double-Blind Method; Finasteride; Humans; Male; Pressure; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Urodynamics	1999
Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. The Prostate, 1999, Jun-01, Volume: 39, Issue:4 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Treatment Outcome; United States; United States Department of Veterans Affairs	1999
[Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume]. Archivos espanoles de urologia, 1999, Volume: 52, Issue:3 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	1999
Validation of a population pharmacokinetic/pharmacodynamic model for 5 alpha-reductase inhibitors. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 1999, Volume: 8, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Animals; Azasteroids; Bayes Theorem; Double-Blind Method; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Mice; Middle Aged; Models, Biological; Placebos; Prostatic Hyperplasia; Reproducibility of Results	1999
Continued improvement in pressure-flow parameters in men receiving finasteride for 2 years. Finasteride Urodynamics Study Group. Urology, 1999, Volume: 54, Issue:2 Topics: Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Time Factors; Urinary Bladder Neck Obstruction; Urodynamics	1999
Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology, 1999, Volume: 54, Issue:4 Topics: Aged; Double-Blind Method; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Hyperplasia; Quality of Life; Time Factors	1999
Improvement in androgenetic alopecia in 53-76-year-old men using oral finasteride. International journal of dermatology, 1999, Volume: 38, Issue:12 Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Aged; Alopecia; Double-Blind Method; Enzyme Inhibitors; Finasteride; Hair; Humans; Male; Middle Aged; Prostatic Hyperplasia	1999
Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5 . The Prostate, 2000, Feb-15, Volume: 42, Issue:3 Topics: Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Immunohistochemistry; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 4; Insulin-Like Growth Factor Binding Protein 5; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Male; Middle Aged; Prostate; Prostatic Hyperplasia	2000
A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. The Journal of urology, 2000, Volume: 163, Issue:2 Topics: Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Hematuria; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia	2000
Finasteride following balloon dilatation of the prostate. A double-blind, placebo-controlled, multicenter study. Annales chirurgiae et gynaecologiae, 1999, Volume: 88, Issue:4 Topics: Catheterization; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Treatment Outcome	1999
Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH). Journal of endocrinological investigation, 1999, Volume: 22, Issue:10 Suppl Topics: Aged; Body Composition; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Humans; Lipoproteins; Male; Middle Aged; Oxidoreductases; Prostatic Hyperplasia	1999
Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group. European urology, 2000, Volume: 37, Issue:5 Topics: Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Time Factors; Urinary Retention	2000
Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU international, 2000, Volume: 86, Issue:4 Topics: Aged; Aged, 80 and over; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Finasteride; Humans; Magnoliopsida; Male; Middle Aged; Organ Size; Phytotherapy; Plant Extracts; Prostatic Hyperplasia; Serenoa; Treatment Outcome; Urination Disorders; Urodynamics	2000
Changes in HDL-cholesterol and lipoprotein Lp(a) after 6-month treatment with finasteride in males affected by benign prostatic hyperplasia (BPH). Atherosclerosis, 2000, Volume: 152, Issue:1 Topics: Aged; Analysis of Variance; Cholesterol, HDL; Drug Administration Schedule; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Finasteride; Humans; Lipoprotein(a); Male; Middle Aged; Prostatic Hyperplasia; Reference Values	2000
Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group. Urology, 2000, Oct-01, Volume: 56, Issue:4 Topics: Aged; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Treatment Outcome; Urinary Retention	2000
Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. European urology, 2000, Volume: 38, Issue:5 Topics: Acute Disease; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Predictive Value of Tests; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Urinary Retention	2000
Prostatic expression of human 5alpha-reductase type 2 during finasteride therapy: a randomized, double-blind, placebo-controlled study. World journal of urology, 2000, Volume: 18, Issue:6 Topics: Aged; Aged, 80 and over; Biopsy; Cholestenone 5 alpha-Reductase; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; In Situ Hybridization; Isoenzymes; Male; Middle Aged; Oxidoreductases; Prostate; Prostatic Hyperplasia	2000
Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin for bladder outlet obstruction. Urologia internationalis, 2001, Volume: 66, Issue:2 Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction	2001
Effects of finasteride on size of the prostate gland and semen quality in dogs with benign prostatic hypertrophy. Journal of the American Veterinary Medical Association, 2001, Apr-15, Volume: 218, Issue:8 Topics: Animals; Dihydrotestosterone; Dog Diseases; Dogs; Double-Blind Method; Finasteride; Male; Prostate; Prostatic Hyperplasia; Radiography; Semen; Testosterone; Ultrasonography	2001
Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens. Urology, 2001, Volume: 57, Issue:5 Topics: Aged; Androgen Antagonists; Biopsy, Needle; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Placebos; Plant Extracts; Prostate; Prostatic Hyperplasia; Serenoa; Testosterone; Treatment Outcome	2001
[Long-term therapy of benign prostatic hyperplasia. Our experience]. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2001, Volume: 53, Issue:1 Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Finasteride; Follow-Up Studies; Humans; Male; Mepartricin; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Quinazolines; Time Factors	2001
Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology, 2001, Volume: 57, Issue:6 Topics: Aged; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia	2001
A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from BJU international, 2001, Volume: 88, Issue:1 Topics: Absorbable Implants; Aged; Aged, 80 and over; Combined Modality Therapy; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Lactic Acid; Male; Middle Aged; Pilot Projects; Polyesters; Polymers; Prostatic Hyperplasia; Stents; Treatment Outcome; Urinary Bladder Neck Obstruction; Urinary Retention	2001
Finasteride: a long-term follow-up in the treatment of recurrent hematuria associated with benign prostatic hyperplasia. Urologia internationalis, 2001, Volume: 67, Issue:1 Topics: Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Hematuria; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Recurrence; Time Factors	2001
Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology, 2001, Volume: 58, Issue:2 Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Administration Schedule; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia; Treatment Outcome	2001
Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology, 2001, Volume: 58, Issue:6 Topics: Absorption; Aged; Blood Loss, Surgical; Combined Modality Therapy; Double-Blind Method; Finasteride; Humans; Male; Microcirculation; Middle Aged; Pilot Projects; Prostate; Prostatic Hyperplasia; Transurethral Resection of Prostate	2001
The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia. BMC urology, 2002, Volume: 2 Topics: Finasteride; Humans; Male; Prospective Studies; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Urodynamics	2002
Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study. Urology, 2002, Volume: 59, Issue:3 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Cyproterone Acetate; Finasteride; Hematuria; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Recurrence	2002
Finasteride-induced prostatic involution by apoptosis in dogs with benign prostatic hypertrophy. American journal of veterinary research, 2002, Volume: 63, Issue:4 Topics: Animals; Apoptosis; Dog Diseases; Dogs; Double-Blind Method; Enzyme Inhibitors; Finasteride; In Situ Nick-End Labeling; Male; Prostatic Hyperplasia; Semen	2002
Possible autocrine loop of the epidermal growth factor system in patients with benign prostatic hyperplasia treated with finasteride: a placebo-controlled randomized study. BJU international, 2002, Volume: 89, Issue:6 Topics: Amphiregulin; Betacellulin; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Finasteride; Glycoproteins; Growth Substances; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Male; Prospective Studies; Prostatic Hyperplasia; Receptor, ErbB-2; Transforming Growth Factor alpha	2002
The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. The Journal of urology, 2002, Volume: 167, Issue:5 Topics: 5-alpha Reductase Inhibitors; Absorptiometry, Photon; Aged; Bone Density; Double-Blind Method; Finasteride; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Prostatic Hyperplasia	2002
Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1992, Volume: 24, Issue:10 Topics: 5-alpha Reductase Inhibitors; Aged; Androstenes; Azasteroids; Dose-Response Relationship, Drug; Double-Blind Method; Estradiol; Finasteride; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Prolactin; Prostatic Hyperplasia	1992
Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism. Clinical endocrinology, 1992, Volume: 37, Issue:5 Topics: 5-alpha Reductase Inhibitors; Absorptiometry, Photon; Aged; Androstenes; Azasteroids; Bone and Bones; Bone Density; Calcitriol; Calcium; Dihydrotestosterone; Double-Blind Method; Drug Administration Schedule; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia	1992
Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. European urology, 1992, Volume: 22, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Androstenes; Azasteroids; Dihydrotestosterone; Double-Blind Method; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Osteocalcin; Prostate-Specific Antigen; Prostatic Hyperplasia; Scandinavian and Nordic Countries; Testosterone; Urination	1992
Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride. Journal of cellular biochemistry. Supplement, 1992, Volume: 16H Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Dihydrotestosterone; Finasteride; Humans; Male; Orchiectomy; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Testosterone	1992
Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. The Journal of clinical endocrinology and metabolism, 1992, Volume: 74, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Androstenes; Azasteroids; Dihydrotestosterone; Dose-Response Relationship, Drug; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Testosterone	1992
The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. The Journal of urology, 1992, Volume: 147, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Androstenes; Azasteroids; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia	1992
Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation. British journal of urology, 1992, Volume: 70, Issue:1 Topics: Aged; Aged, 80 and over; Androstenes; Azasteroids; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Testosterone; Urinary Retention; Urination; Urodynamics	1992
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. The New England journal of medicine, 1992, Oct-22, Volume: 327, Issue:17 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Androstenes; Azasteroids; Dihydrotestosterone; Double-Blind Method; Erectile Dysfunction; Finasteride; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Urodynamics	1992
Is the prostate pill finally here? The New England journal of medicine, 1992, Oct-22, Volume: 327, Issue:17 Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Finasteride; Humans; Long-Term Care; Male; Prostatectomy; Prostatic Hyperplasia	1992
C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. The Journal of clinical endocrinology and metabolism, 1990, Volume: 70, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Androstenedione; Androstenes; Androsterone; Azasteroids; Corticosterone; Dihydrotestosterone; Disorders of Sex Development; Etiocholanolone; Finasteride; Gas Chromatography-Mass Spectrometry; Humans; Hydrocortisone; Liver; Luteinizing Hormone; Male; Middle Aged; Prostatic Hyperplasia; Radioimmunoassay; Randomized Controlled Trials as Topic; Steroids, Heterocyclic; Testosterone	1990
The clinical development of a 5 alpha-reductase inhibitor, finasteride. The Journal of steroid biochemistry and molecular biology, 1990, Nov-20, Volume: 37, Issue:3 Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Drug Evaluation; Finasteride; Humans; Male; Prostatic Hyperplasia	1990
5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review. European urology, 1991, Volume: 20 Suppl 1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Androstenes; Azasteroids; Dihydrotestosterone; Disorders of Sex Development; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia	1991
Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia. European urology, 1991, Volume: 20 Suppl 1 Topics: 5-alpha Reductase Inhibitors; Androgens; Androstenes; Azasteroids; Dose-Response Relationship, Drug; Drug Evaluation; Estradiol; Finasteride; Humans; Luteinizing Hormone; Male; Prostatic Hyperplasia; Testosterone	1991

Other Studies

420 other study(ies) available for finasteride and Adenoma, Prostatic

Article	Year
Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. Journal of medicinal chemistry, 2006, Oct-19, Volume: 49, Issue:21 Topics: Animals; Binding Sites; Crystallography, X-Ray; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Flavonoids; Humans; Ligands; Male; Mice; Models, Molecular; Molecular Structure; Prostate; Prostatic Hyperplasia; Selective Estrogen Receptor Modulators; Structure-Activity Relationship	2006
Synthesis and bioactivity of new Finasteride conjugate. Bioorganic & medicinal chemistry letters, 2011, Jun-01, Volume: 21, Issue:11 Topics: 5-alpha Reductase Inhibitors; Acylation; Animals; Cell Proliferation; Disease Models, Animal; Finasteride; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Male; Prostatic Hyperplasia; Rats	2011
Effects of resveratrol on benign prostatic hyperplasia by the regulation of inflammatory and apoptotic proteins. Journal of natural products, 2015, Apr-24, Volume: 78, Issue:4 Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cyclooxygenase 2; Humans; Male; Molecular Structure; Nitric Oxide Synthase Type II; Prostatic Hyperplasia; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Resveratrol; Stilbenes	2015
Oleanolic Acid Ameliorates Benign Prostatic Hyperplasia by Regulating PCNA-Dependent Cell Cycle Progression Journal of natural products, 2020, 04-24, Volume: 83, Issue:4 Topics: Animals; Cell Cycle; Cell Proliferation; Down-Regulation; Humans; Male; Molecular Structure; Oleanolic Acid; Proliferating Cell Nuclear Antigen; Prostatic Hyperplasia; Rats; Testosterone; Testosterone Propionate	2020
The one-pot synthesis of butyl-1H-indol-3-alkylcarboxylic acid derivatives in ionic liquid as potent dual-acting agent for management of BPH. European journal of medicinal chemistry, 2020, Nov-01, Volume: 205 Topics: Androgen Receptor Antagonists; Butyric Acid; Carboxylic Acids; Chemistry Techniques, Synthetic; Humans; Ionic Liquids; Male; Prostatic Hyperplasia; Receptors, Androgen	2020
Chemical profiles of the active fraction from Prinsepia utilis Royle leaves and its anti-benign prostatic hyperplasia evaluation in animal models. BMC complementary medicine and therapies, 2021, Oct-29, Volume: 21, Issue:1 Topics: Animals; China; Disease Models, Animal; Finasteride; Male; Plant Extracts; Plant Leaves; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Urological Agents	2021
Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy. JAMA network open, 2021, 11-01, Volume: 4, Issue:11 Topics: Aged; Aged, 80 and over; Disease Progression; Doxazosin; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Finasteride; Follow-Up Studies; Frail Elderly; Frailty; Geriatric Assessment; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Proportional Hazards Models; Prostatic Hyperplasia; Severity of Illness Index; Urological Agents	2021
Berberine ameliorates testosterone-induced benign prostate hyperplasia in rats. BMC complementary medicine and therapies, 2021, Dec-20, Volume: 21, Issue:1 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Berberine; Dihydrotestosterone; Disease Models, Animal; Drugs, Chinese Herbal; Finasteride; Interleukin-1beta; Male; Oxidative Stress; Prostate; Prostatic Hyperplasia; Rats; Rats, Wistar; Testosterone; Tumor Necrosis Factor-alpha	2021
Photothermal therapeutic potency of plasmonic silver nanoparticles for apoptosis and anti-angiogenesis in testosterone induced benign prostate hyperplasia in rats. Life sciences, 2022, Feb-15, Volume: 291 Topics: Animals; Antioxidants; Apoptosis; Dihydrotestosterone; Drug Delivery Systems; Finasteride; Hyperplasia; Male; Metal Nanoparticles; Neovascularization, Pathologic; Phototherapy; Plant Extracts; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Silver; Surface Plasmon Resonance; Testosterone; Testosterone Propionate	2022
Combination of Tadalafil and Finasteride for the Treatment of Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Commercialization of the Prescribing Cascade. European urology, 2022, Volume: 81, Issue:4 Topics: Drug Therapy, Combination; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia; Tadalafil; Treatment Outcome; Urinary Tract	2022
The extract of Celtis choseniana Nakai alleviates testosterone-induced benign prostatic hyperplasia through inhibiting 5α reductase type 2 and the Akt/NF-κB/AR pathway. Chinese journal of natural medicines, 2022, Volume: 20, Issue:7 Topics: Animals; Cholestenone 5 alpha-Reductase; Finasteride; Male; NF-kappa B; Plant Extracts; Prostatic Hyperplasia; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Testosterone; Ulmaceae	2022
A fixed-dose combination of finasteride and tadalafil (Entadfi) for BPH. The Medical letter on drugs and therapeutics, 2022, 09-05, Volume: 64, Issue:1658 Topics: Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia; Tadalafil	2022
Inhibitory effects of Food & function, 2022, Oct-03, Volume: 13, Issue:19 Topics: Animals; Centella; Corn Oil; Dihydrotestosterone; Finasteride; Humans; Male; Phosphatidylinositol 3-Kinases; Plant Extracts; Prostate; Prostatic Hyperplasia; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Signal Transduction; Testosterone; Testosterone Propionate; Triterpenes	2022
Modeling of Benign Prostatic Hyperplasia in Rats with a High Dose of Testosterone. Bulletin of experimental biology and medicine, 2022, Volume: 173, Issue:5 Topics: Animals; Finasteride; Humans; Male; Orchiectomy; Prostatic Hyperplasia; Rats; Rats, Wistar; Reproducibility of Results; Testosterone; Testosterone Propionate	2022
5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort. Urologic oncology, 2023, Volume: 41, Issue:1 Topics: 5-alpha Reductase Inhibitors; Dutasteride; Finasteride; Humans; Male; Ontario; Oxidoreductases; Prostatic Hyperplasia; Retrospective Studies; Urinary Bladder Neoplasms	2023
Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide. JAMA network open, 2022, 12-01, Volume: 5, Issue:12 Topics: 5-alpha Reductase Inhibitors; Alzheimer Disease; Antineoplastic Agents; Cohort Studies; Dementia, Vascular; Depression; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; Retrospective Studies; Suicide	2022
Development of a machine learning-based predictive model for prediction of success or failure of medical management for benign prostatic hyperplasia. Neurourology and urodynamics, 2023, Volume: 42, Issue:4 Topics: 5-alpha Reductase Inhibitors; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Machine Learning; Male; Prostatic Hyperplasia	2023
Alteration of Gut Microbes in Benign Prostatic Hyperplasia Model and Finasteride Treatment Model. International journal of molecular sciences, 2023, Mar-21, Volume: 24, Issue:6 Topics: Apoptosis; Finasteride; Gastrointestinal Microbiome; Humans; Male; Prostate; Prostatic Hyperplasia	2023
Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study. Scientific reports, 2023, 03-31, Volume: 13, Issue:1 Topics: Aged; Cohort Studies; Dutasteride; Finasteride; Humans; Male; Oxidoreductases; Prostatic Hyperplasia; Suicidal Ideation	2023
Comparative effects of finasteride and laser-irradiated silver nanoparticles on testicular function and histology in testosterone induced benign prostatic hyperplasia in rats. Life sciences, 2023, Jul-01, Volume: 324 Topics: Animals; Finasteride; Humans; Male; Metal Nanoparticles; Plant Extracts; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Semen; Silver; Testosterone	2023
Synchronous fluorescence as a green and selective method for the simultaneous determination of finasteride and tadalafil in dosage form and spiked human plasma. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2023, Oct-15, Volume: 299 Topics: Capsules; Finasteride; Fluorescence; Humans; Male; Prostatic Hyperplasia; Spectrometry, Fluorescence; Tadalafil	2023
Canagliflozin alleviates experimentally induced benign prostate hyperplasia in a rat model: exploring potential mechanisms involving mir-128b/EGFR/EGF and JAK2/STAT3 signaling pathways through in silico and in vivo investigations. European journal of pharmacology, 2023, Oct-15, Volume: 957 Topics: Aged; Animals; Canagliflozin; Epidermal Growth Factor; ErbB Receptors; Finasteride; Humans; Hyperplasia; Janus Kinase 2; Male; MicroRNAs; Prostate; Prostatic Hyperplasia; Rats; Sodium-Glucose Transporter 2 Inhibitors; STAT3 Transcription Factor	2023
Tomato lipidic extract plus selenium decrease prostatic hyperplasia, dihydrotestosterone and androgen receptor expression versus finasteride in rats. World journal of urology, 2023, Volume: 41, Issue:10 Topics: Androgens; Animals; Antioxidants; Dihydrotestosterone; Finasteride; Male; Prostatic Hyperplasia; Rats; Rats, Wistar; Receptors, Androgen; Selenium; Solanum lycopersicum; Testosterone	2023
The effect of acupuncture on oestrogen receptors in rats with benign prostatic hyperplasia. The Journal of steroid biochemistry and molecular biology, 2023, Volume: 234 Topics: Acupuncture Therapy; Animals; Estrogen Receptor alpha; Estrogen Receptor beta; Finasteride; Humans; Male; Prostatic Hyperplasia; Rats; Receptors, Estrogen; RNA, Messenger; Testosterone	2023
[Long-term effect of finasteride on high-risk patients with benign prostatic hyperplasia after implantation of thermo-expandable spiral prostatic stent]. Zhonghua nan ke xue = National journal of andrology, 2022, Volume: 28, Issue:12 Topics: Finasteride; Hematuria; Humans; Male; Prostatic Hyperplasia; Retrospective Studies; Stents; Treatment Outcome	2022
Inflammatory pathway employed by Red Maca to treat induced benign prostatic hyperplasia in rats. Andrologia, 2020, Volume: 52, Issue:3 Topics: 5-alpha Reductase Inhibitors; Animals; Disease Models, Animal; Finasteride; Humans; Interferon-gamma; Interleukin-4; Lepidium; Male; Plant Extracts; Prostate; Prostatic Hyperplasia; Rats; Signal Transduction; Testosterone; Th1 Cells; Th2 Cells; Tumor Necrosis Factor-alpha	2020
Development of finasteride/PHBV@polyvinyl alcohol/chitosan reservoir-type microspheres as a potential embolic agent: from in vitro evaluation to animal study. Biomaterials science, 2020, May-21, Volume: 8, Issue:10 Topics: Animals; Chitosan; Drug Delivery Systems; Drug Liberation; Embolization, Therapeutic; Finasteride; Male; Microspheres; Polyesters; Polyvinyl Alcohol; Prostatic Hyperplasia; Rabbits	2020
Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride. Topics in companion animal medicine, 2020, Volume: 38 Topics: 5-alpha Reductase Inhibitors; Acid Phosphatase; Animals; Biomarkers; Dihydrotestosterone; Dog Diseases; Dogs; Esterases; Estradiol; Finasteride; Male; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Testosterone; Ultrasonography	2020
High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia. The Journal of urology, 2020, Volume: 204, Issue:2 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Dutasteride; Finasteride; Humans; Male; Medicare; Medication Adherence; Prostatic Hyperplasia; United States	2020
[Ruyi Jinhuang Plaster suppresses BPH by reducing the expressions of P38, JNK2, NF-кBP65 and STAT3 in the prostate tissue of rats]. Zhonghua nan ke xue = National journal of andrology, 2018, Volume: 24, Issue:12 Topics: Animals; Disease Models, Animal; Drugs, Chinese Herbal; Finasteride; Male; Mitogen-Activated Protein Kinase 9; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Plant Extracts; Prostatic Hyperplasia; Rats; STAT3 Transcription Factor; Testosterone; Testosterone Propionate	2018
Lack of Association between 5α-Reductase Inhibitors and Depression. The Journal of urology, 2020, Volume: 204, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Depression; Dutasteride; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Retrospective Studies	2020
May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications? Medical hypotheses, 2020, Volume: 140 Topics: 5-alpha Reductase Inhibitors; Animals; Betacoronavirus; Coronavirus Infections; COVID-19; Finasteride; Humans; Lung; Male; Pandemics; Pneumonia, Viral; Prognosis; Prostatic Hyperplasia; Respiratory Mucosa; SARS-CoV-2; Sex Factors	2020
Prostatic hyperplasia: Vascularization, hemodynamic and hormonal analysis of dogs treated with finasteride or orchiectomy. PloS one, 2020, Volume: 15, Issue:6 Topics: Animals; Dog Diseases; Dogs; Finasteride; Gene Expression Regulation; Hemodynamics; Hormones; Male; Neovascularization, Pathologic; Orchiectomy; Prostatic Hyperplasia; Ultrasonography, Doppler; Vascular Endothelial Growth Factor A	2020
An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors. World journal of urology, 2021, Volume: 39, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Dutasteride; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; United States	2021
Water-stable and finasteride-loaded polyvinyl alcohol nanofibrous particles with sustained drug release for improved prostatic artery embolization - In vitro and in vivo evaluation. Materials science & engineering. C, Materials for biological applications, 2020, Volume: 115 Topics: 5-alpha Reductase Inhibitors; Animals; Cell Survival; Combined Modality Therapy; Delayed-Action Preparations; Disease Models, Animal; Dogs; Drug Stability; Embolization, Therapeutic; Finasteride; Male; Nanofibers; Particle Size; Polyvinyl Alcohol; Prostatic Hyperplasia; Treatment Outcome	2020
Immunomodulatory effect of diallyl sulfide on experimentally-induced benign prostate hyperplasia via the suppression of CD4+T/IL-17 and TGF-β1/ERK pathways. Inflammopharmacology, 2020, Volume: 28, Issue:5 Topics: Allyl Compounds; Animals; Anti-Inflammatory Agents; CD4-Positive T-Lymphocytes; Disease Models, Animal; Finasteride; Immunologic Factors; Interleukin-17; Male; MAP Kinase Signaling System; Prostate-Specific Antigen; Prostatic Hyperplasia; Rats; Rats, Wistar; Receptors, Androgen; Sulfides; Testosterone Propionate; Transforming Growth Factor beta1	2020
Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System. Skinmed, 2020, Volume: 18, Issue:3 Topics: 5-alpha Reductase Inhibitors; Adult; Adverse Drug Reaction Reporting Systems; Alopecia; Databases, Factual; Female; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Sleep Apnea, Obstructive; United States; United States Food and Drug Administration; Young Adult	2020
Reproductive and endocrinological effects of Benign Prostatic Hyperplasia and finasteride therapy in dogs. Scientific reports, 2020, 09-09, Volume: 10, Issue:1 Topics: Animals; Dihydrotestosterone; Dog Diseases; Dogs; Estrogens; Finasteride; Hormones; Male; Prostatic Hyperplasia; Reproduction; Spermatozoa; Testosterone	2020
5α-reductase inhibitors impact prognosis of urothelial carcinoma. BMC cancer, 2020, Sep-11, Volume: 20, Issue:1 Topics: 5-alpha Reductase Inhibitors; Aged; Carcinoma; Carcinoma, Transitional Cell; Cholestenone 5 alpha-Reductase; Dutasteride; Finasteride; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prostatic Hyperplasia; Receptors, Androgen; Taiwan; Urothelium	2020
Statewide Price Variation for Generic Benign Prostatic Hyperplasia Medications. Urology, 2021, Volume: 148 Topics: Costs and Cost Analysis; Drugs, Generic; Finasteride; Humans; Male; Mandelic Acids; Pennsylvania; Prostatic Hyperplasia; Tamsulosin	2021
Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. JAMA dermatology, 2021, 01-01, Volume: 157, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Alopecia; Anxiety; Case-Control Studies; Depression; Female; Finasteride; Humans; Male; Pharmacovigilance; Prostatic Hyperplasia; Sex Factors; Suicide; Young Adult	2021
Endocrine, prostatic vascular, and proapoptotic changes in dogs with benign prostatic hyperplasia treated medically or surgically. Domestic animal endocrinology, 2021, Volume: 75 Topics: Animals; Dihydrotestosterone; Dog Diseases; Dogs; Finasteride; Male; Prostate; Prostatic Hyperplasia; Testosterone	2021
Carica papaya leaf extract inhibits prostatitis-associated prostatic hyperplasia via the TRAF6/TAK1/MEK/NF-κB pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 135 Topics: Animals; Anti-Inflammatory Agents; Carica; Cell Line; Cell Proliferation; Cytokines; Disease Models, Animal; Finasteride; Inflammation Mediators; Male; MAP Kinase Kinase Kinases; Mice, Inbred BALB C; NF-kappa B; Plant Extracts; Plant Leaves; Prostate; Prostatic Hyperplasia; Prostatitis; Rats, Wistar; Signal Transduction; TNF Receptor-Associated Factor 6	2021
Prostatic Urethral Lift Versus Medical Therapy: Examining the Impact on Sexual Function in Men with Benign Prostatic Hyperplasia. European urology focus, 2022, Volume: 8, Issue:1 Topics: Doxazosin; Erectile Dysfunction; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia	2022
Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population. The Journal of urology, 2021, Volume: 206, Issue:1 Topics: 5-alpha Reductase Inhibitors; Aged; Black or African American; Finasteride; Hispanic or Latino; Humans; Male; Middle Aged; Prostatic Hyperplasia; Retrospective Studies; Risk Assessment; Urinary Bladder Neoplasms; White People	2021
Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate. Proceedings of the National Academy of Sciences of the United States of America, 2021, 03-30, Volume: 118, Issue:13 Topics: Active Transport, Cell Nucleus; Androgen Antagonists; Androstenes; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Cell Nucleus; Cohort Studies; ErbB Receptors; Estrogen Receptor beta; Finasteride; Humans; Male; Mice; Mice, Knockout; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Phytoestrogens; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Receptors, Estrogen	2021
Yohimbine hydrochloride inhibits benign prostatic hyperplasia by downregulating steroid 5α-reductase type 2. European journal of pharmacology, 2021, Oct-05, Volume: 908 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Dihydrotestosterone; Finasteride; Male; Prostatic Hyperplasia; Rats; Yohimbine	2021
Association of Suicidality and Depression With 5α-Reductase Inhibitors. JAMA internal medicine, 2017, 05-01, Volume: 177, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Case-Control Studies; Depression; Depressive Disorder; Dutasteride; Finasteride; Humans; Male; Ontario; Prostatic Hyperplasia; Retrospective Studies; Risk Factors; Self-Injurious Behavior; Suicidal Ideation; Suicide; Time Factors	2017
Protective Effects of Lepidium meyenii (Maca) Aqueous Extract and Lycopene on Testosterone Propionate-Induced Prostatic Hyperplasia in Mice. Phytotherapy research : PTR, 2017, Volume: 31, Issue:8 Topics: Animals; Carotenoids; Estradiol; Finasteride; Lepidium; Lycopene; Male; Mice; Mice, Inbred ICR; Plant Extracts; Prostatic Hyperplasia; Testosterone; Testosterone Propionate	2017
Re: Rates of Prostate Surgery and Acute Urinary Retention for Benign Prostatic Hyperplasia in Men Treated with Dutasteride or Finasteride. The Journal of urology, 2017, Volume: 198, Issue:4 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; Urinary Retention	2017
Re: Analysis of Risk Factors Leading to Postoperative Urethral Stricture and Bladder Neck Contracture following Transurethral Resection of Prostate. The Journal of urology, 2017, Volume: 198, Issue:4 Topics: Contracture; Dutasteride; Finasteride; Humans; Male; Postoperative Complications; Prostatic Hyperplasia; Risk Factors; Transurethral Resection of Prostate; Urethral Stricture; Urinary Bladder Neck Obstruction; Urinary Retention	2017
Methyl jasmonate reduces testosterone-induced benign prostatic hyperplasia through regulation of inflammatory and apoptotic processes in rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 95 Topics: Acetates; Animals; Apoptosis; Biomarkers; Cyclopentanes; Finasteride; Inflammation; Lipids; Male; Metabolic Detoxication, Phase I; Nitric Oxide; Organ Size; Oxylipins; Prostate; Prostatic Hyperplasia; Rats, Wistar; Testosterone; Weight Gain	2017
Women Also Use 5α-Reductase Inhibitors-Reply. JAMA internal medicine, 2017, 11-01, Volume: 177, Issue:11 Topics: 5-alpha Reductase Inhibitors; Female; Finasteride; Humans; Oxidoreductases; Prostatic Hyperplasia	2017
Finasteride accelerates prostate wound healing after thulium laser resection through DHT and AR signalling. Cell proliferation, 2018, Volume: 51, Issue:3 Topics: Animals; Cell Line; Cell Movement; Cell Proliferation; Dihydrotestosterone; Dogs; Down-Regulation; Drug Evaluation, Preclinical; Epithelium; Finasteride; Humans; Laser Therapy; Male; Prostate; Prostatic Hyperplasia; Proto-Oncogene Proteins c-myc; Receptors, Androgen; Receptors, Tumor Necrosis Factor, Type I; Signal Transduction; Testosterone; Tumor Necrosis Factor-alpha; Wound Healing	2018
Finasteride treatment and male breast cancer: a register-based cohort study in four Nordic countries. Cancer medicine, 2018, Volume: 7, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Breast Neoplasms, Male; Child; Child, Preschool; Finasteride; Follow-Up Studies; Humans; Incidence; Infant; Infant, Newborn; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Registries; Scandinavian and Nordic Countries; Young Adult	2018
Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:3 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Age Factors; Aged; Aged, 80 and over; Dementia; Dutasteride; Finasteride; Follow-Up Studies; Humans; Incidence; Male; Medicare; Prostatic Hyperplasia; Retrospective Studies; Risk Factors; Tamsulosin; United States	2018
Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men. American journal of men's health, 2018, Volume: 12, Issue:4 Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Adult; Alopecia; Cohort Studies; Estrogens; Exercise; Finasteride; Humans; Male; Middle Aged; Prognosis; Prostatic Hyperplasia; Psychology; Retrospective Studies; Risk Assessment; Self Report; Testosterone	2018
Risk of rhabdomyolysis from 5-α reductase inhibitors. Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Cohort Studies; Dutasteride; Finasteride; Humans; Male; Matched-Pair Analysis; Myositis; Ontario; Prostatic Hyperplasia; Rhabdomyolysis; Risk Factors	2018
Effect of finasteride particle size reduction on its pharmacokinetic, tissue distribution and cellular permeation. Drug delivery, 2018, Volume: 25, Issue:1 Topics: Administration, Oral; Animals; Biological Availability; Epithelial Cells; Finasteride; Male; Nanoparticles; Particle Size; Permeability; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Solubility; Tissue Distribution	2018
Re: Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States. The Journal of urology, 2018, Volume: 199, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; United States	2018
[Effects of Kudzu Root plus Cinnamon Granules on prostatic hyperplasia in mice]. Zhonghua nan ke xue = National journal of andrology, 2017, Volume: 23, Issue:4 Topics: Animals; Apoptosis; Cholestenone 5 alpha-Reductase; Cinnamomum zeylanicum; Fibroblast Growth Factor 2; Finasteride; In Situ Nick-End Labeling; Ki-67 Antigen; Male; Mice; Organ Size; Phytotherapy; Plant Roots; Prostate; Prostatic Hyperplasia; Pueraria; Random Allocation; Testosterone Propionate; Transforming Growth Factor beta1; Urological Agents	2017
[Effects of Xialiqi Capsules on the expressions of PCNA and caspase-3 in rats withbenign prostatic hyperplasia]. Zhonghua nan ke xue = National journal of andrology, 2017, Volume: 23, Issue:8 Topics: Animals; Capsules; Caspase 3; Drugs, Chinese Herbal; Finasteride; Male; Orchiectomy; Organ Size; Proliferating Cell Nuclear Antigen; Prostate; Prostatic Hyperplasia; Random Allocation; Rats; Rats, Sprague-Dawley; Urological Agents	2017
Finasteride-Nemesis of More Than 1 Urological Cancer? The Journal of urology, 2018, Volume: 200, Issue:4 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Oxidoreductases; Prostatic Hyperplasia; Prostatic Neoplasms; Urinary Bladder Neoplasms	2018
Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model. Drug design, development and therapy, 2018, Volume: 12 Topics: Administration, Oral; Animals; Benzofurans; Disease Models, Animal; Drug Therapy, Combination; Finasteride; Indoles; Male; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Testosterone	2018
Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data. Advances in therapy, 2018, Volume: 35, Issue:8 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; China; Combined Modality Therapy; Drug Therapy, Combination; Electronic Health Records; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Treatment Outcome	2018
Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis. World journal of urology, 2019, Volume: 37, Issue:5 Topics: Aged; Aged, 80 and over; Costs and Cost Analysis; Drug Therapy, Combination; Finasteride; France; Germany; Humans; Italy; Male; Middle Aged; Prostatic Hyperplasia; Spain; Tamsulosin; Transurethral Resection of Prostate; United Kingdom; Urological Agents	2019
[Efficacy of Kangshuailing Gao on benign prostatic hyperplasia in rats]. Zhonghua nan ke xue = National journal of andrology, 2018, Volume: 24, Issue:8 Topics: Androgens; Animals; Dihydrotestosterone; Drugs, Chinese Herbal; Estradiol; Finasteride; Male; Organ Size; Prostate; Prostatic Hyperplasia; Random Allocation; Rats; Testosterone; Urological Agents	2018
Cost-Effectiveness of Combination Therapy Versus Monotherapy in Benign Prostatic Hyperplasia: A Colombian Experience. Value in health regional issues, 2018, Volume: 17 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Adult; Colombia; Cost-Benefit Analysis; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia	2018
Why Odds Ratios Can Be Tricky Statistics: The Case of Finasteride, Dutasteride, and Sexual Dysfunction. The Journal of clinical psychiatry, 2018, 11-27, Volume: 79, Issue:6 Topics: 5-alpha Reductase Inhibitors; Dutasteride; Erectile Dysfunction; Finasteride; Humans; Libido; Male; Meta-Analysis as Topic; Odds Ratio; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Risk Assessment	2018
Re: Transurethral Resection of Prostate and Bleeding: . The Journal of urology, 2019, Volume: 201, Issue:2 Topics: Blood Loss, Surgical; Double-Blind Method; Dutasteride; Finasteride; Humans; Male; Microvessels; Prospective Studies; Prostatic Hyperplasia; Transurethral Resection of Prostate	2019
Chinese Skullcap (Scutellaria baicalensis Georgi) inhibits inflammation and proliferation on benign prostatic hyperplasia in rats. Journal of ethnopharmacology, 2019, May-10, Volume: 235 Topics: 5-alpha Reductase Inhibitors; Animals; Apoptosis; Biomarkers; Disease Models, Animal; Finasteride; Inflammation; Male; Medicine, Chinese Traditional; Plant Extracts; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Scutellaria baicalensis; Testosterone	2019
Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia. Pharmaceutical biology, 2019, Volume: 57, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Cytokines; Dihydrotestosterone; Finasteride; Lespedeza; Male; Organ Size; Plant Extracts; Proliferating Cell Nuclear Antigen; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Rats; Rats, Wistar; Receptors, Androgen; Testosterone	2019
Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study. BMJ (Clinical research ed.), 2019, Apr-10, Volume: 365 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dutasteride; Finasteride; Humans; Incidence; Male; Middle Aged; Prostatic Hyperplasia; Tamsulosin	2019
Iodine Bonded with Milk Protein Inhibits Benign Prostatic Hyperplasia Development in Rats. Anti-cancer agents in medicinal chemistry, 2019, Volume: 19, Issue:13 Topics: Androgen Antagonists; Animals; Finasteride; Iodine; Male; Milk Proteins; Prostatic Hyperplasia; Rats; Rats, Wistar	2019
A retrospective study of clinical outcomes of α-blocker or finasteride monotherapy followed by combination therapy: determination of the period of combination therapy of α-blocker and finasteride. International journal of clinical practice, 2013, Volume: 67, Issue:4 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Drug Administration Schedule; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Organ Size; Prostate-Specific Antigen; Prostatic Hyperplasia; Quality of Life; Retrospective Studies; Treatment Outcome; Urological Agents	2013
On call. I have read several news reports that claim finasteride, which I take for my prostate problem, can cause permanent impotence. Should I be concerned? Harvard men's health watch, 2013, Volume: 17, Issue:6 Topics: 5-alpha Reductase Inhibitors; Erectile Dysfunction; Finasteride; Health Status; Humans; Male; Prostatic Hyperplasia	2013
Inhibition of androgen induces autophagy in benign prostate epithelial cells. International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:2 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androgens; Apoptosis; Autophagy; Cell Line; Cell Survival; Dihydrotestosterone; Epithelial Cells; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia	2014
[Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia]. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2013, Volume: 65, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Azasteroids; Dutasteride; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Retrospective Studies	2013
Development of a doxazosin and finasteride transdermal system for combination therapy of benign prostatic hyperplasia. Journal of pharmaceutical sciences, 2013, Volume: 102, Issue:11 Topics: 5-alpha Reductase Inhibitors; Administration, Cutaneous; Adrenergic alpha-1 Receptor Antagonists; Animals; Azepines; Doxazosin; Finasteride; Humans; Lauric Acids; Male; Permeability; Pharmaceutical Vehicles; Prostatic Hyperplasia; Skin Absorption; Swine	2013
MRI characterization of the dynamic effects of 5α-reductase inhibitors on prostate zonal volumes. The Canadian journal of urology, 2013, Volume: 20, Issue:6 Topics: 5-alpha Reductase Inhibitors; Aged; Azasteroids; Dutasteride; Finasteride; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Prostate; Prostatic Hyperplasia; Retrospective Studies	2013
Re: inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction. The Journal of urology, 2014, Volume: 191, Issue:3 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Erectile Dysfunction; Finasteride; Humans; Male; Prostatic Hyperplasia; Sexual Dysfunction, Physiological; Sleep Wake Disorders	2014
Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues. The Prostate, 2014, Volume: 74, Issue:9 Topics: 5-alpha Reductase Inhibitors; Aged; Finasteride; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Kallikreins; Keratin-5; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Receptors, Androgen; Regression Analysis; Retrospective Studies	2014
Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediators of inflammation, 2014, Volume: 2014 Topics: CD8-Positive T-Lymphocytes; Cell Line; Cell Movement; Chemokine CCL5; Dihydrotestosterone; Finasteride; Flow Cytometry; Humans; Immunohistochemistry; In Vitro Techniques; Male; Prostate; Prostatic Hyperplasia	2014
A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. The International journal of biological markers, 2014, Dec-09, Volume: 29, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Drug-Related Side Effects and Adverse Reactions; Finasteride; Genetic Predisposition to Disease; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Prostatic Hyperplasia; Receptors, Androgen; Retrospective Studies; Surveys and Questionnaires	2014
Long-term use of 5α-reductase inhibitors and the risk of male breast cancer. Cancer causes & control : CCC, 2014, Volume: 25, Issue:11 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Breast Neoplasms, Male; Case-Control Studies; Dutasteride; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Risk Factors; United Kingdom	2014
A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia. Clinical endocrinology, 2015, Volume: 82, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Case-Control Studies; Comorbidity; Databases, Factual; Dihydrotestosterone; Female; Finasteride; Humans; Longitudinal Studies; Male; Odds Ratio; Osteoporosis; Prostate; Prostatic Hyperplasia; Risk Factors; Testosterone	2015
Treatment of benign prostatic hyperplasia with Croton membranaceus in an experimental animal model. Journal of ethnopharmacology, 2014, Nov-18, Volume: 157 Topics: Animals; Croton; Dihydrotestosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Finasteride; Male; Medicine, Traditional; Plant Extracts; Plant Roots; Prostate-Specific Antigen; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley	2014
Effects of E/Z isomers of lycopene on experimental prostatic hyperplasia in mice. Fitoterapia, 2014, Volume: 99 Topics: Acid Phosphatase; Animals; Carotenoids; Disease Models, Animal; Estradiol; Finasteride; Lycopene; Male; Mice; Mice, Inbred ICR; Prostate; Prostatic Hyperplasia; Protein Tyrosine Phosphatases; Solanum lycopersicum; Testosterone	2014
The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia. Collegium antropologicum, 2014, Volume: 38, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Azasteroids; Bone Density; Dutasteride; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia	2014
Inhibition of spontaneous canine benign prostatic hyperplasia by an Urtica fissa polysaccharide fraction. Planta medica, 2015, Volume: 81, Issue:1 Topics: Administration, Oral; Animals; Case-Control Studies; Dogs; Finasteride; Male; Polysaccharides; Prostatic Hyperplasia; Urticaceae	2015
Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia. Korean journal of urology, 2014, Volume: 55, Issue:12 Topics: Aged; Case-Control Studies; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Metabolic Syndrome; Middle Aged; Patient Selection; Prazosin; Prostatic Hyperplasia; Treatment Outcome; Urological Agents	2014
Re: Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues. The Journal of urology, 2015, Volume: 193, Issue:3 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Receptors, Androgen	2015
5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia. Journal of endocrinological investigation, 2015, Volume: 38, Issue:7 Topics: 5-alpha Reductase Inhibitors; Acute Coronary Syndrome; Aged; Aged, 80 and over; Case-Control Studies; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Middle Aged; National Health Programs; Odds Ratio; Prostatic Hyperplasia; Risk; Taiwan	2015
Editorial Comment from Dr Oh-oka to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, random International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:6 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil	2015
Editorial Comment from Dr Masumori to Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, rand International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:6 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatism; Tadalafil	2015
Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats. Oncotarget, 2015, Volume: 6, Issue:12 Topics: Aging; Animals; Antibiotics, Antineoplastic; Disease Models, Animal; Drug Administration Schedule; Finasteride; Male; Nanomedicine; Prostate; Prostatic Hyperplasia; Rats; Rats, Wistar; Sirolimus; Sulpiride; Testosterone; TOR Serine-Threonine Kinases	2015
Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. Hormone molecular biology and clinical investigation, 2015, Volume: 23, Issue:3 Topics: Aged; Cohort Studies; Erectile Dysfunction; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Testosterone; Urological Agents	2015
5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA oncology, 2015, Volume: 1, Issue:3 Topics: 5-alpha Reductase Inhibitors; Databases, Factual; Dutasteride; Finasteride; Humans; Incidence; Kaplan-Meier Estimate; Linear Models; Logistic Models; Male; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United Kingdom	2015
Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate Cancer. JAMA oncology, 2015, Volume: 1, Issue:3 Topics: 5-alpha Reductase Inhibitors; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2015
Finasteride and Bladder Cancer. European urology, 2016, Volume: 69, Issue:3 Topics: Enzyme Inhibitors; Finasteride; Humans; Prostatic Hyperplasia; Prostatic Neoplasms; Urinary Bladder Neoplasms	2016
Expression of Heat Shock Protein 27 in Benign Prostatic Hyperplasia with Chronic Inflammation. Medical science monitor : international medical journal of experimental and clinical research, 2015, Oct-03, Volume: 21 Topics: Adrenergic alpha-Antagonists; Biomarkers, Tumor; CD3 Complex; Chronic Disease; Cross-Sectional Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Finasteride; Gene Expression Regulation; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Immunohistochemistry; Inflammation; Interleukin-6; Lower Urinary Tract Symptoms; Male; Molecular Chaperones; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Transurethral Resection of Prostate; Tumor Necrosis Factor-alpha	2015
Re: Finasteride, Not Tamsulosin, Increases Severity of Erectile Dysfunction and Decreases Testosterone Levels in Men with Benign Prostatic Hyperplasia. The Journal of urology, 2016, Volume: 195, Issue:1 Topics: Erectile Dysfunction; Finasteride; Humans; Male; Prostatic Hyperplasia; Testosterone; Urological Agents	2016
The new insight of prostate-specific antigen reduction during finasteride therapy in aging men. Aging clinical and experimental research, 2016, Volume: 28, Issue:6 Topics: Aged; Asian People; Doxazosin; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	2016
Comments concerning the real risk of sexual adverse events secondary to the use of 5-ARIs. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2016, Jan-14, Volume: 87, Issue:4 Topics: 5-alpha Reductase Inhibitors; Alopecia; Drug Monitoring; Dutasteride; Erectile Dysfunction; Evidence-Based Medicine; Finasteride; Humans; Male; Patient Selection; Prostatic Hyperplasia; Risk Assessment; Risk Factors	2016
Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia? Actas urologicas espanolas, 2016, Volume: 40, Issue:4 Topics: 5-alpha Reductase Inhibitors; Dutasteride; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Hyperplasia	2016
Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study. International urology and nephrology, 2016, Volume: 48, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Longitudinal Studies; Lower Urinary Tract Symptoms; Male; Middle Aged; Phytotherapy; Plant Extracts; Prospective Studies; Prostatic Hyperplasia; Prostatism; Quality of Life; Serenoa; Severity of Illness Index; Sulfonamides; Tamsulosin; Watchful Waiting	2016
Optimisation of microstructured biodegradable finasteride formulation for depot parenteral application. Journal of microencapsulation, 2016, Volume: 33, Issue:3 Topics: Animals; Biocompatible Materials; Caproates; Delayed-Action Preparations; Drug Compounding; Finasteride; Humans; Injections; Lactic Acid; Lactones; Male; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prostatic Hyperplasia; Rabbits; Urological Agents	2016
Patterns of finasteride use in the male populations of four Nordic countries: A cross-national drug utilization study. Scandinavian journal of urology, 2016, Volume: 50, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Drug Utilization; Finasteride; Humans; Male; Practice Patterns, Physicians'; Prostatic Hyperplasia; Scandinavian and Nordic Countries	2016
Cost effectiveness comparison of dutasteride and finasteride in patients with benign prostatic hyperplasia--The Markov model based on data from Montenegro. Vojnosanitetski pregled, 2016, Volume: 73, Issue:1 Topics: 5-alpha Reductase Inhibitors; Aged; Aging; Budgets; Cost-Benefit Analysis; Dutasteride; Finasteride; Humans; Male; Markov Chains; Montenegro; Prostatic Hyperplasia; Quality of Life; Treatment Outcome	2016
Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine-containing Compound in Prostate and Hair Follicle Cell-based Assays. Phytotherapy research : PTR, 2016, Volume: 30, Issue:6 Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgens; Carnitine; Finasteride; Hair Follicle; Humans; Male; Phytotherapy; Prostatic Hyperplasia; Sterols; Thioctic Acid	2016
Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern? Actas dermo-sifiliograficas, 2016, Volume: 107, Issue:9 Topics: 5-alpha Reductase Inhibitors; Alopecia; Dutasteride; Erectile Dysfunction; Finasteride; Humans; Insulin Resistance; Libido; Male; Osteoporosis; Prostatic Hyperplasia; Prostatic Neoplasms	2016
Assessment of Urologists' Knowledge of Intraoperative Floppy Iris Syndrome. Urology, 2016, Volume: 97 Topics: Adrenergic alpha-1 Receptor Antagonists; Clinical Competence; Fellowships and Scholarships; Female; Finasteride; Health Knowledge, Attitudes, Practice; Humans; Internship and Residency; Intraoperative Complications; Iris Diseases; Male; Medical Staff, Hospital; Ophthalmology; Patient Education as Topic; Prazosin; Prostatic Hyperplasia; Referral and Consultation; Sulfonamides; Surveys and Questionnaires; Syndrome; Tamsulosin; Urological Agents; Urology; Vision Disorders	2016
Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride. BMC urology, 2016, Aug-31, Volume: 16, Issue:1 Topics: 5-alpha Reductase Inhibitors; Acute Disease; Aged; Aged, 80 and over; Dutasteride; Finasteride; Humans; Incidence; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Urinary Retention	2016
Re: Treatment Satisfaction and Clinically Meaningful Symptom Improvement in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia: Secondary Results from a 6-Month, Randomized, Double-Blind Study Compari The Journal of urology, 2016, Volume: 196, Issue:4 Topics: Double-Blind Method; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Personal Satisfaction; Prostatic Hyperplasia; Tadalafil; Treatment Outcome	2016
Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States. Journal of managed care & specialty pharmacy, 2016, Volume: 22, Issue:10 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Disease Progression; Dutasteride; Finasteride; Health Care Costs; Humans; Longitudinal Studies; Male; Middle Aged; Prostatic Hyperplasia; Retrospective Studies; Treatment Outcome; United States; Urinary Retention	2016
Dapoxetine attenuates testosterone-induced prostatic hyperplasia in rats by the regulation of inflammatory and apoptotic proteins. Toxicology and applied pharmacology, 2016, Nov-15, Volume: 311 Topics: Animals; Benzylamines; Biomarkers; Dihydrotestosterone; Dose-Response Relationship, Drug; Finasteride; Male; Naphthalenes; Organ Size; Proliferating Cell Nuclear Antigen; Prostate; Prostatic Hyperplasia; Rats; Rats, Wistar; Receptors, Androgen; Testosterone	2016
The Cardiovascular Safety of Dutasteride. The Journal of urology, 2017, Volume: 197, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Cohort Studies; Databases, Factual; Dutasteride; Finasteride; Heart Failure; Hospitalization; Humans; Male; Myocardial Infarction; Ontario; Prostatic Hyperplasia; Stroke	2017
Chrysophanic acid reduces testosterone-induced benign prostatic hyperplasia in rats by suppressing 5α-reductase and extracellular signal-regulated kinase. Oncotarget, 2017, Feb-07, Volume: 8, Issue:6 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Anthraquinones; Cell Line; Cell Proliferation; Disease Models, Animal; Down-Regulation; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Finasteride; Male; Nuclear Receptor Coactivator 1; Organ Size; Phosphorylation; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Rats, Sprague-Dawley; Receptors, Androgen; Signal Transduction; Testosterone Propionate; Time Factors	2017
Re: Finasteride, Not Tamsulosin, Increases Severity of Erectile Dysfunction and Decreases Testosterone Levels in Men with Benign Prostatic Hyperplasia. The Journal of urology, 2017, Volume: 197, Issue:1 Topics: Erectile Dysfunction; Finasteride; Humans; Male; Prostatic Hyperplasia; Tamsulosin; Testosterone	2017
Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH). International urology and nephrology, 2017, Volume: 49, Issue:3 Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Organ Size; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatism; Treatment Failure; Ultrasonography; Urinary Bladder; Urological Agents	2017
CD8+ T cells promote proliferation of benign prostatic hyperplasia epithelial cells under low androgen level via modulation of CCL5/STAT5/CCND1 signaling pathway. Scientific reports, 2017, 02-20, Volume: 7 Topics: CD8-Positive T-Lymphocytes; Cell Line; Cell Proliferation; Chemokine CCL5; Coculture Techniques; Cyclin D1; Dihydrotestosterone; Epithelial Cells; Finasteride; Gene Expression Regulation; Humans; Male; Phosphorylation; Pimozide; Prostatic Hyperplasia; Signal Transduction; STAT5 Transcription Factor	2017
Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. The American journal of managed care, 2008, Volume: 14, Issue:5 Suppl 2 Topics: 5-alpha Reductase Inhibitors; Acute Disease; Aged; Aged, 80 and over; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatectomy; Prostatic Hyperplasia; Retrospective Studies; United States; Urinary Retention	2008
5-Alpha reductase inhibitors in men with an enlarged prostate: an evaluation of outcomes and therapeutic alternatives. The American journal of managed care, 2008, Volume: 14, Issue:5 Suppl 2 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Medicare; Prostatic Hyperplasia; Treatment Outcome; United States; Urinary Retention	2008
Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men. The American journal of managed care, 2008, Volume: 14, Issue:5 Suppl 2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Azasteroids; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Managed Care Programs; Medicare; Prostatic Hyperplasia; Retrospective Studies; Treatment Outcome; United States	2008
Cost comparison of finasteride and dutasteride for enlarged prostate in a managed care setting among Medicare-aged men. The American journal of managed care, 2008, Volume: 14, Issue:5 Suppl 2 Topics: Aged; Aged, 80 and over; Azasteroids; Drug Costs; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Managed Care Programs; Medicare; Prevalence; Prostatic Hyperplasia; Retrospective Studies; United States	2008
How many drugs for LUTS due to BPH are too many? The Journal of urology, 2008, Volume: 180, Issue:3 Topics: Adrenergic alpha-Antagonists; Benzhydryl Compounds; Cresols; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Humans; Imidazoles; Male; Muscarinic Antagonists; Phenylpropanolamine; Piperazines; Prostatic Hyperplasia; Sulfonamides; Sulfones; Tamsulosin; Tolterodine Tartrate; Triazines; Urination Disorders; Vardenafil Dihydrochloride	2008
Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma. International journal of andrology, 2009, Volume: 32, Issue:6 Topics: Androgens; Dihydrotestosterone; Finasteride; Humans; Male; Nandrolone; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Testosterone; Testosterone Congeners	2009
Preventing prostate cancer: new analyses put finasteride back on the map. Journal of the National Cancer Institute, 2008, Aug-20, Volume: 100, Issue:16 Topics: 5-alpha Reductase Inhibitors; Anticarcinogenic Agents; Azasteroids; Bias; Biopsy, Needle; Carcinogens; Confounding Factors, Epidemiologic; Drug Approval; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Patents as Topic; Prostatic Hyperplasia; Prostatic Neoplasms; Severity of Illness Index; United States; United States Food and Drug Administration	2008
By the way, doctor. I have been taking Avodart for my BPH, along with Flomax, but finasteride may be less expensive. Should I switch? Harvard health letter, 2008, Volume: 33, Issue:9 Topics: Antineoplastic Agents; Drug Therapy, Combination; Drugs, Generic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Sulfonamides; Tamsulosin	2008
Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA, 2008, Oct-08, Volume: 300, Issue:14 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Azasteroids; Case-Control Studies; Dose-Response Relationship, Drug; Dutasteride; Enzyme Inhibitors; Finasteride; Hip Fractures; Humans; Logistic Models; Male; Prostatic Hyperplasia; Risk Factors	2008
Does Proscar prevent prostate cancer? The Johns Hopkins medical letter health after 50, 2008, Volume: 20, Issue:8 Topics: Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	2008
Histologic influence of doxazosin and finasteride in benign prostatic hyperplasia accompanying chronic inflammation. Urologia internationalis, 2008, Volume: 81, Issue:4 Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antihypertensive Agents; CD3 Complex; Cyclooxygenase 2; Doxazosin; Enzyme Inhibitors; Finasteride; Glutathione Transferase; Humans; Immunohistochemistry; Inflammation; Male; Middle Aged; Prostatic Hyperplasia; Prostatitis; Vascular Endothelial Growth Factor A	2008
Finasteride in polycythaemia. BJU international, 2003, Volume: 92 Suppl 3 Topics: Aged; Erythrocyte Indices; Finasteride; Hematocrit; Hemoglobins; Humans; Male; Polycythemia; Prostatic Hyperplasia; Urological Agents	2003
5-Alpha reductase inhibitors and risk of hip fracture. JAMA, 2009, Mar-04, Volume: 301, Issue:9 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Hip Fractures; Humans; Male; Osteoporosis; Prostatic Hyperplasia; Risk Factors	2009
[Finasteride: an effective therapeutic for benign prostatic hyperplasia related gross hematuria in patients receiving anticoagulant]. Zhonghua nan ke xue = National journal of andrology, 2009, Volume: 15, Issue:1 Topics: Aged; Aged, 80 and over; Anticoagulants; Fibrinolytic Agents; Finasteride; Follow-Up Studies; Hematuria; Humans; Male; Middle Aged; Prostatic Hyperplasia; Treatment Outcome	2009
Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. The Journal of urology, 2009, Volume: 181, Issue:5 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adult; Age Factors; Aged; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Finasteride; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Patient Dropouts; Probability; Proportional Hazards Models; Prostatic Hyperplasia; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index	2009
Editorial comment. Urology, 2009, Volume: 73, Issue:5 Topics: Aged; Biopsy; Enzyme Inhibitors; Finasteride; Health Education; Humans; Male; Marketing of Health Services; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms	2009
On call. I am 76 years old, and I've had an enlarged prostate for at least 10 years. I've been taking Proscar for about a year, and it seems to be helping quite a bit. I have not noticed any side effects, but I'm worried that if the medicine reduces testo Harvard men's health watch, 2009, Volume: 13, Issue:9 Topics: Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Osteoporosis; Prostatic Hyperplasia	2009
Continuous finasteride therapy for benign prostate hypertrophy upgrades both neuroendorcine differentiation and aggressive prostate cancer. Anticancer research, 2009, Volume: 29, Issue:5 Topics: Cell Differentiation; Enzyme Inhibitors; Finasteride; Humans; Male; Neurosecretory Systems; Prostatic Hyperplasia; Prostatic Neoplasms	2009
Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology. International journal of andrology, 2010, Jun-01, Volume: 33, Issue:3 Topics: Androgens; Animals; Cell Proliferation; Dihydrotestosterone; Doxazosin; Epithelial Cells; Extracellular Matrix; Finasteride; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Rats; Rats, Wistar; RNA, Messenger; Testosterone; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transforming Growth Factor beta1	2010
Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex. The Journal of biological chemistry, 2009, Jul-24, Volume: 284, Issue:30 Topics: Binding, Competitive; Crystallography, X-Ray; Enzyme Inhibitors; Finasteride; Humans; Male; Models, Molecular; Molecular Structure; NADP; Oxidoreductases; Progesterone; Prostatic Hyperplasia; Protein Binding; Protein Conformation; Testosterone	2009
By the way, doctor. Finasteride has been prescribed for my BPH. I think that the most frequent side effect is erectile dysfunction or loss of sexual desire. Would Levita or a similar drug (like Viagra or Cialis) overcome the side effects of finasteride Harvard health letter, 2009, Volume: 34, Issue:8 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Drug Synergism; Enzyme Inhibitors; Finasteride; Humans; Imidazoles; Male; Piperazines; Prostatic Hyperplasia; Purines; Sexual Dysfunction, Physiological; Sildenafil Citrate; Sulfones; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents	2009
Is it worth the wait? BJU international, 2009, Volume: 104, Issue:1 Topics: Antineoplastic Agents; Azasteroids; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2009
Finasteride treatment and neuroactive steroid formation. Prague medical report, 2009, Volume: 110, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Brain; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Receptors, GABA-A; Receptors, N-Methyl-D-Aspartate; Steroids	2009
Urticarial rush due to finasteride. Allergy, 2010, Volume: 65, Issue:3 Topics: Aged; Anti-Inflammatory Agents; Drug Hypersensitivity; Enzyme Inhibitors; Exanthema; Finasteride; Histamine Antagonists; Humans; Male; Prostatic Hyperplasia; Skin Tests; Urticaria	2010
When you just can't go: my patient, a 63-year old stockbroker, recalled his experience with acute urinary retention. Consumer reports, 2009, Volume: 74, Issue:8 Topics: Acute Disease; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Urinary Retention	2009
On call. My brother needed surgery for an enlarged prostate at age 60. I am a few months shy of my 50th birthday, and my urine stream is starting to slow down a bit. Is there anything I can do to avoid following in my brother's footsteps? Harvard men's health watch, 2009, Volume: 14, Issue:3 Topics: Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Life Style; Male; Middle Aged; Prostatic Hyperplasia	2009
Inappropriate sexual behaviors in patients with vascular dementia: possible response to finasteride. Journal of the American Geriatrics Society, 2009, Volume: 57, Issue:11 Topics: Aged; Aged, 80 and over; Dementia, Vascular; Drug Therapy, Combination; Enzyme Inhibitors; Exhibitionism; Finasteride; Humans; Male; Masturbation; Mental Status Schedule; Prostatic Hyperplasia; Sexual Behavior	2009
[Treatment of benign prostate hyperplasia]. Orvosi hetilap, 2010, Mar-21, Volume: 151, Issue:12 Topics: Adrenergic alpha-Antagonists; Adult; Azasteroids; Cholinergic Antagonists; Diagnosis, Differential; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Laser Therapy; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Transurethral Resection of Prostate; Ultrasonography, Interventional	2010
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. The Journal of urology, 2010, Volume: 183, Issue:5 Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Reductase; Chromatography, High Pressure Liquid; Doxazosin; Drug Contamination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tablets; Tamsulosin	2010
Chemoprevention of prostate cancer. The New England journal of medicine, 2010, Apr-01, Volume: 362, Issue:13 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Biopsy; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Risk	2010
Treatment of benign essential blepharospasm with finasteride: a case report. Clinical neuropharmacology, 2010, Volume: 33, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Blepharospasm; Botulinum Toxins, Type A; Finasteride; Humans; Levodopa; Male; Parkinson Disease; Prostatic Hyperplasia	2010
Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Drug metabolism and pharmacokinetics, 2010, Volume: 25, Issue:2 Topics: 5-alpha Reductase Inhibitors; Animals; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Male; Nonlinear Dynamics; Prostatic Hyperplasia; Prostatic Neoplasms; Rats	2010
Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia. Asian journal of andrology, 2010, Volume: 12, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aging; Animals; Cell Line; Cell Proliferation; Estrogen Antagonists; Finasteride; Humans; Male; Models, Animal; Proliferating Cell Nuclear Antigen; Prostate; Prostatic Hyperplasia; Raloxifene Hydrochloride; Rats; Rats, Wistar; Selective Estrogen Receptor Modulators; Tamoxifen	2010
Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity. The Journal of urology, 2010, Volume: 184, Issue:1 Topics: Aged; Azasteroids; Chi-Square Distribution; Cholestenone 5 alpha-Reductase; Cholinergic Antagonists; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Linear Models; Male; Phosphodiesterase Inhibitors; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Quality of Life	2010
Effects of the chronic use of finasteride and doxazosin mesylate on the histomorphometric characteristics of the prostate: experimental study in rats. International urology and nephrology, 2011, Volume: 43, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Doxazosin; Drug Administration Schedule; Drug Therapy, Combination; Finasteride; Follow-Up Studies; Male; Prostate; Prostatic Hyperplasia; Rats; Rats, Wistar; Time Factors; Treatment Outcome	2011
Evidence-based urology in practice: composite endpoints. BJU international, 2010, Volume: 106, Issue:5 Topics: 5-alpha Reductase Inhibitors; Doxazosin; Drug Therapy, Combination; Endpoint Determination; Evidence-Based Medicine; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatism; Risk Reduction Behavior; Treatment Outcome	2010
Blood dripping from the penis of a German Shepherd dog. Australian veterinary journal, 2010, Volume: 88, Issue:6 Topics: Animals; Diagnosis, Differential; Dog Diseases; Dogs; Enzyme Inhibitors; Finasteride; Hemorrhage; Histocytochemistry; Male; Prostatic Hyperplasia; Triptorelin Pamoate; Ultrasonography	2010
Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II. Advances in therapy, 2010, Volume: 27, Issue:8 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Antagonists; Cell-Free System; Drug Evaluation, Preclinical; Finasteride; HEK293 Cells; Humans; In Vitro Techniques; Male; Plant Extracts; Prostatic Hyperplasia; Prostatic Neoplasms; Serenoa	2010
[The influence of benign prostatic hyperplasia drugs on incidence and pathology grading of prostate cancer]. Zhonghua wai ke za zhi [Chinese journal of surgery], 2010, May-15, Volume: 48, Issue:10 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Finasteride; Humans; Incidence; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies	2010
Change in International Prostate Symptom storage subscore after long-term medical therapy in BPH patients: finasteride and alpha-blocker combination therapy in men with moderate-to-severe LUTS/BPH in Korea. Urology, 2011, Volume: 77, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Drug Therapy, Combination; Finasteride; Humans; Korea; Male; Prostatic Hyperplasia; Prostatism; Retrospective Studies; Severity of Illness Index; Time Factors	2011
Evolving role of 5-alpha reductase inhibitors in chemoprevention. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:9 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Dutasteride; Finasteride; Humans; Male; Primary Prevention; Prostatic Hyperplasia; Prostatic Neoplasms	2010
82-year-old man with bilateral leg swelling. Mayo Clinic proceedings, 2010, Volume: 85, Issue:9 Topics: Aged, 80 and over; Diagnosis, Differential; Edema; Finasteride; Humans; Hydronephrosis; Leg; Male; Prostatic Hyperplasia; Venous Thrombosis	2010
Dutasteride and prostate cancer. The New England journal of medicine, 2010, 08-19, Volume: 363, Issue:8 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms	2010
Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: 5-alpha Reductase Inhibitors; Animals; Apoptosis; Aromatase; Benzopyrans; Cell Proliferation; Cell Survival; Cells, Cultured; Dihydrotestosterone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Finasteride; Gene Expression Regulation; Humans; Male; Piperidines; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Receptors, Androgen; RNA, Messenger; Selective Estrogen Receptor Modulators; Signal Transduction; Stromal Cells; Tamoxifen; Testosterone; Tissue Culture Techniques	2012
The effects of 5α-reductase inhibition on benign prostatic hyperplasia treated by photoselective vaporization prostatectomy with the 120 Watt GreenLight HPS laser system. Journal of the American College of Surgeons, 2011, Volume: 212, Issue:2 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Azasteroids; Dutasteride; Finasteride; Humans; Laser Therapy; Light; Male; Microcirculation; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Treatment Outcome; Volatilization	2011
Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic. Urologia internationalis, 2011, Volume: 86, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Czech Republic; Finasteride; Humans; Male; Middle Aged; Muscarinic Antagonists; Prevalence; Prospective Studies; Prostatic Hyperplasia; Retrospective Studies; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive	2011
Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer. The Prostate, 2011, Volume: 71, Issue:10 Topics: 5-alpha Reductase Inhibitors; Aged; Androgens; Cells, Cultured; Dihydrotestosterone; Finasteride; Humans; Immunohistochemistry; Male; Prostate; Prostatic Hyperplasia; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Testosterone; Up-Regulation	2011
Ganoderma lucidum is an inhibitor of testosterone-induced prostatic hyperplasia in rats. Andrologia, 2012, Volume: 44 Suppl 1 Topics: Animals; Chromatography, Thin Layer; Finasteride; Male; Plant Extracts; Prostate-Specific Antigen; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Reishi; Testosterone	2012
Effect of red maca (Lepidium meyenii) on prostate zinc levels in rats with testosterone-induced prostatic hyperplasia. Andrologia, 2012, Volume: 44 Suppl 1 Topics: Animals; Finasteride; Lepidium; Male; Organ Size; Plant Extracts; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Testosterone; Zinc	2012
Improving lower urinary tract symptoms in BPH. The Practitioner, 2011, Volume: 255, Issue:1739 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Urinary Bladder Calculi; Urination Disorders	2011
Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia, 2012, Volume: 44 Suppl 1 Topics: Animals; Body Weight; Chromatography, Thin Layer; Finasteride; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Male; Mice; Organ Size; Plant Extracts; Prostate-Specific Antigen; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Testosterone; Urtica dioica	2012
Effects of in utero exposure to D-004, a lipid extract from Roystonea regia fruits, in the male rat: a comparison with finasteride. Journal of medicinal food, 2011, Volume: 14, Issue:12 Topics: Androgens; Animals; Arecaceae; Female; Finasteride; Fruit; Lipids; Male; Plant Extracts; Pregnancy; Prenatal Exposure Delayed Effects; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Testosterone	2011
[Does St. John's wort interact with finasteride?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:34-35 Topics: 5-alpha Reductase Inhibitors; Cytochrome P-450 CYP3A; Depressive Disorder; Drug Interactions; Enzyme Activation; Finasteride; Humans; Hypericum; Male; Phytotherapy; Plant Extracts; Prostate-Specific Antigen; Prostatic Hyperplasia	2011
Comment on "Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer" by Hsieh et al. The Prostate, 2012, May-15, Volume: 72, Issue:7 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Androgen; Up-Regulation	2012
The benefit of stratification in clinical trials revisited. Statistics in medicine, 2011, Oct-30, Volume: 30, Issue:24 Topics: 5-alpha Reductase Inhibitors; Analysis of Variance; Biostatistics; Clinical Trials as Topic; Finasteride; Humans; Male; Models, Statistical; Multicenter Studies as Topic; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Sample Size	2011
What's wrong with chemoprevention of prostate cancer? The American journal of bioethics : AJOB, 2011, Volume: 11, Issue:12 Topics: 5-alpha Reductase Inhibitors; Advisory Committees; Aged; Antineoplastic Agents; Azasteroids; Biomarkers, Tumor; Chemoprevention; Cost of Illness; Dutasteride; Early Detection of Cancer; Evidence-Based Medicine; Finasteride; Humans; Informed Consent; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment	2011
Finasteride adherence-associated factors in Chinese benign prostatic hyperplasia patients. Urologia internationalis, 2012, Volume: 88, Issue:2 Topics: 5-alpha Reductase Inhibitors; Age Factors; Aged; Aged, 80 and over; Asian People; China; Drug Prescriptions; Drug Substitution; Finasteride; Health Knowledge, Attitudes, Practice; Humans; Logistic Models; Male; Medically Uninsured; Medication Adherence; Middle Aged; Multivariate Analysis; Odds Ratio; Prostatic Hyperplasia; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors	2012
Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU international, 2012, Volume: 110, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androgen Antagonists; Azasteroids; Biopsy; Disease Progression; Dutasteride; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies	2012
Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study. Genetic testing and molecular biomarkers, 2012, Volume: 16, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Diseases, Metabolic; Finasteride; Flutamide; Gene Frequency; Genotype; Humans; Male; Pilot Projects; Polymorphism, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Receptor, Serotonin, 5-HT1B; Serotonin	2012
5α-reductase inhibitors: preventing the treatable. European urology, 2012, Volume: 62, Issue:2 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2012
Prostate, baldness drugs linked to sexual dysfunction. JAMA, 2012, May-09, Volume: 307, Issue:18 Topics: 5-alpha Reductase Inhibitors; Alopecia; Drug Labeling; Finasteride; Humans; Infertility, Male; Male; Prostatic Hyperplasia; Sexual Dysfunction, Physiological; United States; United States Food and Drug Administration	2012
A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia. The oncologist, 2012, Volume: 17, Issue:7 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms; Taiwan	2012
Finasteride and prostate cancer: a commentary. The oncologist, 2012, Volume: 17, Issue:7 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2012
[Finasteride in the treatment of benign prostatic hyperplasia]. Der Urologe. Ausg. A, 2012, Volume: 51, Issue:7 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Finasteride; Germany; Humans; Male; Middle Aged; Prevalence; Prostatic Hyperplasia; Treatment Outcome	2012
Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction. Journal of endocrinological investigation, 2012, Volume: 35, Issue:10 Topics: 5-alpha Reductase Inhibitors; Aged; Azasteroids; Case-Control Studies; Cholestenone 5 alpha-Reductase; Dutasteride; Ejaculation; Erectile Dysfunction; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prostatic Hyperplasia; Retrospective Studies; Risk Factors; Sexual Behavior; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Testosterone	2012
A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. International journal of clinical practice, 2012, Volume: 66, Issue:11 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Drug Substitution; Dutasteride; Ejaculation; Erectile Dysfunction; Finasteride; Gynecomastia; Humans; Libido; Lower Urinary Tract Symptoms; Male; Middle Aged; Prostatic Hyperplasia; Retrospective Studies	2012
Reversible visual loss caused by combination therapy of alfuzosin and finasteride in a patient with uveitic glaucoma. Cutaneous and ocular toxicology, 2013, Volume: 32, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Drug Therapy, Combination; Finasteride; Glaucoma; Humans; Male; Middle Aged; Optic Neuropathy, Ischemic; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Vision Disorders	2013
The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis. World journal of urology, 2013, Volume: 31, Issue:3 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Azasteroids; Cohort Studies; Dutasteride; Finasteride; Follow-Up Studies; Hospitalization; Humans; Incidence; Lower Urinary Tract Symptoms; Male; Medical Record Linkage; Middle Aged; Proportional Hazards Models; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Outcome	2013
[Factors influencing finasteride medication compliance in outpatients with benign prostatic hyperplasia]. Zhonghua nan ke xue = National journal of andrology, 2012, Volume: 18, Issue:10 Topics: Aged; Aged, 80 and over; Female; Finasteride; Humans; Male; Medication Adherence; Middle Aged; Outpatients; Prostatic Hyperplasia; Retrospective Studies; Treatment Outcome	2012
Finasteride-induced thrombocytopenia. BJU international, 2002, Volume: 90, Issue:3 Topics: Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Thrombocytopenia	2002
Nonsurgical management of benign prostatic hyperplasia in men with bladder calculi. Urology, 2002, Volume: 60, Issue:2 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Cystoscopy; Drug Therapy, Combination; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Retrospective Studies; Urinary Bladder Calculi	2002
Two-drug therapy is best for symptomatic prostate enlargement: combination should change clinical practice. Journal of the American College of Surgeons, 2002, Volume: 195, Issue:2 Topics: Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Hyperplasia; Treatment Outcome	2002
Study of the association between ischemic heart disease and use of alpha-blockers and finasteride indicated for the treatment of benign prostatic hyperplasia. European urology, 2002, Volume: 42, Issue:3 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Enzyme Inhibitors; Finasteride; Hospitalization; Humans; Male; Middle Aged; Myocardial Ischemia; Prostatic Hyperplasia	2002
Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia. Urologia internationalis, 2002, Volume: 69, Issue:4 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Retrospective Studies	2002
[Efficacy of finasteride in the treatment of hematuria associated with benign prostatic hypertrophy]. Archivos espanoles de urologia, 2002, Volume: 55, Issue:8 Topics: 5-alpha Reductase Inhibitors; Aged; Comorbidity; Diabetes Mellitus; Enzyme Inhibitors; Finasteride; Hematuria; Humans; Hypertension; Male; Middle Aged; Myocardial Ischemia; Postoperative Complications; Prospective Studies; Prostatectomy; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Severity of Illness Index; Transurethral Resection of Prostate; Treatment Outcome; Vascular Diseases	2002
[5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia]. MMW Fortschritte der Medizin, 2002, Oct-31, Volume: 144, Issue:44 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Time Factors	2002
Dutasteride (Avodart) for benign prostatic hyperplasia. The Medical letter on drugs and therapeutics, 2002, Dec-23, Volume: 44, Issue:1146 Topics: Abnormalities, Drug-Induced; Administration, Oral; Azasteroids; Biological Availability; Clinical Trials as Topic; Drug Combinations; Dutasteride; Finasteride; Humans; Male; Metformin; Prostatic Hyperplasia; Thiazoles	2002
[Drugs against symptomatic, benign prostatic hyperplasia]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2002, Oct-30, Volume: 122, Issue:26 Topics: Adrenergic alpha-Antagonists; Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2002
Second opinion. I have benign prostatic hyperplasia. The drug my doctor prescribed has helped somewhat, but I'm still making a lot of trips to the bathroom at night. Short of surgery, are there any new approaches to managing this condition that might be m Mayo Clinic health letter (English ed.), 2002, Volume: 20, Issue:12 Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2002
Benign prostatic hyperplasia. Hospital medicine (London, England : 1998), 2003, Volume: 64, Issue:2 Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quinazolines	2003
[Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks]. MMW Fortschritte der Medizin, 2003, Feb-27, Volume: 145, Issue:9 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Clinical Trials, Phase III as Topic; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Infant, Newborn; Male; Placebos; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors; Testosterone; Time Factors; Ultrasonography	2003
Doxazosin and finasteride alone or in combination: the PREDICT study. BJU international, 2003, Volume: 91, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Finasteride; Humans; Male; Prostatic Hyperplasia; Urination Disorders	2003
Drug treatment of benign prostatic hyperplasia and hospital admission for BPH-related surgery. European urology, 2003, Volume: 43, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Risk Factors	2003
Benign prostatic hyperplasia: from A - Z. The Canadian journal of urology, 2003, Volume: 10, Issue:2 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2003
By the way, doctor. I'm 77 and have an enlarged prostate. I take Proscar once a day and saw palmetto three times a day. Yet I still have to get up two to seven times a night to urinate. What can I do to reduce the frequency of urination? Harvard health letter, 2003, Volume: 28, Issue:6 Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Urination Disorders	2003
Identification of baseline clinical factors which predict medical treatment failure of benign prostatic hyperplasia: an observational cohort study. European urology, 2003, Volume: 44, Issue:1 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Biopsy, Needle; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Prostatic Hyperplasia; Risk Assessment; Severity of Illness Index; Treatment Failure; Urinary Retention; Urodynamics	2003
Chemoprevention for prostate cancer: the Prostate Cancer Prevention Trial. BJU international, 2003, Volume: 92, Issue:4 Topics: Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors	2003
Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. The Prostate, 2003, Oct-01, Volume: 57, Issue:2 Topics: Case-Control Studies; Cholestenone 5 alpha-Reductase; Databases, Genetic; Enzyme Inhibitors; Finasteride; Gene Expression; Gene Expression Profiling; Humans; Male; Nucleic Acid Amplification Techniques; Oligonucleotide Array Sequence Analysis; Oxidoreductases; Prostatic Hyperplasia; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction	2003
Finasteride may prevent prostate cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Aug-01, Volume: 60, Issue:15 Topics: Antineoplastic Agents; Clinical Trials as Topic; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms	2003
Preventing prostate cancer. Finasteride shrinks enlarged prostates and may prevent some cases of prostate cancer. But it's no panacea. Health news (Waltham, Mass.), 2003, Volume: 9, Issue:8 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	2003
[5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked]. MMW Fortschritte der Medizin, 2003, Jul-10, Volume: 145, Issue:27-28 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Age Factors; Aged; Doxazosin; Drug Therapy, Combination; Finasteride; Germany; Humans; Male; Middle Aged; Placebos; Prostatic Hyperplasia; Quality of Life; Randomized Controlled Trials as Topic	2003
[The tested combination is recommended. Are 5-alpha reductase inhibitors interchangeable?]. MMW Fortschritte der Medizin, 2003, Jul-10, Volume: 145, Issue:27-28 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Practice Guidelines as Topic; Prostatic Hyperplasia; Time Factors	2003
Mixed reviews for drug studied to prevent prostate cancer. Mayo Clinic health letter (English ed.), 2003, Volume: 21, Issue:10 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms; Risk	2003
[Benign prostatic syndrome. 3-step plan for the treatment]. MMW Fortschritte der Medizin, 2003, Sep-25, Volume: 145, Issue:39 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Placebos; Prognosis; Prostate-Specific Antigen; Prostatic Hyperplasia; Risk Factors; Ultrasonography	2003
Medical management of benign prostatic hyperplasia--are two drugs better than one? The New England journal of medicine, 2003, Dec-18, Volume: 349, Issue:25 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Severity of Illness Index	2003
[Two drugs have a better outcome. Finasteride plus alpha blocker improves urine flow]. MMW Fortschritte der Medizin, 2003, Nov-20, Volume: 145, Issue:47 Topics: Adrenergic alpha-Antagonists; Aged; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urinary Bladder Neck Obstruction; Urodynamics	2003
Herbal and vitamin supplement use in a prostate cancer screening population. Urology, 2004, Volume: 63, Issue:2 Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietary Supplements; Doxazosin; Drug Utilization; Family; Finasteride; Health Surveys; Humans; Male; Mass Screening; Middle Aged; Penile Erection; Phytotherapy; Plant Preparations; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Self Medication; Socioeconomic Factors; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Urination Disorders; Vitamins	2004
A current review of medical therapy for benign prostatic hyperplasia. The Journal of the American Osteopathic Association, 2004, Volume: 104, Issue:2 Suppl 2 Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination Disorders	2004
Finasteride in benign prostatic hyperplasia. The New England journal of medicine, 2004, Mar-25, Volume: 350, Issue:13 Topics: 5-alpha Reductase Inhibitors; Breast Neoplasms, Male; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; United States	2004
Finasteride in benign prostatic hyperplasia. The New England journal of medicine, 2004, Mar-25, Volume: 350, Issue:13 Topics: 5-alpha Reductase Inhibitors; Acute Disease; Adrenergic alpha-Antagonists; Cohort Studies; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Retrospective Studies; Urinary Retention	2004
[Finasteride and prostate cancer]. Duodecim; laaketieteellinen aikakauskirja, 2004, Volume: 120, Issue:5 Topics: Finasteride; Finland; Humans; Male; Monitoring, Physiologic; Prognosis; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	2004
5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. European urology, 2004, Volume: 45, Issue:5 Topics: 5-alpha Reductase Inhibitors; Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Prostatic Hyperplasia; Regression Analysis; Retrospective Studies; Urinary Retention	2004
Two-drug therapy is best for symptomatic prostate enlargement: could a combination of doxazosin and finasteride change clinical practice? BJU international, 2004, Volume: 93, Issue:7 Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2004
Reduction of rat prostate weight by combined quercetin-finasteride treatment is associated with cell cycle deregulation. The Journal of endocrinology, 2004, Volume: 181, Issue:3 Topics: Animals; Cell Cycle; Cell Cycle Proteins; Dihydrotestosterone; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Finasteride; Male; Organ Size; Prostate; Prostatic Hyperplasia; Quercetin; Rats; Rats, Sprague-Dawley; Testosterone	2004
Meta-analysis: creating a level playing field for the patient with symptomatic benign prostatic hyperplasia? BJU international, 2004, Volume: 94, Issue:1 Topics: Antineoplastic Agents; Catheter Ablation; Finasteride; Humans; Male; Meta-Analysis as Topic; Prazosin; Prostatic Hyperplasia	2004
Benign prostate hyperplasia: evaluation of treatment response with DCE MRI. Magma (New York, N.Y.), 2004, Volume: 17, Issue:1 Topics: Animals; Contrast Media; Dogs; Enzyme Inhibitors; Finasteride; Gadolinium; Heterocyclic Compounds; Kinetics; Magnetic Resonance Imaging; Male; Organometallic Compounds; Prostate; Prostatic Hyperplasia; Time Factors; Treatment Outcome	2004
Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology, 2004, Volume: 145, Issue:12 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgens; Animals; Enzyme Inhibitors; Finasteride; Flutamide; Male; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Testis	2004
An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. The Canadian journal of urology, 2004, Volume: 11, Issue:4 Topics: Adrenergic alpha-Antagonists; Cost-Benefit Analysis; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Models, Economic; Prostatic Hyperplasia	2004
[Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination]. Aktuelle Urologie, 2004, Volume: 35, Issue:5 Topics: Adrenergic alpha-Antagonists; Controlled Clinical Trials as Topic; Disease Progression; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Placebos; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors	2004
Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:1 Topics: Aged; Aged, 80 and over; Apoptosis; Caspase 3; Caspase 6; Caspase 9; Caspases; Enzyme Activation; Enzyme Inhibitors; Finasteride; Humans; Immunohistochemistry; Male; Middle Aged; Prostatic Hyperplasia; Retrospective Studies; RNA, Messenger	2005
MTOPS: conclusions about invasive therapy for BPH should be interpreted with caution. BJU international, 2004, Volume: 94, Issue:7 Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia	2004
Two for the price of one? British journal of pharmacology, 2005, Volume: 144, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Agonists; Angiotensin II; Apoptosis; Azasteroids; Cell Line; Cell Proliferation; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Mitogens; Prostatic Hyperplasia; Receptor, Angiotensin, Type 1; Stromal Cells	2005
Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells. Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Androgens; Antineoplastic Agents, Hormonal; Azasteroids; Cell Line, Tumor; Cell Proliferation; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Staging; Prostatic Hyperplasia; Prostatic Neoplasms	2005
Finasteride with doxazosin to reduce BPH progression. The Nurse practitioner, 2005, Volume: 30, Issue:3 Topics: Disease Progression; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Prostatic Hyperplasia	2005
Re: an economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. The Canadian journal of urology, 2005, Volume: 12, Issue:1 Topics: Adrenergic alpha-Antagonists; Cost-Benefit Analysis; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quality-Adjusted Life Years	2005
A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. The Journal of urology, 2005, Volume: 173, Issue:6 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cross-Sectional Studies; Finasteride; Health Surveys; Humans; Incidence; Male; Middle Aged; Minimally Invasive Surgical Procedures; Minnesota; Phytotherapy; Population Surveillance; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; Retrospective Studies; Urinary Bladder Neck Obstruction	2005
A cost comparison of medical management and transurethral needle ablation for treatment of benign prostatic hyperplasia during a 5-year period. The Journal of urology, 2005, Volume: 173, Issue:6 Topics: Aged; Combined Modality Therapy; Costs and Cost Analysis; Cystoscopy; Drug Costs; Drug Therapy, Combination; Finasteride; Follow-Up Studies; Humans; Male; Medicare Assignment; Middle Aged; Models, Economic; Prostatic Hyperplasia; Retreatment; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome; United States	2005
Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. Clinical prostate cancer, 2005, Volume: 3, Issue:4 Topics: Antineoplastic Agents, Hormonal; Chemoprevention; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Toremifene	2005
Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. European urology, 2005, Volume: 48, Issue:2 Topics: Adrenergic alpha-Antagonists; Androgen Antagonists; Enzyme Inhibitors; Finasteride; Humans; Male; Plant Extracts; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Serenoa; Sexual Behavior; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Treatment Outcome; Urodynamics	2005
Bayesian analysis of multicentre trial outcomes. Statistical methods in medical research, 2005, Volume: 14, Issue:3 Topics: Antacids; Bayes Theorem; Double-Blind Method; Drugs, Investigational; Famotidine; Finasteride; Heartburn; Humans; Male; Multicenter Studies as Topic; Outcome Assessment, Health Care; Placebo Effect; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; United States	2005
Evaluation and medical management of benign prostatic hyperplasia. Mayo Clinic proceedings, 2005, Volume: 80, Issue:10 Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Physical Examination; Prostate-Specific Antigen; Prostatic Hyperplasia; Urodynamics	2005
The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). BJU international, 2005, Volume: 96, Issue:7 Topics: 5-alpha Reductase Inhibitors; Adenoma; Adrenergic alpha-Antagonists; Age Factors; Aged; Chi-Square Distribution; Cross-Sectional Studies; Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Patient Selection; Phytotherapy; Prostate; Prostatectomy; Prostatic Hyperplasia; Retrospective Studies	2005
[Analysis of the scientific evidence of the combination therapy in benign prostatic hyperplasia]. Actas urologicas espanolas, 2005, Volume: 29, Issue:8 Topics: Adrenergic alpha-Antagonists; Combined Modality Therapy; Enzyme Inhibitors; Evidence-Based Medicine; Finasteride; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Treatment Outcome	2005
Should patients with benign prostatic hypertrophy stop taking doxazosin in the light of the ALLHAT study? International journal of cardiology, 2006, Feb-15, Volume: 107, Issue:2 Topics: Adrenergic alpha-Antagonists; Anticholesteremic Agents; Antihypertensive Agents; Clinical Trials as Topic; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Glucose Intolerance; Humans; Hyperlipidemias; Hypertension; Male; Myocardial Infarction; Prostatic Hyperplasia	2006
Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia. The Journal of urology, 2006, Volume: 175, Issue:3 Pt 1 Topics: Adrenergic alpha-Antagonists; Cross-Sectional Studies; Drug Utilization; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; United States; Urologic Surgical Procedures	2006
Finasteride: middle-age cure-all for alopecia and benign prostatic hyperplasia? Mayo Clinic proceedings, 2006, Volume: 81, Issue:2 Topics: 5-alpha Reductase Inhibitors; Alopecia; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms	2006
Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. The Prostate, 2006, Aug-01, Volume: 66, Issue:11 Topics: Apoptosis; Cell Adhesion; Cells, Cultured; Factor VIII; Finasteride; Humans; In Situ Nick-End Labeling; Male; Microcirculation; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies; Tumor Cells, Cultured	2006
Pharmacokinetic parameters as a potential predictor of response to pharmacotherapy in benign prostatic hyperplasia: a preclinical trial using dynamic contrast-enhanced MRI. Magnetic resonance imaging, 2006, Volume: 24, Issue:6 Topics: Animals; Contrast Media; Disease Models, Animal; Dogs; Enzyme Inhibitors; Finasteride; Gadolinium; Heterocyclic Compounds; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Microcirculation; Organometallic Compounds; Prospective Studies; Prostate; Prostatic Hyperplasia; Random Allocation; Statistics, Nonparametric; Treatment Outcome	2006
Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study. Bangladesh Medical Research Council bulletin, 2005, Volume: 31, Issue:2 Topics: Adrenergic alpha-Antagonists; Aged; Bangladesh; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Treatment Outcome	2005
Benign prostatic hyperplasia: caveat for finasteride should be discussed before prescribing. BMJ (Clinical research ed.), 2006, Sep-23, Volume: 333, Issue:7569 Topics: Antineoplastic Agents; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2006
Benign prostatic hyperplasia (BPH). Harvard men's health watch, 2006, Volume: 11, Issue:1 Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	2006
Prostate cancer risk among users of finasteride and alpha-blockers - a population based case-control study. European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:4 Topics: Adrenergic alpha-Antagonists; Case-Control Studies; Enzyme Inhibitors; Finasteride; Humans; Male; Odds Ratio; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors	2007
Benign prostatic hypertrophy: update on drug therapy. Canadian family physician Medecin de famille canadien, 2006, Volume: 52, Issue:9 Topics: Aged; Androgen Antagonists; Azasteroids; Canada; Dose-Response Relationship, Drug; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prognosis; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome	2006
Differences in alpha blocker usage among enlarged prostate patients receiving combination therapy with 5 ARIs. The American journal of managed care, 2007, Volume: 13 Suppl 1 Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Azasteroids; Cohort Studies; Drug Therapy, Combination; Dutasteride; Finasteride; Follow-Up Studies; Humans; Male; Managed Care Programs; Middle Aged; Probability; Proportional Hazards Models; Prostatic Hyperplasia; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome	2007
Finasteride versus dutasteride: a real-world economic evaluation. The American journal of managed care, 2007, Volume: 13 Suppl 1 Topics: Aged; Azasteroids; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Dutasteride; Finasteride; Global Health; Health Care Costs; Humans; Male; Managed Care Programs; Middle Aged; Prostatic Hyperplasia; Registries; Retrospective Studies; Severity of Illness Index	2007
Effect of two different extracts of red maca in male rats with testosterone-induced prostatic hyperplasia. Asian journal of andrology, 2007, Volume: 9, Issue:2 Topics: Alcohols; Animals; Finasteride; Lepidium; Male; Organ Size; Plant Extracts; Prostate; Prostatic Hyperplasia; Rats; Testosterone; Thiocyanates; Thioglucosides; Water	2007
Repetitive prostatic massage and drug therapy as an alternative to transurethral resection of the prostate. MedGenMed : Medscape general medicine, 2006, Oct-25, Volume: 8, Issue:4 Topics: Adrenergic alpha-Antagonists; Aged; Anti-Infective Agents; Complementary Therapies; Finasteride; Humans; Male; Massage; Middle Aged; Prostate; Prostatic Hyperplasia; Prostatitis; Retrospective Studies; Transurethral Resection of Prostate; Urinary Catheterization; Urinary Retention	2006
Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway. Scandinavian journal of urology and nephrology, 2007, Volume: 41, Issue:2 Topics: Azasteroids; Costs and Cost Analysis; Dutasteride; Finasteride; Humans; Male; Norway; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Time Factors; Transurethral Resection of Prostate	2007
Anabolic effects of testosterone are preserved during inhibition of 5alpha-reductase. American journal of physiology. Endocrinology and metabolism, 2007, Volume: 293, Issue:2 Topics: Animals; Apoptosis; Body Composition; Body Weight; Bone and Bones; Bone Density; Cholestenone 5 alpha-Reductase; Eating; Finasteride; Hemoglobins; Male; Muscle Fibers, Skeletal; Muscle Strength; Orchiectomy; Prostate; Prostatic Hyperplasia; Rats; Rats, Inbred F344; Testosterone	2007
Advances in the medical management of benign prostatic hyperplasia. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Jun-19, Volume: 176, Issue:13 Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2007
Finasteride: new indication. Benign prostatic hypertrophy: sexual disorders. Prescrire international, 2007, Volume: 16, Issue:90 Topics: Enzyme Inhibitors; Finasteride; France; Humans; Male; Prostatic Hyperplasia; Sexual Behavior; Urinary Retention	2007
Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperplasia. Urology, 2007, Volume: 70, Issue:3 Topics: Aged; Blood Pressure; Doxazosin; Finasteride; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Organ Size; Pituitary-Adrenal System; Prostate; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Saliva; Stress, Psychological; Sympathetic Nervous System; Testosterone; Ultrasonography; Urinary Bladder; Urination Disorders	2007
Predictability of irritative voiding symptoms following photoselective laser vaporization of the prostate. The Canadian journal of urology, 2007, Volume: 14, Issue:5 Topics: Aged; Dysuria; Enzyme Inhibitors; Finasteride; Humans; Laser Therapy; Male; Middle Aged; Predictive Value of Tests; Prostate; Prostatic Hyperplasia; Retrospective Studies; Urinary Incontinence, Urge; Urination Disorders	2007
Inhibitory effect of traditional Chinese medicine Zi-Shen Pill on benign prostatic hyperplasia in rats. Journal of ethnopharmacology, 2008, Jan-17, Volume: 115, Issue:2 Topics: Administration, Oral; Anemarrhena; Animals; Cinnamomum aromaticum; Drugs, Chinese Herbal; Enzyme Inhibitors; Fibroblast Growth Factor 2; Finasteride; Gene Expression Regulation; Male; Medicine, Chinese Traditional; Phellodendron; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A	2008
Intraoperative floppy-iris syndrome and finasteride intake. Journal of cataract and refractive surgery, 2007, Volume: 33, Issue:12 Topics: Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Humans; Intraoperative Complications; Iris Diseases; Male; Phacoemulsification; Prostatic Hyperplasia; Pupil; Syndrome	2007
Decreased efficiency of potassium-titanyl-phosphate laser photoselective vaporization prostatectomy with long-term 5 alpha-reductase inhibition therapy: is it true? Urology, 2007, Volume: 70, Issue:5 Topics: Aged; Azasteroids; Cholestenone 5 alpha-Reductase; Combined Modality Therapy; Dutasteride; Finasteride; Humans; Lasers, Solid-State; Male; Prospective Studies; Prostatic Hyperplasia; Time Factors; Transurethral Resection of Prostate	2007
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. American journal of epidemiology, 2008, Apr-15, Volume: 167, Issue:8 Topics: Aged; Aged, 80 and over; Alcohol Drinking; Diet; Dietary Supplements; Feeding Behavior; Finasteride; Humans; Incidence; Male; Middle Aged; Nutrition Surveys; Nutritional Status; Odds Ratio; Prospective Studies; Prostatic Hyperplasia; Prostatic Neoplasms; Proteins; Risk Assessment; Risk Factors; Surveys and Questionnaires; United States	2008
Finasteride therapy for benign prostatic hyperplasia. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008, Feb-26, Volume: 178, Issue:5 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2008
[Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18 Suppl 3 Topics: Chemoprevention; Decision Trees; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Urination Disorders	2008
Antagonistic effect of Lepidium meyenii (red maca) on prostatic hyperplasia in adult mice. Andrologia, 2008, Volume: 40, Issue:3 Topics: Animals; Enzyme Inhibitors; Estradiol; Finasteride; Lepidium; Male; Mice; Phytotherapy; Prostatic Hyperplasia; Testosterone	2008
[Drug treatment of benign prostatic hyperplasia]. Praxis, 1995, Sep-26, Volume: 84, Issue:39 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androgen Antagonists; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prostatic Hyperplasia	1995
[Finasteride. A new 5 alpha reductase inhibitor registered for treatment of benign prostatic hypertrophy with the purpose of avoiding or postponing surgery]. Ugeskrift for laeger, 1993, Dec-13, Volume: 155, Issue:50 Topics: Contraindications; Finasteride; Humans; Male; Prostatectomy; Prostatic Hyperplasia	1993
Finasteride, MSD: Innovation in the Management of Benign Prostatic Hyperplasia. Proceedings of a symposium. Seville, Spain, November 3, 1991. European urology, 1994, Volume: 25 Suppl 1 Topics: Animals; Finasteride; Humans; Male; Prostatic Hyperplasia	1994
Benign prostatic hyperplasia: diagnosis and treatment. Agency for Health Care Policy and Research. Clinical practice guideline. Quick reference guide for clinicians, 1994, Issue:8 Topics: Adrenergic alpha-Antagonists; Catheterization; Decision Trees; Finasteride; Humans; Male; Prostatectomy; Prostatic Hyperplasia	1994
Men's health issues. Archives of family medicine, 1993, Volume: 2, Issue:9 Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms	1993
[Finasteride (Proscar) for benign prostatic hypertrophy]. Harefuah, 1993, Dec-15, Volume: 125, Issue:12 Topics: Aged; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prostatic Hyperplasia; Time Factors	1993
The medication minute: Finasteride. Urologic nursing, 1994, Volume: 14, Issue:1 Topics: Finasteride; Humans; Male; Patient Care Planning; Prostatic Hyperplasia	1994
Benign prostatic hyperplasia: diagnosis and treatment. Benign Prostatic Hyperplasia Guideline Panel. Agency for Health Care Policy and Research. American family physician, 1994, Volume: 49, Issue:5 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Catheterization; Clinical Protocols; Decision Trees; Diagnosis, Differential; Finasteride; Humans; Male; Middle Aged; Patient Education as Topic; Prevalence; Prostatectomy; Prostatic Hyperplasia; Risk Factors; Severity of Illness Index; Treatment Outcome	1994
Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor. Urology, 1994, Volume: 43, Issue:5 Topics: 5-alpha Reductase Inhibitors; Animals; Atrophy; Finasteride; Humans; Male; Organ Size; Prostate; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Testosterone; Time Factors	1994
Medical therapy for BPH. Urology, 1994, Volume: 43, Issue:5 Topics: Diathermy; Finasteride; Humans; Male; Prostatic Hyperplasia; Quality of Life	1994
Drugs recently released in Belgium. Eflornithine--finasteride. Acta clinica Belgica, 1994, Volume: 49, Issue:1 Topics: Eflornithine; Finasteride; Humans; Male; Prostatic Hyperplasia	1994
[Non surgical treatment of benign prostatic hypertrophy. Past, present and future]. Journal d'urologie, 1993, Volume: 99, Issue:6 Topics: Adrenergic alpha-Antagonists; Androgen Antagonists; Aromatase Inhibitors; Finasteride; History, 17th Century; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Male; Prostatic Hyperplasia	1993
Benign prostatic hypertrophy. Options for management. The Medical journal of Australia, 1994, Aug-01, Volume: 161, Issue:3 Topics: Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Laser Therapy; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia	1994
Treating benign prostatic hyperplasia with medications. Nurse practitioner forum, 1994, Volume: 5, Issue:3 Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Prostatic Hyperplasia	1994
Effect of 5-alpha-reductase inhibition on sex-hormone-binding globulin in elderly men. Hormone research, 1994, Volume: 41, Issue:5-6 Topics: Aged; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Finasteride; Humans; Male; Middle Aged; Oxidoreductases; Prostatic Hyperplasia; Radioimmunoassay; Sex Hormone-Binding Globulin; Testosterone	1994
[Prostatic adenoma and specific prostatic antigen]. Actas urologicas espanolas, 1994, Volume: 18, Issue:8 Topics: Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia	1994
Medical therapy for benign prostatic hyperplasia. AJR. American journal of roentgenology, 1995, Volume: 164, Issue:1 Topics: Adrenergic alpha-Antagonists; Androstenedione; Aromatase Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Hyperplasia	1995
Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression. The Prostate, 1995, Volume: 26, Issue:2 Topics: 5-alpha Reductase Inhibitors; Animals; Dihydrotestosterone; DNA; Dogs; Finasteride; Magnetic Resonance Imaging; Male; Molecular Structure; Organ Size; Prostate; Prostatic Hyperplasia; Proteins; Structure-Activity Relationship; Time Factors	1995
5 alpha-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia. Steroids, 1994, Volume: 59, Issue:11 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Epithelium; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Stromal Cells	1994
Prostate cancer. Current therapy in endocrinology and metabolism, 1994, Volume: 5 Topics: 5-alpha Reductase Inhibitors; Aged; Anticarcinogenic Agents; Disease-Free Survival; Estrogens; Finasteride; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Lymphatic Metastasis; Male; Neoplasm Metastasis; Neoplasm Staging; Prevalence; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Radiotherapy	1994
Benign prostatic hyperplasia. Current therapy in endocrinology and metabolism, 1994, Volume: 5 Topics: Aged; Aged, 80 and over; Drug Interactions; Finasteride; Follow-Up Studies; Humans; Male; Prostatic Hyperplasia	1994
The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia. The Australian and New Zealand journal of surgery, 1995, Volume: 65, Issue:5 Topics: Electrocardiography; Finasteride; Humans; Male; Myocardial Infarction; Prostate; Prostatic Hyperplasia; Urodynamics	1995
[PSA values before and after finasteride treatment in patients with benign prostatic hypertrophy]. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 1995, Volume: 67, Issue:1 Topics: Aged; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Time Factors; Ultrasonography	1995
Case report: finasteride-induced gynecomastia in a 62-year-old man. The American journal of the medical sciences, 1995, Volume: 309, Issue:6 Topics: Dihydrotestosterone; Finasteride; Gynecomastia; Humans; Male; Middle Aged; Prolactin; Prostatic Hyperplasia; Testosterone	1995
[5-alpha-reductase inhibitors]. Acta urologica Belgica, 1994, Volume: 62, Issue:4 Topics: 5-alpha Reductase Inhibitors; Dihydrotestosterone; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia	1994
Combination drug therapy for benign prostatic hyperplasia. JAMA, 1995, Jul-26, Volume: 274, Issue:4 Topics: Adrenergic alpha-Antagonists; Drug Synergism; Drug Therapy, Combination; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia	1995
Potential activities of androgen metabolizing enzymes in human prostate. The Journal of steroid biochemistry and molecular biology, 1995, Volume: 53, Issue:1-6 Topics: Adult; Aged; Aging; Androgens; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Epithelium; Finasteride; Humans; Kinetics; Male; Middle Aged; Oxidoreductases; Prostate; Prostatic Hyperplasia	1995
[Therapeutic approach to prostatic adenoma in primary care]. Atencion primaria, 1994, Mar-31, Volume: 13, Issue:5 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Finasteride; Humans; Male; Middle Aged; Phytotherapy; Primary Health Care; Prostatic Hyperplasia	1994
Benign prostatic hyperplasia. Age and type of treatment. Journal d'urologie, 1995, Volume: 101, Issue:1 Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Erectile Dysfunction; Finasteride; Humans; Male; Middle Aged; Postoperative Complications; Prostatectomy; Prostatic Hyperplasia	1995
I-PSS and type of treatment. Journal d'urologie, 1995, Volume: 101, Issue:1 Topics: Data Interpretation, Statistical; Finasteride; Humans; Male; Prostatectomy; Prostatic Hyperplasia; Quality of Life; Urination Disorders	1995
Benign prostatic hyperplasia (BPH) therapy: when? how? why? the take-home message. Journal d'urologie, 1995, Volume: 101, Issue:1 Topics: Adrenergic alpha-Antagonists; Catheterization; Finasteride; Health Care Costs; Humans; Male; Prostatectomy; Prostatic Hyperplasia	1995
The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. The Journal of urology, 1995, Volume: 154, Issue:5 Topics: Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Hematuria; Humans; Male; Prostatic Hyperplasia; Retrospective Studies	1995
Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors. The Prostate, 1995, Volume: 27, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epithelium; Finasteride; Male; Muscle, Smooth; Prostate; Prostatic Hyperplasia; Random Allocation; Stromal Cells; Time Factors	1995
Finasteride for benign prostatic hyperplasia. The New England journal of medicine, 1993, Feb-11, Volume: 328, Issue:6 Topics: Androstenes; Azasteroids; Finasteride; Humans; Male; Prostatic Hyperplasia	1993
Finasteride for benign prostatic hyperplasia. The New England journal of medicine, 1993, Feb-11, Volume: 328, Issue:6 Topics: Androstenes; Azasteroids; Finasteride; Humans; Male; Prostatic Hyperplasia; Sexual Behavior	1993
Finasteride for benign prostatic hyperplasia. The New England journal of medicine, 1993, Feb-11, Volume: 328, Issue:6 Topics: Aged; Aging; Androstenes; Azasteroids; Finasteride; Humans; Male; Prostatic Hyperplasia; Urodynamics	1993
New options for patients with benign prostatic hyperplasia. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1993, Feb-15, Volume: 148, Issue:4 Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Finasteride; Humans; Male; Prostatic Hyperplasia	1993
Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model. The Journal of urology, 1993, Volume: 149, Issue:3 Topics: 5-alpha Reductase Inhibitors; Androstenes; Animals; Azasteroids; Dihydrotestosterone; Disease Models, Animal; Fibroblast Growth Factor 3; Fibroblast Growth Factors; Finasteride; Flutamide; Genes, Viral; Male; Mammary Tumor Virus, Mouse; Mice; Mice, Transgenic; Orchiectomy; Phenotype; Prostate; Prostatic Hyperplasia; Proto-Oncogene Proteins; Sexual Maturation; Testosterone	1993
Transurethral resection of the prostate: still the gold standard? Canadian journal of surgery. Journal canadien de chirurgie, 1993, Volume: 36, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Androstenes; Azasteroids; Catheterization; Finasteride; Humans; Hyperthermia, Induced; Incidence; Male; Middle Aged; Prazosin; Prostatectomy; Prostatic Hyperplasia	1993
Finasteride for benign prostatic hyperplasia. The Nurse practitioner, 1993, Volume: 18, Issue:3 Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Finasteride; Humans; Male; Prostatic Hyperplasia	1993
Thoughts on finasteride for benign prostatic hyperplasia. American family physician, 1993, Sep-15, Volume: 48, Issue:4 Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia	1993
Finasteride, a steroid 5 alpha-reductase inhibitor, does not affect the oxidative metabolism of antipyrine. Journal of clinical pharmacology, 1993, Volume: 33, Issue:10 Topics: Administration, Oral; Aged; Antipyrine; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Single-Blind Method	1993
[The treatment of prostatic hypertrophy]. Recenti progressi in medicina, 1993, Volume: 84, Issue:10 Topics: Finasteride; Humans; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia	1993
Prostatic specific antigen (PSA) Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 1993, Volume: 45, Issue:2 Topics: Biomarkers, Tumor; Diagnosis, Differential; False Negative Reactions; Finasteride; Humans; Male; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Reference Values	1993
The effect of low dose finasteride therapy in a man with prostatism. The Journal of urology, 1996, Volume: 155, Issue:2 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia	1996
The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work? The Journal of urology, 1996, Volume: 155, Issue:6 Topics: Adrenergic alpha-Antagonists; Cohort Studies; Evaluation Studies as Topic; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Prostatectomy; Prostatic Hyperplasia; Societies, Medical; Time Factors; Urination Disorders; Urology	1996
Treatment of benign prostatic hyperplasia. The Scandinavian BPH Study Group. Lancet (London, England), 1996, May-04, Volume: 347, Issue:9010 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	1996
Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond. Journal of clinical pathology, 1996, Volume: 49, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Case-Control Studies; Finasteride; Humans; Immunoenzyme Techniques; Male; Middle Aged; Prostate; Prostatectomy; Prostatic Hyperplasia; Treatment Failure	1996
[Variation in the diagnosis and treatment of benign prostatic hyperplasia in urological practice]. Nederlands tijdschrift voor geneeskunde, 1996, Apr-13, Volume: 140, Issue:15 Topics: Adrenergic alpha-Antagonists; Aged; Clinical Protocols; Cross-Sectional Studies; Enzyme Inhibitors; Finasteride; Humans; Logistic Models; Male; Middle Aged; Practice Patterns, Physicians'; Prostatectomy; Prostatic Hyperplasia; Sampling Studies; Urodynamics	1996
Treatment of benign prostatic hyperplasia. The New England journal of medicine, 1996, Aug-22, Volume: 335, Issue:8 Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Oxidoreductases; Prazosin; Prostatic Hyperplasia	1996
[Drugs for prostatic adenoma]. Soins; la revue de reference infirmiere, 1995, Issue:599 Topics: Adrenergic alpha-Antagonists; Drug Monitoring; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quinazolines	1995
5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor. Cellular and molecular biology (Noisy-le-Grand, France), 1995, Volume: 41, Issue:8 Topics: Base Sequence; Cells, Cultured; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; DNA Primers; DNA, Complementary; Enzyme Inhibitors; Epithelial Cells; Epithelium; Finasteride; Humans; Isoenzymes; Male; Molecular Sequence Data; Oxidoreductases; Polymerase Chain Reaction; Prostate; Prostatic Hyperplasia	1995
Analyzing finasteride data. Neurourology and urodynamics, 1995, Volume: 14, Issue:6 Topics: Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Prostate; Prostatic Hyperplasia; Time Factors	1995
Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study. The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:3 Topics: Aged; Biomarkers; Bone and Bones; Bone Density; Dihydrotestosterone; Finasteride; Humans; Male; Parathyroid Hormone; Prostatic Hyperplasia	1996
Gynecomastia and breast cancer during finasteride therapy. The New England journal of medicine, 1996, Sep-12, Volume: 335, Issue:11 Topics: Breast Neoplasms, Male; Finasteride; Gynecomastia; Humans; Male; Prostatic Hyperplasia	1996
[Assessment of the effect of a 5-alpha-reductase inhibitor on cultured explants of human prostate]. Actas urologicas espanolas, 1996, Volume: 20, Issue:4 Topics: Culture Techniques; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	1996
Finasteride-related cutaneous vaculitis. Postgraduate medical journal, 1996, Volume: 72, Issue:844 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Vasculitis, Leukocytoclastic, Cutaneous	1996
The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. British journal of urology, 1996, Volume: 78, Issue:3 Topics: Adolescent; Adult; Aged; Cohort Studies; Ejaculation; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Gynecomastia; Hair Diseases; Humans; Libido; Male; Middle Aged; Product Surveillance, Postmarketing; Prostatic Hyperplasia; Urination Disorders	1996
Study provides head-to-head comparison of terazosin, finasteride. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1996, Oct-15, Volume: 53, Issue:20 Topics: Adrenergic alpha-Antagonists; Cholestenone 5 alpha-Reductase; Drug Therapy, Combination; Finasteride; Humans; Male; Oxidoreductases; Prazosin; Prostatic Hyperplasia	1996
[Benign prostatic hyperplasia--its treatment with Proscar]. Khirurgiia, 1996, Volume: 49, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Cholestenone 5 alpha-Reductase; Chronic Disease; Drug Evaluation; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Oxidoreductases; Prostatic Hyperplasia; Remission Induction; Urodynamics	1996
Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy. World journal of urology, 1996, Volume: 14, Issue:6 Topics: Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia	1996
The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia. The Mount Sinai journal of medicine, New York, 1997, Volume: 64, Issue:1 Topics: Antineoplastic Agents, Hormonal; Enzyme Inhibitors; Estrogen Antagonists; Estrogens; Finasteride; Humans; Leuprolide; Male; Prostatic Hyperplasia; Testosterone	1997
[Treatment of prostate adenoma with finasteride. Contribution of cases]. Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 1996, Volume: 48, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Treatment Outcome; Ultrasonography	1996
Clinical and biological characteristics of familial benign prostatic hyperplasia. The Journal of urology, 1997, Volume: 157, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Clinical Trials, Phase III as Topic; Finasteride; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prostate-Specific Antigen; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	1997
Managing benign prostatic hyperplasia. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 1997, Apr-01, Volume: 156, Issue:7 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	1997
Economics of different treatment options of benign prostatic hyperplasia in Turkey. International urology and nephrology, 1996, Volume: 28, Issue:4 Topics: Cost-Benefit Analysis; Costs and Cost Analysis; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostatectomy; Prostatic Hyperplasia; Turkey	1996
Reversible severe myopathy during treatment with finasteride. Muscle & nerve, 1997, Volume: 20, Issue:4 Topics: Aged; Biopsy; Enzyme Inhibitors; Finasteride; Humans; Male; Muscle, Skeletal; Neuromuscular Diseases; Prostatic Hyperplasia; Urination Disorders	1997
Lovastatin-induced apoptosis in prostate stromal cells. The Journal of clinical endocrinology and metabolism, 1997, Volume: 82, Issue:5 Topics: Apoptosis; Cholesterol; Dihydrotestosterone; Diterpenes; DNA; Enzyme Inhibitors; Finasteride; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Male; Mevalonic Acid; Prostate; Prostatic Hyperplasia; Stromal Cells; Testosterone	1997
Drug treatment for benign prostatic hyperplasia. BMJ (Clinical research ed.), 1997, Apr-26, Volume: 314, Issue:7089 Topics: Adrenergic Agonists; Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Female; Finasteride; Humans; Male; Middle Aged; Muscle Tonus; Prostatic Hyperplasia	1997
Optimising the medical management of benign prostatic hyperplasia. The British journal of clinical practice, 1997, Volume: 51, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Prostatic Hyperplasia; Treatment Outcome	1997
[Ureteral jet in patients with benign prostatic hypertrophy: prognostic evaluation during single and combined therapy]. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 1996, Volume: 68, Issue:5 Suppl Topics: Adrenergic alpha-Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Ultrasonography, Doppler, Color; Urethra; Urination	1996
[Drug therapy of benign prostatic hyperplasia concentrates on early stages]. Fortschritte der Medizin, 1997, Feb-20, Volume: 115, Issue:5 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia	1997
What is the best medical treatment for benign prostate hyperplasia? Canadian family physician Medecin de famille canadien, 1997, Volume: 43 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Therapy, Combination; Family Practice; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Treatment Outcome	1997
Finasteride induced gynecomastia. The Journal of urology, 1997, Volume: 158, Issue:2 Topics: Aged; Enzyme Inhibitors; Finasteride; Gynecomastia; Humans; Male; Prostatic Hyperplasia	1997
Pharmacological and molecular evidence for the expression of the two steroid 5 alpha-reductase isozymes in normal and hyperplastic human prostatic cells in culture. The Prostate, 1997, Aug-01, Volume: 32, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androstadienes; Base Sequence; Benzoquinones; Blotting, Northern; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epithelial Cells; Epithelium; Fibroblasts; Finasteride; Gene Expression Regulation, Enzymologic; Humans; Isoenzymes; Male; Oligonucleotides; Polymerase Chain Reaction; Prostate; Prostatic Hyperplasia; RNA, Messenger	1997
Drug treatment for benign prostatic hyperplasia. Health authorities must audit use of finasteride. BMJ (Clinical research ed.), 1997, Aug-09, Volume: 315, Issue:7104 Topics: Cost-Benefit Analysis; Drug Costs; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	1997
Drug treatment for benign prostatic hyperplasia. Several trials have shown benefit of finasteride. BMJ (Clinical research ed.), 1997, Aug-09, Volume: 315, Issue:7104 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Meta-Analysis as Topic; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	1997
Drug treatment for benign prostatic hyperplasia. To interpret PSA concentrations in patients taking finasteride, multiply them by two. BMJ (Clinical research ed.), 1997, Aug-09, Volume: 315, Issue:7104 Topics: Biomarkers; Data Interpretation, Statistical; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia	1997
[5-alpha-reductase inhibitors in benign prostatic hyperplasia]. Khirurgiia, 1997, Volume: 50, Issue:1 Topics: 5-alpha Reductase Inhibitors; Aged; Drug Evaluation; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Urodynamics	1997
Effect of finasteride (Proscar MSD) on seminal composition, prostate function and fertility in male dogs. Journal of reproduction and fertility. Supplement, 1997, Volume: 51 Topics: 5-alpha Reductase Inhibitors; Animals; Dog Diseases; Dogs; Enzyme Inhibitors; Female; Fertility; Finasteride; Male; Prostate; Prostatic Hyperplasia; Semen; Sexual Behavior, Animal; Sperm Count; Sperm Motility	1997
Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Urology, 1997, Volume: 50, Issue:6 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Drug Evaluation; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Retrospective Studies; Statistics, Nonparametric	1997
Finasteride to prevent morbidity from benign prostatic hyperplasia. The New England journal of medicine, 1998, Feb-26, Volume: 338, Issue:9 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Quality of Life; Risk Assessment; Urinary Retention	1998
Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Analytical chemistry, 1998, Mar-01, Volume: 70, Issue:5 Topics: Chromatography, High Pressure Liquid; Chromatography, Liquid; Enzyme Inhibitors; Finasteride; Humans; Male; Mass Spectrometry; Prostatic Hyperplasia; Reproducibility of Results	1998
[Combined sabal and urtica extract vs. finasteride in benign prostatic hyperplasia (Alken stages I to II). Comment on the contribution by J. Sokeland and J. Albrech]. Der Urologe. Ausg. A, 1998, Volume: 37, Issue:1 Topics: Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Plant Extracts; Prostatic Hyperplasia; Treatment Outcome; Urinary Bladder Neck Obstruction; Urodynamics	1998
Drug therapy for prostate problems. Health news (Waltham, Mass.), 1998, Mar-31, Volume: 4, Issue:4 Topics: Finasteride; Humans; Male; Prostatic Hyperplasia	1998
[Histomorphometry study of the effect of an inhibitor of 5-alpha reductase on the coating of human prostate explants in tissue culture]. Actas urologicas espanolas, 1998, Volume: 22, Issue:1 Topics: 5-alpha Reductase Inhibitors; Culture Media; Enzyme Inhibitors; Finasteride; Humans; Male; Organ Culture Techniques; Prostate; Prostatic Hyperplasia; Testosterone	1998
Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependent EGFr mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride. International journal of cancer, 1998, May-18, Volume: 76, Issue:4 Topics: Cholestenone 5 alpha-Reductase; Culture Techniques; Enzyme Inhibitors; Epithelium; ErbB Receptors; Finasteride; Gene Expression; Humans; Male; Oxidoreductases; Polymerase Chain Reaction; Prostatic Hyperplasia; Receptor, ErbB-2; RNA, Messenger; Testosterone	1998
Study shows controversial prostate drug is beneficial. Mayo Clinic health letter (English ed.), 1998, Volume: 16, Issue:6 Topics: Finasteride; Humans; Male; Prostatic Hyperplasia	1998
Re: Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. The Journal of urology, 1998, Volume: 160, Issue:1 Topics: Age Factors; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia	1998
Finasteride for BPH. The Journal of family practice, 1998, Volume: 46, Issue:6 Topics: Acute Disease; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Reproducibility of Results; Urinary Retention	1998
A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia. Methods and findings in experimental and clinical pharmacology, 1998, Volume: 20, Issue:4 Topics: 5-alpha Reductase Inhibitors; Animals; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Finasteride; Kinetics; Male; Microsomes, Liver; NADP; Prostatic Hyperplasia; Rats; Rats, Sprague-Dawley; Spectrophotometry	1998
[Use of transrectal ultrasonography in prostate pathology: determination and clinical usefulness of the prostate transition zone]. Revue medicale de Bruxelles, 1998, Volume: 19, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Catheter Ablation; Diagnosis, Differential; Enzyme Inhibitors; Finasteride; Forecasting; Humans; Laser Coagulation; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Survival Rate; Ultrasonography	1998
Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia. East African medical journal, 1998, Volume: 75, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Disease Progression; Finasteride; Humans; Male; Middle Aged; Prospective Studies; Prostatic Hyperplasia; Urinary Retention; Urodynamics	1998
Effect of dual inhibition of 5-alpha-reductase and aromatase on spontaneously developed canine prostatic hypertrophy. The Prostate, 1998, Oct-01, Volume: 37, Issue:2 Topics: Anastrozole; Animals; Aromatase; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Dogs; Enzyme Inhibitors; Finasteride; Male; Nitriles; Oxidoreductases; Prostate; Prostatic Hyperplasia; Testosterone; Triazoles	1998
Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-beta receptor expression. The Prostate, 1998, Oct-01, Volume: 37, Issue:2 Topics: Apoptosis; Atrophy; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Transforming Growth Factor beta; Up-Regulation	1998
In vitro inhibition of androstenedione 5alpha-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia. The Journal of steroid biochemistry and molecular biology, 1998, Volume: 67, Issue:1 Topics: Aged; Aged, 80 and over; Cholestenone 5 alpha-Reductase; Epithelial Cells; Finasteride; Humans; Kinetics; Male; Middle Aged; Oxidoreductases; Prostate; Prostatectomy; Prostatic Hyperplasia; Stromal Cells	1998
Comment on the appropriateness of The Prostate publishing a trial comparing Permixon to finasteride without a placebo control group. The Prostate, 1998, Nov-01, Volume: 37, Issue:3 Topics: Androgen Antagonists; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Placebos; Plant Extracts; Prostatic Hyperplasia; Research Design; Serenoa	1998
Prostate size dependence of proscar efficacy. Urology, 1998, Volume: 52, Issue:5 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia	1998
Benign prostatic hyperplasia. BMJ (Clinical research ed.), 1999, Feb-06, Volume: 318, Issue:7180 Topics: Acute Disease; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Risk Factors; Urinary Retention	1999
Urology. JAMA, 1999, Feb-10, Volume: 281, Issue:6 Topics: Circumcision, Male; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Humans; Male; Mass Screening; Pain; Piperazines; Plant Extracts; Prostatic Hyperplasia; Prostatic Neoplasms; Purines; Serenoa; Sildenafil Citrate; Sulfones; Urology	1999
Current management and future trends in benign prostatic hyperplasia (BPH) Irish medical journal, 1997, Volume: 90, Issue:7 Topics: Aged; Enzyme Inhibitors; Finasteride; Forecasting; Humans; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia	1997
Saw palmetto extracts for benign prostatic hyperplasia. The Journal of family practice, 1999, Volume: 48, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Phytotherapy; Plant Extracts; Plants, Medicinal; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Treatment Outcome	1999
Nodular hyperplasia of the prostate. Quantitative evaluation of secretory cell changes after treatment with finasteride. Analytical and quantitative cytology and histology, 1999, Volume: 21, Issue:1 Topics: Aged; Cell Nucleolus; Cell Nucleus; Cytoplasm; Finasteride; Humans; Immunohistochemistry; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Ultrasonography	1999
BPH: what really works? Contemporary urology, 1995, Volume: 7, Issue:4 Topics: Aged; Catheter Ablation; Finasteride; Humans; Laser Coagulation; Laser Therapy; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Ultrasonic Therapy	1995
Current management options for benign prostatic hyperplasia. Contemporary internal medicine, 1994, Volume: 6, Issue:11 Topics: Adrenergic alpha-Antagonists; Diagnosis, Differential; Finasteride; Guidelines as Topic; Hormones; Humans; Male; Prognosis; Prostatectomy; Prostatic Hyperplasia	1994
An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. PharmacoEconomics, 1996, Volume: 9, Issue:5 Topics: Aged; Canada; Cost-Benefit Analysis; Decision Trees; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatectomy; Prostatic Hyperplasia; Treatment Outcome	1996
Tamsulosine: new preparation. Capsules: alphablocker. Prescrire international, 1998, Volume: 7, Issue:33 Topics: Adrenergic alpha-Antagonists; Aged; Clinical Trials as Topic; Dizziness; Double-Blind Method; Drug Interactions; Ejaculation; Enzyme Inhibitors; Europe; Finasteride; Humans; Hypotension, Orthostatic; Japan; Male; Middle Aged; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Treatment Outcome	1998
Finasteride: a steroid-unsparing drug? Rheumatology (Oxford, England), 1999, Volume: 38, Issue:3 Topics: Eczema; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Polymyalgia Rheumatica; Prostatic Hyperplasia	1999
Planning and analysis of repeated measures at key time-points in clinical trials sponsored by pharmaceutical companies. Statistics in medicine, 1999, Apr-30, Volume: 18, Issue:8 Topics: Alendronate; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Data Collection; Decision Making; Drug Industry; Enzyme Inhibitors; Female; Finasteride; Humans; Longitudinal Studies; Male; Osteoporosis; Periodontal Diseases; Prostatic Hyperplasia; Statistics as Topic; Time Factors; United States; United States Food and Drug Administration	1999
Waxing and waning gynecomastia: an indication of noncompliant use of prescribed medication. Southern medical journal, 1999, Volume: 92, Issue:6 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Gynecomastia; Humans; Male; Middle Aged; Patient Compliance; Prostatic Hyperplasia	1999
Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. The Prostate, 1999, Jul-01, Volume: 40, Issue:2 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Fibroblast Growth Factor 2; Finasteride; Gene Expression; Humans; Immunohistochemistry; Male; Prostate; Prostatic Hyperplasia; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Fibroblast Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	1999
Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Clinical therapeutics, 1999, Volume: 21, Issue:6 Topics: Adrenergic alpha-Antagonists; Aged; Decision Trees; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Models, Economic; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Randomized Controlled Trials as Topic	1999
[Benign hypertrophy of the prostate: which treatment, for whom?]. Revue medicale de Bruxelles, 1999, Volume: 20, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Blood Pressure; Endoscopy; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Minimally Invasive Surgical Procedures; Muscle, Smooth; Organ Size; Prostate; Prostatic Hyperplasia; Time Factors; Transurethral Resection of Prostate; Urinary Bladder Diseases; Urination Disorders	1999
By the way, doctor... I'm 78 and have more and more difficulty urinating. I get up three times a night - sometimes more - to go to the bathroom and it takes me a while to start urinating and even longer to stop. I know that this is probably a prostate pro Harvard health letter, 1999, Volume: 24, Issue:12 Topics: Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Urination Disorders	1999
Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride. Journal of clinical pathology, 1999, Volume: 52, Issue:5 Topics: Aged; Drug Administration Schedule; Enzyme Inhibitors; Finasteride; Glutathione Transferase; Humans; Immunoenzyme Techniques; Male; Middle Aged; Prostate; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Up-Regulation	1999
Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:11 Topics: Chromosome Aberrations; Chromosome Mapping; Chromosomes, Human, Pair 6; Enzyme Inhibitors; Finasteride; Humans; In Situ Hybridization, Fluorescence; Male; Neoplasm Staging; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Androgen; X Chromosome	1999
[Appropriate treatment of benign prostatic hyperplasia; refining the indications for treatment by systematic analysis of expert opinion]. Nederlands tijdschrift voor geneeskunde, 1999, Nov-27, Volume: 143, Issue:48 Topics: Adrenergic alpha-Antagonists; Delphi Technique; Enzyme Inhibitors; Finasteride; Humans; Logistic Models; Male; Prostatic Hyperplasia; Transurethral Resection of Prostate; Urology; Workforce	1999
A pilot study of a bioabsorbable self-reinforced poly L-lactic acid urethral stent combined with finasteride in the treatment of acute urinary retention from benign prostatic enlargement. BJU international, 2000, Volume: 85, Issue:1 Topics: Acute Disease; Aged; Aged, 80 and over; Ambulatory Care; Combined Modality Therapy; Enzyme Inhibitors; Finasteride; Humans; Lactic Acid; Male; Middle Aged; Pilot Projects; Polyesters; Polymers; Prostatic Hyperplasia; Stents; Urinary Retention; Urination	2000
Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride. The Prostate, 2000, Apr-01, Volume: 43, Issue:1 Topics: Androgen Antagonists; Animals; Enzyme Inhibitors; Finasteride; Hyperprolactinemia; Male; Organ Size; Plant Extracts; Prostate; Prostatic Hyperplasia; Rats; Rats, Wistar; Serenoa	2000
Diet and herbs for BPH? RN, 2000, Volume: 63, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia	2000
[Benign prostatic hyperplasia. Finasteride controls progression of BPH]. MMW Fortschritte der Medizin, 2000, Jun-22, Volume: 142, Issue:25 Topics: Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Treatment Outcome	2000
The fundamental concept, that interindividual differences among prostate glands can explain varying responses to treatment, remains intact. A simple test to pinpoint those differences remains the challenge. Urology, 2000, Aug-01, Volume: 56, Issue:2 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Research Design; Treatment Outcome	2000
Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride. The Journal of urology, 2001, Volume: 165, Issue:1 Topics: Androgen Antagonists; Animals; Apoptosis; Chlormadinone Acetate; Dihydrotestosterone; Dog Diseases; Dogs; Estradiol; Finasteride; Male; Prostate; Prostatic Hyperplasia; Testosterone	2001
Neural network prediction of prostate tissue composition based on magnetic resonance imaging analysis. A pilot study. Analytical and quantitative cytology and histology, 2000, Volume: 22, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Androgen Antagonists; Double-Blind Method; Epithelial Cells; Finasteride; Humans; Image Cytometry; Magnetic Resonance Imaging; Male; Middle Aged; Neural Networks, Computer; Pilot Projects; Plant Extracts; Prospective Studies; Prostate; Prostatic Hyperplasia; Retrospective Studies; Serenoa; Stromal Cells	2000
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. The Prostate, 2001, Jan-01, Volume: 46, Issue:1 Topics: Adrenergic alpha-Antagonists; Antibodies, Monoclonal; Apoptosis; Cell Division; Drug Combinations; Enzyme Inhibitors; Finasteride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Linear Models; Male; Prazosin; Prostate; Prostatic Hyperplasia; Receptors, Transforming Growth Factor beta; Regression Analysis; Retrospective Studies; Transforming Growth Factor beta	2001
Re: A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. The Journal of urology, 2000, Volume: 164, Issue:5 Topics: Enzyme Inhibitors; Finasteride; Hematuria; Humans; Male; Prospective Studies; Prostatic Hyperplasia	2000
Benign prostatic hyperplasia. Patient evaluation and relief of obstructive symptoms. Geriatrics, 2001, Volume: 56, Issue:3 Topics: Adrenergic alpha-Antagonists; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Plants, Medicinal; Prostatic Hyperplasia	2001
Evaluating adverse cardiovascular effects of drug treatment for benign prostatic hyperplasia (BPH): methodological considerations. Journal of clinical epidemiology, 2001, Volume: 54, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Adult; Aged; Bias; Cardiovascular Diseases; Case-Control Studies; Finasteride; Humans; Male; Middle Aged; Morbidity; Netherlands; Prazosin; Prognosis; Prostatic Hyperplasia; Quinazolines; Research Design; Risk Factors; Sulfonamides; Tamsulosin	2001
Questions whether clients were properly informed about treatment protocol. Journal of the American Veterinary Medical Association, 2001, Jun-01, Volume: 218, Issue:11 Topics: Animals; Dog Diseases; Dogs; Double-Blind Method; Enzyme Inhibitors; Ethics, Professional; Finasteride; Informed Consent; Male; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Veterinary Medicine	2001
Finasteride and tamsulosin used in benign prostatic hypertrophy: a review of the prescription-event monitoring data. BJU international, 2001, Volume: 87, Issue:9 Topics: Adrenergic alpha-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Cohort Studies; Drug Prescriptions; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome	2001
[Gynecomastia and finasteride]. Annales de dermatologie et de venereologie, 2001, Volume: 128, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adult; Alopecia; Finasteride; Gynecomastia; Humans; Male; Prostatic Hyperplasia; Time Factors	2001
[Prostate problems. More clarity regarding prognosis]. MMW Fortschritte der Medizin, 2001, Jul-26, Volume: 143, Issue:30 Topics: Aged; Clinical Trials as Topic; Finasteride; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Hyperplasia; Treatment Outcome	2001
The impact of participation in a study of medical treatment of lower urinary tract symptoms on the incidence of prostate surgery. World journal of urology, 2001, Volume: 19, Issue:4 Topics: 5-alpha Reductase Inhibitors; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Multicenter Studies as Topic; Physician-Patient Relations; Prostate; Prostatic Hyperplasia; Retrospective Studies; Urination Disorders	2001
Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. International urology and nephrology, 2001, Volume: 32, Issue:3 Topics: Adrenergic alpha-Antagonists; Aged; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Phytotherapy; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin	2001
Lower urinary tract symptoms: what are the implications for the patients? European urology, 2001, Volume: 40 Suppl 4 Topics: Adrenergic alpha-Antagonists; Data Collection; Europe; Finasteride; Humans; Life Style; Male; Patient Acceptance of Health Care; Penile Erection; Prevalence; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin; Urinary Retention	2001
The effect of finasteride in men with benign prostatic hyperplasia. 1992. The Journal of urology, 2002, Volume: 167, Issue:2 Pt 2 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; History, 20th Century; Humans; Male; Prostatic Hyperplasia	2002
Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. The Journal of urology, 2002, Volume: 167, Issue:4 Topics: Aged; Enzyme Inhibitors; Finasteride; Hemorrhage; Humans; Male; Microcirculation; Prospective Studies; Prostate; Prostatic Diseases; Prostatic Hyperplasia	2002
Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. The Journal of urology, 2002, Volume: 167, Issue:6 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Anticoagulants; Enzyme Inhibitors; Finasteride; Hematuria; Humans; Male; Middle Aged; Prostatic Hyperplasia; Retrospective Studies	2002
[With alpha blockers, finasteride and nettle root against benign prostatic hyperplasia. Which patients are helped by conservative therapy?]. MMW Fortschritte der Medizin, 2002, Apr-18, Volume: 144, Issue:16 Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Phytotherapy; Plant Preparations; Plant Roots; Prostatic Hyperplasia; Treatment Outcome; Urtica dioica	2002
Laboratory monitoring of androgenic activity in benign prostate hypertrophy treated with a 5 alpha-reductase inhibitor. Clinical chemistry, 1992, Volume: 38, Issue:7 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androstenes; Androsterone; Azasteroids; Dose-Response Relationship, Drug; Etiocholanolone; Finasteride; Humans; Male; Prostatic Hyperplasia	1992
Finasteride for benign prostatic hypertrophy. The Medical letter on drugs and therapeutics, 1992, Sep-04, Volume: 34, Issue:878 Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Clinical Trials as Topic; Finasteride; Humans; Male; Prostatic Hyperplasia	1992
From the Food and Drug Administration. JAMA, 1992, Sep-16, Volume: 268, Issue:11 Topics: 5-alpha Reductase Inhibitors; Alkaloids; Androstenes; Antineoplastic Agents, Phytogenic; Azasteroids; Female; Finasteride; Humans; Male; Mammaplasty; Neoplasm Metastasis; Ovarian Neoplasms; Paclitaxel; Prostatic Hyperplasia; Prostheses and Implants; Silicones; United States; United States Food and Drug Administration	1992
The effect of the steroidal androgen receptor antagonist, Win 49,596, on the prostate and testis of beagle dogs. Endocrinology, 1990, Volume: 126, Issue:5 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstenes; Anilides; Animals; Azasteroids; DNA; Dogs; Finasteride; Hypertrophy; Male; Nitriles; Orchiectomy; Organ Size; Pregnanes; Prostate; Prostatic Hyperplasia; Pyrazoles; Receptors, Androgen; Semen; Spermatogenesis; Testis; Testosterone; Tosyl Compounds; Ultrasonography	1990
Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. The Journal of clinical endocrinology and metabolism, 1990, Volume: 71, Issue:6 Topics: 5-alpha Reductase Inhibitors; Androgens; Androstenes; Antigens, Neoplasm; Azasteroids; Dihydrotestosterone; Epithelium; Estradiol; Finasteride; Humans; Male; Megestrol; Megestrol Acetate; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; Testosterone	1990
[5-alpha reductase inhibitor in prostatic adenoma?]. Medizinische Monatsschrift fur Pharmazeuten, 1990, Volume: 13, Issue:12 Topics: 5-alpha Reductase Inhibitors; Aged; Androstenes; Azasteroids; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Testosterone	1990
Magnetic resonance imaging of the efficacy of specific inhibition of 5 alpha-reductase in canine spontaneous benign prostatic hyperplasia. Magnetic resonance in medicine, 1991, Volume: 21, Issue:1 Topics: 5-alpha Reductase Inhibitors; Androstenes; Animals; Azasteroids; Dihydrotestosterone; Dog Diseases; Dogs; Finasteride; Magnetic Resonance Imaging; Male; Prostate; Prostatic Hyperplasia	1991
Changing attitudes in the treatment of benign prostatic hyperplasia: the role of 5 alpha-reductase inhibition. Proceedings of two symposia: Nice, France, November 11, 1989 and Amsterdam, The Netherlands, June 14, 1990. European urology, 1991, Volume: 20 Suppl 1 Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Finasteride; Humans; Male; Prostatic Hyperplasia	1991
Optimism expressed over prostate drug. Journal of the National Cancer Institute, 1991, Dec-04, Volume: 83, Issue:23 Topics: Androstenes; Antineoplastic Agents; Azasteroids; Dihydrotestosterone; Finasteride; Humans; Male; Pilot Projects; Prostatic Hyperplasia; Prostatic Neoplasms; Recurrence	1991
Medical treatment of benign prostatic hyperplasia. The Western journal of medicine, 1991, Volume: 155, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androgen Antagonists; Androstenes; Azasteroids; Buserelin; Finasteride; Goserelin; Humans; Leuprolide; Male; Prostatic Hyperplasia	1991